US20180071309A9 - Fulvestrant compositions and method of use - Google Patents
Fulvestrant compositions and method of use Download PDFInfo
- Publication number
- US20180071309A9 US20180071309A9 US15/615,295 US201715615295A US2018071309A9 US 20180071309 A9 US20180071309 A9 US 20180071309A9 US 201715615295 A US201715615295 A US 201715615295A US 2018071309 A9 US2018071309 A9 US 2018071309A9
- Authority
- US
- United States
- Prior art keywords
- fulvestrant
- cyclodextrin
- inclusion complex
- compound
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 title claims abstract description 529
- 229960002258 fulvestrant Drugs 0.000 title claims abstract description 511
- 238000000034 method Methods 0.000 title claims abstract description 123
- 239000000203 mixture Substances 0.000 title claims description 257
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 433
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 216
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 65
- 201000011510 cancer Diseases 0.000 claims abstract description 62
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 37
- 238000009472 formulation Methods 0.000 claims description 204
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 100
- 150000001875 compounds Chemical class 0.000 claims description 85
- 239000000872 buffer Substances 0.000 claims description 74
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 64
- 239000002904 solvent Substances 0.000 claims description 57
- 239000012046 mixed solvent Substances 0.000 claims description 40
- 238000002156 mixing Methods 0.000 claims description 25
- 239000000725 suspension Substances 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 24
- 239000002246 antineoplastic agent Substances 0.000 claims description 23
- 239000012453 solvate Substances 0.000 claims description 22
- ATTZFSUZZUNHBP-UHFFFAOYSA-N Piperonyl sulfoxide Chemical compound CCCCCCCCS(=O)C(C)CC1=CC=C2OCOC2=C1 ATTZFSUZZUNHBP-UHFFFAOYSA-N 0.000 claims description 20
- 239000003085 diluting agent Substances 0.000 claims description 16
- JVFGXECLSQXABC-UHFFFAOYSA-N ac1l3obq Chemical compound O1C(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(O)C2O)C(COCC(O)C)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC2C(O)C(O)C1OC2COCC(C)O JVFGXECLSQXABC-UHFFFAOYSA-N 0.000 claims description 15
- 239000008367 deionised water Substances 0.000 claims description 15
- 229910021641 deionized water Inorganic materials 0.000 claims description 15
- 229940046836 anti-estrogen Drugs 0.000 claims description 11
- 230000001833 anti-estrogenic effect Effects 0.000 claims description 11
- 239000007884 disintegrant Substances 0.000 claims description 11
- 239000000328 estrogen antagonist Substances 0.000 claims description 11
- 239000000945 filler Substances 0.000 claims description 11
- 239000000314 lubricant Substances 0.000 claims description 11
- 239000008139 complexing agent Substances 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 10
- 239000003979 granulating agent Substances 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 8
- 239000011230 binding agent Substances 0.000 claims description 5
- 239000003002 pH adjusting agent Substances 0.000 claims description 5
- 239000008181 tonicity modifier Substances 0.000 claims description 4
- 230000000536 complexating effect Effects 0.000 claims description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract description 24
- YZOUYRAONFXZSI-SBHWVFSVSA-N (1S,3R,5R,6R,8R,10R,11R,13R,15R,16R,18R,20R,21R,23R,25R,26R,28R,30R,31S,33R,35R,36R,37S,38R,39S,40R,41S,42R,43S,44R,45S,46R,47S,48R,49S)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-37,39,40,41,42,43,44,45,46,47,48,49-dodecamethoxy-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,38-diol Chemical compound O([C@@H]([C@H]([C@@H]1OC)OC)O[C@H]2[C@@H](O)[C@@H]([C@@H](O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3O)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O3)O[C@@H]2CO)OC)[C@H](CO)[C@H]1O[C@@H]1[C@@H](OC)[C@H](OC)[C@H]3[C@@H](CO)O1 YZOUYRAONFXZSI-SBHWVFSVSA-N 0.000 description 82
- -1 but not limited to Substances 0.000 description 70
- 239000003795 chemical substances by application Substances 0.000 description 56
- 241000700159 Rattus Species 0.000 description 54
- 239000003963 antioxidant agent Substances 0.000 description 43
- 235000006708 antioxidants Nutrition 0.000 description 43
- 206010006187 Breast cancer Diseases 0.000 description 38
- 239000000243 solution Substances 0.000 description 37
- 239000008177 pharmaceutical agent Substances 0.000 description 35
- 238000011282 treatment Methods 0.000 description 33
- 208000026310 Breast neoplasm Diseases 0.000 description 32
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 230000003078 antioxidant effect Effects 0.000 description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 26
- 238000002474 experimental method Methods 0.000 description 25
- 230000036470 plasma concentration Effects 0.000 description 23
- 206010060862 Prostate cancer Diseases 0.000 description 22
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 22
- 229960004853 betadex Drugs 0.000 description 22
- 239000003814 drug Substances 0.000 description 22
- 230000001965 increasing effect Effects 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 21
- 230000001225 therapeutic effect Effects 0.000 description 21
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 20
- 239000003755 preservative agent Substances 0.000 description 20
- 239000001116 FEMA 4028 Substances 0.000 description 19
- 241000282414 Homo sapiens Species 0.000 description 19
- 229940087861 faslodex Drugs 0.000 description 19
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 18
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 18
- 238000004128 high performance liquid chromatography Methods 0.000 description 18
- 239000004615 ingredient Substances 0.000 description 18
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 18
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 17
- 201000010099 disease Diseases 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 238000002347 injection Methods 0.000 description 17
- 239000007924 injection Substances 0.000 description 17
- 239000000546 pharmaceutical excipient Substances 0.000 description 17
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 16
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 16
- 239000003981 vehicle Substances 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 238000010521 absorption reaction Methods 0.000 description 15
- 229940097362 cyclodextrins Drugs 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 230000002708 enhancing effect Effects 0.000 description 15
- 239000007788 liquid Substances 0.000 description 15
- 239000000375 suspending agent Substances 0.000 description 15
- PMNLUUOXGOOLSP-UHFFFAOYSA-N 2-mercaptopropanoic acid Chemical compound CC(S)C(O)=O PMNLUUOXGOOLSP-UHFFFAOYSA-N 0.000 description 14
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 14
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 14
- 230000000845 anti-microbial effect Effects 0.000 description 14
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 14
- 239000007927 intramuscular injection Substances 0.000 description 14
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 14
- 229920000642 polymer Polymers 0.000 description 14
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 description 14
- 239000008215 water for injection Substances 0.000 description 14
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 13
- 239000002253 acid Substances 0.000 description 13
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 13
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 13
- 108091008039 hormone receptors Proteins 0.000 description 13
- 238000010255 intramuscular injection Methods 0.000 description 13
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- 239000003826 tablet Substances 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 229960003437 aminoglutethimide Drugs 0.000 description 12
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 12
- 229960004421 formestane Drugs 0.000 description 12
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 12
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 12
- 229960005353 testolactone Drugs 0.000 description 12
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 12
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 12
- 229960001771 vorozole Drugs 0.000 description 12
- XLMPPFTZALNBFS-INIZCTEOSA-N vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 11
- 229930006000 Sucrose Natural products 0.000 description 11
- 229920004482 WACKER® Polymers 0.000 description 11
- 239000007864 aqueous solution Substances 0.000 description 11
- 239000005720 sucrose Substances 0.000 description 11
- 229960004793 sucrose Drugs 0.000 description 11
- PLHJCIYEEKOWNM-HHHXNRCGSA-N tipifarnib Chemical compound CN1C=NC=C1[C@](N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-HHHXNRCGSA-N 0.000 description 11
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 10
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 235000010980 cellulose Nutrition 0.000 description 10
- 229920002678 cellulose Polymers 0.000 description 10
- 239000001913 cellulose Substances 0.000 description 10
- 239000003086 colorant Substances 0.000 description 10
- 239000002552 dosage form Substances 0.000 description 10
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 10
- 238000001704 evaporation Methods 0.000 description 10
- 230000008020 evaporation Effects 0.000 description 10
- 238000003305 oral gavage Methods 0.000 description 10
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 10
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 10
- 239000002002 slurry Substances 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 229940035024 thioglycerol Drugs 0.000 description 10
- 206010055113 Breast cancer metastatic Diseases 0.000 description 9
- 241000282472 Canis lupus familiaris Species 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 229960005070 ascorbic acid Drugs 0.000 description 9
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 238000010668 complexation reaction Methods 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 238000003304 gavage Methods 0.000 description 9
- 238000007918 intramuscular administration Methods 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- RWPGFSMJFRPDDP-UHFFFAOYSA-L potassium metabisulfite Chemical compound [K+].[K+].[O-]S(=O)S([O-])(=O)=O RWPGFSMJFRPDDP-UHFFFAOYSA-L 0.000 description 9
- 229940043349 potassium metabisulfite Drugs 0.000 description 9
- 235000010263 potassium metabisulphite Nutrition 0.000 description 9
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 9
- 229940001584 sodium metabisulfite Drugs 0.000 description 9
- 235000010262 sodium metabisulphite Nutrition 0.000 description 9
- 229940001482 sodium sulfite Drugs 0.000 description 9
- 235000010265 sodium sulphite Nutrition 0.000 description 9
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 8
- 206010014733 Endometrial cancer Diseases 0.000 description 8
- 206010014759 Endometrial neoplasm Diseases 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 8
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 8
- 229960004308 acetylcysteine Drugs 0.000 description 8
- 238000010241 blood sampling Methods 0.000 description 8
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 8
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 8
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 229920000159 gelatin Polymers 0.000 description 8
- 235000019322 gelatine Nutrition 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 238000005070 sampling Methods 0.000 description 8
- 239000003765 sweetening agent Substances 0.000 description 8
- 239000000454 talc Substances 0.000 description 8
- 229910052623 talc Inorganic materials 0.000 description 8
- 235000012222 talc Nutrition 0.000 description 8
- 241000416162 Astragalus gummifer Species 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 7
- CIWBSHSKHKDKBQ-MVHIGOERSA-N D-ascorbic acid Chemical compound OC[C@@H](O)[C@@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-MVHIGOERSA-N 0.000 description 7
- 108010010803 Gelatin Proteins 0.000 description 7
- 108010024636 Glutathione Proteins 0.000 description 7
- 239000002211 L-ascorbic acid Substances 0.000 description 7
- 235000000069 L-ascorbic acid Nutrition 0.000 description 7
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 7
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 7
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 7
- 229920001615 Tragacanth Polymers 0.000 description 7
- 230000002411 adverse Effects 0.000 description 7
- 229960002932 anastrozole Drugs 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 238000002648 combination therapy Methods 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 7
- 229960000255 exemestane Drugs 0.000 description 7
- 235000003599 food sweetener Nutrition 0.000 description 7
- 239000001530 fumaric acid Substances 0.000 description 7
- 229960002584 gefitinib Drugs 0.000 description 7
- 239000008273 gelatin Substances 0.000 description 7
- 229940014259 gelatin Drugs 0.000 description 7
- 235000011852 gelatine desserts Nutrition 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 229960003180 glutathione Drugs 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 229960003881 letrozole Drugs 0.000 description 7
- 201000005202 lung cancer Diseases 0.000 description 7
- 208000020816 lung neoplasm Diseases 0.000 description 7
- 229960003951 masoprocol Drugs 0.000 description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 7
- 239000008108 microcrystalline cellulose Substances 0.000 description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 229940124531 pharmaceutical excipient Drugs 0.000 description 7
- 239000007981 phosphate-citrate buffer Substances 0.000 description 7
- DJEHXEMURTVAOE-UHFFFAOYSA-M potassium bisulfite Chemical compound [K+].OS([O-])=O DJEHXEMURTVAOE-UHFFFAOYSA-M 0.000 description 7
- 229940099427 potassium bisulfite Drugs 0.000 description 7
- 235000010259 potassium hydrogen sulphite Nutrition 0.000 description 7
- 229940069328 povidone Drugs 0.000 description 7
- 235000010388 propyl gallate Nutrition 0.000 description 7
- 239000000473 propyl gallate Substances 0.000 description 7
- 229940075579 propyl gallate Drugs 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 description 7
- 235000010378 sodium ascorbate Nutrition 0.000 description 7
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 7
- 229960005055 sodium ascorbate Drugs 0.000 description 7
- 229940001607 sodium bisulfite Drugs 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 7
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 7
- 229940001474 sodium thiosulfate Drugs 0.000 description 7
- 235000019345 sodium thiosulphate Nutrition 0.000 description 7
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 7
- 235000010487 tragacanth Nutrition 0.000 description 7
- 239000000196 tragacanth Substances 0.000 description 7
- 229940116362 tragacanth Drugs 0.000 description 7
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 7
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 6
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 6
- UKCVAQGKEOJTSR-UHFFFAOYSA-N Fadrozole hydrochloride Chemical compound Cl.C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 UKCVAQGKEOJTSR-UHFFFAOYSA-N 0.000 description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 6
- 229920000715 Mucilage Polymers 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 6
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 229930003268 Vitamin C Natural products 0.000 description 6
- 229930003427 Vitamin E Natural products 0.000 description 6
- 208000009956 adenocarcinoma Diseases 0.000 description 6
- 239000000853 adhesive Substances 0.000 description 6
- 235000010443 alginic acid Nutrition 0.000 description 6
- 229920000615 alginic acid Polymers 0.000 description 6
- 239000000783 alginic acid Substances 0.000 description 6
- 229960001126 alginic acid Drugs 0.000 description 6
- 150000004781 alginic acids Chemical class 0.000 description 6
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 6
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 6
- 229940078010 arimidex Drugs 0.000 description 6
- 229940087620 aromasin Drugs 0.000 description 6
- 235000013734 beta-carotene Nutrition 0.000 description 6
- 239000011648 beta-carotene Substances 0.000 description 6
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 6
- 229960002747 betacarotene Drugs 0.000 description 6
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 6
- 235000018417 cysteine Nutrition 0.000 description 6
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 6
- 229950011548 fadrozole Drugs 0.000 description 6
- 229940087476 femara Drugs 0.000 description 6
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 6
- 229940022353 herceptin Drugs 0.000 description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 6
- 229940084651 iressa Drugs 0.000 description 6
- 239000008297 liquid dosage form Substances 0.000 description 6
- 239000001630 malic acid Substances 0.000 description 6
- 235000011090 malic acid Nutrition 0.000 description 6
- 229940099690 malic acid Drugs 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 230000036407 pain Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000011669 selenium Substances 0.000 description 6
- 229910052711 selenium Inorganic materials 0.000 description 6
- 235000011649 selenium Nutrition 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 229940120982 tarceva Drugs 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 229960000575 trastuzumab Drugs 0.000 description 6
- 235000019154 vitamin C Nutrition 0.000 description 6
- 239000011718 vitamin C Substances 0.000 description 6
- 235000019165 vitamin E Nutrition 0.000 description 6
- 239000011709 vitamin E Substances 0.000 description 6
- 229940046009 vitamin E Drugs 0.000 description 6
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 6
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 5
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 5
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 5
- VWUXBMIQPBEWFH-WIUAIARKSA-N CC12CCC3C4=CC=C(O)C=C4C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)C3C1CCC2O Chemical compound CC12CCC3C4=CC=C(O)C=C4C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)C3C1CCC2O VWUXBMIQPBEWFH-WIUAIARKSA-N 0.000 description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- 102000001301 EGF receptor Human genes 0.000 description 5
- 108060006698 EGF receptor Proteins 0.000 description 5
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 5
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 229930195725 Mannitol Natural products 0.000 description 5
- 206010041067 Small cell lung cancer Diseases 0.000 description 5
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 5
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 5
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 239000008119 colloidal silica Substances 0.000 description 5
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 5
- 229960002433 cysteine Drugs 0.000 description 5
- 238000001647 drug administration Methods 0.000 description 5
- 235000013355 food flavoring agent Nutrition 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 229960005150 glycerol Drugs 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- 239000000594 mannitol Substances 0.000 description 5
- 229960001855 mannitol Drugs 0.000 description 5
- 229920000609 methyl cellulose Polymers 0.000 description 5
- 235000010981 methylcellulose Nutrition 0.000 description 5
- 239000001923 methylcellulose Substances 0.000 description 5
- 229960002900 methylcellulose Drugs 0.000 description 5
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 230000002335 preservative effect Effects 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 235000010413 sodium alginate Nutrition 0.000 description 5
- 239000000661 sodium alginate Substances 0.000 description 5
- 229940005550 sodium alginate Drugs 0.000 description 5
- 239000007909 solid dosage form Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229950009158 tipifarnib Drugs 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 5
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 4
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 4
- 241000220479 Acacia Species 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- 229940122815 Aromatase inhibitor Drugs 0.000 description 4
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 4
- 235000013913 Ceratonia Nutrition 0.000 description 4
- 241001060815 Ceratonia Species 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 4
- 229920002907 Guar gum Polymers 0.000 description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 4
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229920000881 Modified starch Polymers 0.000 description 4
- 239000004368 Modified starch Substances 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 241000288906 Primates Species 0.000 description 4
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 4
- 239000003886 aromatase inhibitor Substances 0.000 description 4
- 239000000440 bentonite Substances 0.000 description 4
- 229910000278 bentonite Inorganic materials 0.000 description 4
- 235000012216 bentonite Nutrition 0.000 description 4
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 4
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 4
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 4
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 4
- 229940105329 carboxymethylcellulose Drugs 0.000 description 4
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 4
- 235000010418 carrageenan Nutrition 0.000 description 4
- 229920001525 carrageenan Polymers 0.000 description 4
- 239000000679 carrageenan Substances 0.000 description 4
- 229940113118 carrageenan Drugs 0.000 description 4
- 229940043431 ceratonia Drugs 0.000 description 4
- 229960004926 chlorobutanol Drugs 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 239000012154 double-distilled water Substances 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 201000003914 endometrial carcinoma Diseases 0.000 description 4
- 229960001433 erlotinib Drugs 0.000 description 4
- 235000010417 guar gum Nutrition 0.000 description 4
- 239000000665 guar gum Substances 0.000 description 4
- 229960002154 guar gum Drugs 0.000 description 4
- 238000001794 hormone therapy Methods 0.000 description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
- 229960003943 hypromellose Drugs 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 4
- 235000010449 maltitol Nutrition 0.000 description 4
- 239000000845 maltitol Substances 0.000 description 4
- 229940035436 maltitol Drugs 0.000 description 4
- 208000037819 metastatic cancer Diseases 0.000 description 4
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 235000019426 modified starch Nutrition 0.000 description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 description 4
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 4
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000008299 semisolid dosage form Substances 0.000 description 4
- 235000011803 sesame oil Nutrition 0.000 description 4
- 239000008159 sesame oil Substances 0.000 description 4
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 4
- 235000010234 sodium benzoate Nutrition 0.000 description 4
- 239000004299 sodium benzoate Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 229930003799 tocopherol Natural products 0.000 description 4
- 235000010384 tocopherol Nutrition 0.000 description 4
- 239000011732 tocopherol Substances 0.000 description 4
- 229960001295 tocopherol Drugs 0.000 description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 4
- 229920001285 xanthan gum Polymers 0.000 description 4
- 235000010493 xanthan gum Nutrition 0.000 description 4
- 239000000230 xanthan gum Substances 0.000 description 4
- 229940082509 xanthan gum Drugs 0.000 description 4
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 3
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 3
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 3
- 229920001100 Polydextrose Polymers 0.000 description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 239000004141 Sodium laurylsulphate Substances 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 235000010233 benzoic acid Nutrition 0.000 description 3
- 239000006172 buffering agent Substances 0.000 description 3
- 210000001217 buttock Anatomy 0.000 description 3
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 3
- 235000013539 calcium stearate Nutrition 0.000 description 3
- 239000008116 calcium stearate Substances 0.000 description 3
- 235000011089 carbon dioxide Nutrition 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 229940096516 dextrates Drugs 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 description 3
- 239000007888 film coating Substances 0.000 description 3
- 238000009501 film coating Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 235000001727 glucose Nutrition 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 231100000682 maximum tolerated dose Toxicity 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000000683 nonmetastatic effect Effects 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 235000013856 polydextrose Nutrition 0.000 description 3
- 239000001259 polydextrose Substances 0.000 description 3
- 229940035035 polydextrose Drugs 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 235000013772 propylene glycol Nutrition 0.000 description 3
- 238000004088 simulation Methods 0.000 description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 230000002110 toxicologic effect Effects 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 2
- DTOUUUZOYKYHEP-UHFFFAOYSA-N 1,3-bis(2-ethylhexyl)-5-methyl-1,3-diazinan-5-amine Chemical compound CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1 DTOUUUZOYKYHEP-UHFFFAOYSA-N 0.000 description 2
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 2
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 2
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 2
- OSDLLIBGSJNGJE-UHFFFAOYSA-N 4-chloro-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1Cl OSDLLIBGSJNGJE-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- 235000003911 Arachis Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000052609 BRCA2 Human genes 0.000 description 2
- 108700020462 BRCA2 Proteins 0.000 description 2
- 206010006002 Bone pain Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 101150008921 Brca2 gene Proteins 0.000 description 2
- LVDKZNITIUWNER-UHFFFAOYSA-N Bronopol Chemical compound OCC(Br)(CO)[N+]([O-])=O LVDKZNITIUWNER-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010065305 Cancer in remission Diseases 0.000 description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- 229940124226 Farnesyltransferase inhibitor Drugs 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 description 2
- 101000669028 Homo sapiens Zinc phosphodiesterase ELAC protein 2 Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100034184 Macrophage scavenger receptor types I and II Human genes 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229920003072 Plasdone™ povidone Polymers 0.000 description 2
- 229920000148 Polycarbophil calcium Polymers 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 2
- 206010038111 Recurrent cancer Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 102100039877 Zinc phosphodiesterase ELAC protein 2 Human genes 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 229940009868 aluminum magnesium silicate Drugs 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 2
- 229960001950 benzethonium chloride Drugs 0.000 description 2
- 229960004365 benzoic acid Drugs 0.000 description 2
- 229960002903 benzyl benzoate Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 238000004638 bioanalytical method Methods 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 229960002645 boric acid Drugs 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 229960003168 bronopol Drugs 0.000 description 2
- 229940067596 butylparaben Drugs 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229960005069 calcium Drugs 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229960002798 cetrimide Drugs 0.000 description 2
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 2
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940045110 chitosan Drugs 0.000 description 2
- 229960003260 chlorhexidine Drugs 0.000 description 2
- 229960002242 chlorocresol Drugs 0.000 description 2
- 229960001701 chloroform Drugs 0.000 description 2
- 229960005443 chloroxylenol Drugs 0.000 description 2
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 2
- 229930003836 cresol Natural products 0.000 description 2
- 229940013361 cresol Drugs 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 229940086555 cyclomethicone Drugs 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 229940077445 dimethyl ether Drugs 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 102000015694 estrogen receptors Human genes 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 2
- JBTWLSYIZRCDFO-UHFFFAOYSA-N ethyl methyl carbonate Chemical compound CCOC(=O)OC JBTWLSYIZRCDFO-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 229940049654 glyceryl behenate Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 2
- 229960003132 halothane Drugs 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229910000271 hectorite Inorganic materials 0.000 description 2
- KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 description 2
- 229960004867 hexetidine Drugs 0.000 description 2
- 239000001341 hydroxy propyl starch Substances 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 2
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 2
- 229940113174 imidurea Drugs 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 2
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 2
- 125000003010 ionic group Chemical group 0.000 description 2
- 229960004592 isopropanol Drugs 0.000 description 2
- 229940074928 isopropyl myristate Drugs 0.000 description 2
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 2
- 229940075495 isopropyl palmitate Drugs 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 229960000448 lactic acid Drugs 0.000 description 2
- 201000003445 large cell neuroendocrine carcinoma Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 229940057917 medium chain triglycerides Drugs 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229960003742 phenol Drugs 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- 229940067107 phenylethyl alcohol Drugs 0.000 description 2
- 229940096826 phenylmercuric acetate Drugs 0.000 description 2
- VUXSPDNLYQTOSY-UHFFFAOYSA-N phenylmercuric borate Chemical compound OB(O)O[Hg]C1=CC=CC=C1 VUXSPDNLYQTOSY-UHFFFAOYSA-N 0.000 description 2
- 229960000247 phenylmercuric borate Drugs 0.000 description 2
- 239000006069 physical mixture Substances 0.000 description 2
- 229950005134 polycarbophil Drugs 0.000 description 2
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 2
- 229940068984 polyvinyl alcohol Drugs 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000010408 potassium alginate Nutrition 0.000 description 2
- 239000000737 potassium alginate Substances 0.000 description 2
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 235000010235 potassium benzoate Nutrition 0.000 description 2
- 239000004300 potassium benzoate Substances 0.000 description 2
- 229940103091 potassium benzoate Drugs 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 229960002816 potassium chloride Drugs 0.000 description 2
- 235000010241 potassium sorbate Nutrition 0.000 description 2
- 239000004302 potassium sorbate Substances 0.000 description 2
- 229940069338 potassium sorbate Drugs 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 229940095574 propionic acid Drugs 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 2
- 229910000275 saponite Inorganic materials 0.000 description 2
- 208000000649 small cell carcinoma Diseases 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 229960004249 sodium acetate Drugs 0.000 description 2
- 229960003885 sodium benzoate Drugs 0.000 description 2
- 229960004599 sodium borate Drugs 0.000 description 2
- 229960002668 sodium chloride Drugs 0.000 description 2
- 239000001540 sodium lactate Substances 0.000 description 2
- 235000011088 sodium lactate Nutrition 0.000 description 2
- 229940005581 sodium lactate Drugs 0.000 description 2
- JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 2
- 235000010334 sodium propionate Nutrition 0.000 description 2
- 239000004324 sodium propionate Substances 0.000 description 2
- 229960003212 sodium propionate Drugs 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 229940012831 stearyl alcohol Drugs 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 229940033663 thimerosal Drugs 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000759 toxicological effect Toxicity 0.000 description 2
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- DKGLSYJXYCJSLA-RJMJUYIDSA-N (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol hydrochloride Chemical compound Cl.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O DKGLSYJXYCJSLA-RJMJUYIDSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- KVHQNWGLVVERFR-ACMTZBLWSA-N (3s)-3-amino-4-[[(2s)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid;6-methyl-2,2-dioxooxathiazin-4-one Chemical compound CC1=CC(=O)[NH2+]S(=O)(=O)O1.[O-]C(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 KVHQNWGLVVERFR-ACMTZBLWSA-N 0.000 description 1
- NUFKRGBSZPCGQB-FLBSXDLDSA-N (3s)-3-amino-4-oxo-4-[[(2r)-1-oxo-1-[(2,2,4,4-tetramethylthietan-3-yl)amino]propan-2-yl]amino]butanoic acid;pentahydrate Chemical compound O.O.O.O.O.OC(=O)C[C@H](N)C(=O)N[C@H](C)C(=O)NC1C(C)(C)SC1(C)C.OC(=O)C[C@H](N)C(=O)N[C@H](C)C(=O)NC1C(C)(C)SC1(C)C NUFKRGBSZPCGQB-FLBSXDLDSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 102100027962 2-5A-dependent ribonuclease Human genes 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- NZAQRZWBQUIBSF-UHFFFAOYSA-N 4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCOCCCCS(O)(=O)=O NZAQRZWBQUIBSF-UHFFFAOYSA-N 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 102000000872 ATM Human genes 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 239000004377 Alitame Substances 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 108010004586 Ataxia Telangiectasia Mutated Proteins Proteins 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 1
- 206010058354 Bronchioloalveolar carcinoma Diseases 0.000 description 1
- 206010067982 Butterfly rash Diseases 0.000 description 1
- JMLHOTSFHJYSEX-UHFFFAOYSA-M C(C1=CC=CC=C1)(=O)[O-].[Na+].C(CCCCCCCCCCCCCCCCC)(=O)O Chemical compound C(C1=CC=CC=C1)(=O)[O-].[Na+].C(CCCCCCCCCCCCCCCCC)(=O)O JMLHOTSFHJYSEX-UHFFFAOYSA-M 0.000 description 1
- 0 C*[C@](Cc1c2)C(C(CCC3O)C3(CC3)C=C)C3c1ccc2O Chemical compound C*[C@](Cc1c2)C(C(CCC3O)C3(CC3)C=C)C3c1ccc2O 0.000 description 1
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 description 1
- 101100245267 Caenorhabditis elegans pas-1 gene Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 201000000274 Carcinosarcoma Diseases 0.000 description 1
- 102100037182 Cation-independent mannose-6-phosphate receptor Human genes 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- MJMCJBFWRBDFQM-UHFFFAOYSA-N ClC(Cl)Cl.OC(=O)c1ccccc1.OC(=O)c1ccccc1.OC(=O)c1ccccc1 Chemical compound ClC(Cl)Cl.OC(=O)c1ccccc1.OC(=O)c1ccccc1.OC(=O)c1ccccc1 MJMCJBFWRBDFQM-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102100035186 DNA excision repair protein ERCC-1 Human genes 0.000 description 1
- 102100035619 DNA-(apurinic or apyrimidinic site) lyase Human genes 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 102100022207 E3 ubiquitin-protein ligase parkin Human genes 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 102100025403 Epoxide hydrolase 1 Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 244000024675 Eruca sativa Species 0.000 description 1
- 235000014755 Eruca sativa Nutrition 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 229940102550 Estrogen receptor antagonist Drugs 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 239000001329 FEMA 3811 Substances 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100037948 GTP-binding protein Di-Ras3 Human genes 0.000 description 1
- 102100030708 GTPase KRas Human genes 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 102100035184 General transcription and DNA repair factor IIH helicase subunit XPD Human genes 0.000 description 1
- 208000008999 Giant Cell Carcinoma Diseases 0.000 description 1
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 description 1
- 101710194460 Growth/differentiation factor 15 Proteins 0.000 description 1
- 101150054472 HER2 gene Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001080057 Homo sapiens 2-5A-dependent ribonuclease Proteins 0.000 description 1
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 1
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 description 1
- 101001028831 Homo sapiens Cation-independent mannose-6-phosphate receptor Proteins 0.000 description 1
- 101000876529 Homo sapiens DNA excision repair protein ERCC-1 Proteins 0.000 description 1
- 101001137256 Homo sapiens DNA-(apurinic or apyrimidinic site) lyase Proteins 0.000 description 1
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 1
- 101001077852 Homo sapiens Epoxide hydrolase 1 Proteins 0.000 description 1
- 101000951235 Homo sapiens GTP-binding protein Di-Ras3 Proteins 0.000 description 1
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 1
- 101000876511 Homo sapiens General transcription and DNA repair factor IIH helicase subunit XPD Proteins 0.000 description 1
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 1
- 101000577881 Homo sapiens Macrophage metalloelastase Proteins 0.000 description 1
- 101001134216 Homo sapiens Macrophage scavenger receptor types I and II Proteins 0.000 description 1
- 101000693721 Homo sapiens SAM and SH3 domain-containing protein 1 Proteins 0.000 description 1
- 101001047642 Homo sapiens Serine/threonine-protein kinase LATS1 Proteins 0.000 description 1
- 101001094647 Homo sapiens Serum paraoxonase/arylesterase 1 Proteins 0.000 description 1
- 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 206010022095 Injection Site reaction Diseases 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 1
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 101150105104 Kras gene Proteins 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010057481 Lupus pneumonitis Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102100027998 Macrophage metalloelastase Human genes 0.000 description 1
- 101710134306 Macrophage scavenger receptor types I and II Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 206010057269 Mucoepidermoid carcinoma Diseases 0.000 description 1
- 101100478455 Mus musculus Sspn gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010052399 Neuroendocrine tumour Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 238000013494 PH determination Methods 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 208000025618 Paget disease of nipple Diseases 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108091008611 Protein Kinase B Proteins 0.000 description 1
- 201000008183 Pulmonary blastoma Diseases 0.000 description 1
- 206010037394 Pulmonary haemorrhage Diseases 0.000 description 1
- 108010068097 Rad51 Recombinase Proteins 0.000 description 1
- 102000002490 Rad51 Recombinase Human genes 0.000 description 1
- 102100025543 SAM and SH3 domain-containing protein 1 Human genes 0.000 description 1
- 101100017043 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HIR3 gene Proteins 0.000 description 1
- 235000012377 Salvia columbariae var. columbariae Nutrition 0.000 description 1
- 240000005481 Salvia hispanica Species 0.000 description 1
- 235000001498 Salvia hispanica Nutrition 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 102100024031 Serine/threonine-protein kinase LATS1 Human genes 0.000 description 1
- 102100035476 Serum paraoxonase/arylesterase 1 Human genes 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 206010042658 Sweat gland tumour Diseases 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000019297 Well-differentiated fetal adenocarcinoma of the lung Diseases 0.000 description 1
- JADBYUOUTJEIQC-WGJAFFAESA-J [Mg+2].C(\C=C\C(=O)O)(=O)O.C(CCCCCCCCCCCCCCCCC)(=O)[O-].[Ca+2].C(CCCCCCCCCCCCCCCCC)(=O)[O-].C(CCCCCCCCCCCCCCCCC)(=O)[O-].C(CCCCCCCCCCCCCCCCC)(=O)[O-] Chemical compound [Mg+2].C(\C=C\C(=O)O)(=O)O.C(CCCCCCCCCCCCCCCCC)(=O)[O-].[Ca+2].C(CCCCCCCCCCCCCCCCC)(=O)[O-].C(CCCCCCCCCCCCCCCCC)(=O)[O-].C(CCCCCCCCCCCCCCCCC)(=O)[O-] JADBYUOUTJEIQC-WGJAFFAESA-J 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 208000002517 adenoid cystic carcinoma Diseases 0.000 description 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 208000018234 adnexal spiradenoma/cylindroma of a sweat gland Diseases 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000019409 alitame Nutrition 0.000 description 1
- 108010009985 alitame Proteins 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 229960001504 aspartame acesulfame Drugs 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000016894 basaloid carcinoma Diseases 0.000 description 1
- 201000000450 basaloid squamous cell carcinoma Diseases 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 229960001716 benzalkonium Drugs 0.000 description 1
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 208000011892 carcinosarcoma of the corpus uteri Diseases 0.000 description 1
- 229950008138 carmellose Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000014167 chia Nutrition 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- RRPFCKLVOUENJB-UHFFFAOYSA-L disodium;2-aminoacetic acid;carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O.NCC(O)=O RRPFCKLVOUENJB-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 201000007273 ductal carcinoma in situ Diseases 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000009261 endocrine therapy Methods 0.000 description 1
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 1
- 201000003908 endometrial adenocarcinoma Diseases 0.000 description 1
- 201000000330 endometrial stromal sarcoma Diseases 0.000 description 1
- 208000029179 endometrioid stromal sarcoma Diseases 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 208000029382 endometrium adenocarcinoma Diseases 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 108700020302 erbB-2 Genes Proteins 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- ZYBWTEQKHIADDQ-UHFFFAOYSA-N ethanol;methanol Chemical compound OC.CCO ZYBWTEQKHIADDQ-UHFFFAOYSA-N 0.000 description 1
- SSVFMICWXDVRQN-UHFFFAOYSA-N ethanol;sodium Chemical compound [Na].CCO SSVFMICWXDVRQN-UHFFFAOYSA-N 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 231100000089 gene mutation induction Toxicity 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 201000005274 large cell carcinoma with rhabdoid phenotype Diseases 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 208000016992 lung adenocarcinoma in situ Diseases 0.000 description 1
- 201000000014 lung giant cell carcinoma Diseases 0.000 description 1
- 201000000966 lung oat cell carcinoma Diseases 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 201000010953 lymphoepithelioma-like carcinoma Diseases 0.000 description 1
- NEMFQSKAPLGFIP-UHFFFAOYSA-N magnesiosodium Chemical compound [Na].[Mg] NEMFQSKAPLGFIP-UHFFFAOYSA-N 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 1
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 1
- 241000514897 mixed subtypes Species 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 208000010492 mucinous cystadenocarcinoma Diseases 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- 208000014761 nasopharyngeal type undifferentiated carcinoma Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- ITVGXXMINPYUHD-CUVHLRMHSA-N neohesperidin dihydrochalcone Chemical compound C1=C(O)C(OC)=CC=C1CCC(=O)C(C(=C1)O)=C(O)C=C1O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ITVGXXMINPYUHD-CUVHLRMHSA-N 0.000 description 1
- 229940089953 neohesperidin dihydrochalcone Drugs 0.000 description 1
- 235000010434 neohesperidine DC Nutrition 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 208000016065 neuroendocrine neoplasm Diseases 0.000 description 1
- 201000011519 neuroendocrine tumor Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- IWZKICVEHNUQTL-UHFFFAOYSA-M potassium hydrogen phthalate Chemical compound [K+].OC(=O)C1=CC=CC=C1C([O-])=O IWZKICVEHNUQTL-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 201000003804 salivary gland carcinoma Diseases 0.000 description 1
- 208000014212 sarcomatoid carcinoma Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000003746 solid phase reaction Methods 0.000 description 1
- 238000003836 solid-state method Methods 0.000 description 1
- 238000010671 solid-state reaction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 201000005290 uterine carcinosarcoma Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Definitions
- the present invention relates to inclusion complexes between fulvestrant and a cyclodextrin, and formulations thereof. Methods of preparing fulvestrant inclusion complexes are also provided. Moreover, the present invention relates to the use of inclusion complexes of, and pharmaceutical formulations comprising, fulvestrant and a cyclodextrin in the treatment of a disease or condition that is or is believed to be responsive to anti-estrogen therapy and/or ER-downregulation, such as cancer.
- Fulvestrant (7-alpha-[9-(4,4,5,5,5-penta fluoropentylsulphinyl)nonyl]estra-1,3,5-(10)-trien-3,17-beta-diol), has the structural formula (I):
- Fulvestrant contains 6 asymmetric carbon atoms and a stereogenic sulphoxide in the side chain.
- the active ingredient of FASLODEXTM is a mixture of 2 diastereoisomers:fulvestrant sulphoxide A and B, having the same absolute configuration at each of the stereogenic centers in the steroid system but different absolute configurations at the sulphur atom.
- Commercially available Fulvestrant is a mixture of two diastereoisomers, Fulvestrant Sulphoxide A and Fulvestrant Sulphoxide B. Fulvestrant formulations have been described in, for example, U.S. Pat. Nos. 6,774,122 and 7,456,160.
- Fulvestrant acts as an estrogen receptor antagonist without agonist properties, blocking the trophic actions of estrogens without itself having any partial agonist (estrogen-like) activity on the endometrium. Fulvestrant binds to estrogen receptors (ERs) in a competitive manner with affinity comparable with that of estradiol and downregulates the ER protein in human breast cancer cells. Data from pro-clinical studies indicated that fulvestrant is effective against human breast cancer cells and xenografts displaying acquired resistance to tamoxifen or letrozole. See, Osborne et al, Cancer Chemother.
- FASLODEX® is currently indicated for use in the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Bross et al., The Oncologist, 7:477-480 (2002).
- Fulvestrant's characteristics such as having a very high lipophilicity, extremely low aqueous solubility and the fact that it is only ionized at very high pH, present formulation challenges and account for its administration as an oily intramuscular injection.
- Commercially available FASLODEX® is an intramuscular injection of 250 mg fulvestrant in a sterile oily solution in either a single 5 ml pre-filled syringe or two 2.5 ml pre-filled syringes, as long acting injection(s).
- the long acting FASLODEX® intramuscular depot formulation contains benzyl alcohol and castor oil as solvents and is designed to deliver the dose of 250 mg of fulvestrant over a 1 month period from a single 5 ml intramuscular injection in the buttock or two 2.5 ml intramuscular injection into the buttocks. Bross et al., The Oncologist, 7:477-480 (2002). While this required monthly dose of 250 mg or bi-monthly dose of 125 mg of fulvestrant is effective, it takes approximately 3-6 months to achieve steady-state plasma levels of fulvestrant.
- Intramuscular injections may also be inconvenient to the patient and be a source of anxiety, which can adversely impact patient compliance.
- the majority of respondants generally preferred administration via daily tablets. L. Fallowfield, et ah, Annals of Oncology, 17: 205-210 (2006).
- intramuscular injections are not suitable for all patients. For example, patients with certain blood disorders (e.g., bleeding diatheses, thrombocytopenia) or receiving anticoagulants may not be suitable candidates for administration of fulvestrant by intramuscular injection.
- fulvestrant via non-invasive formulations, such as oral delivery, have been explored, but adequate bioavailability, aqueous solubility, and target formulation concentration could not be achieved, presumably due to the high lipophilicity and low aqueous solubility of fulvestrant. See, e.g., Harrison M., et al., (2003) Proc. ASCO, 22: 45, abstract 311.
- fulvestrant formulations such as formulations that render fulvestrant suitable for oral, intranasal and/or sublingual administration.
- the present invention provides inclusion complexes, kits, formulations, and unit dosages comprising fulvestrant and a cyclodextrin. Also provided are methods of producing fulvestrant inclusion complexes and methods of treating a disease or indication that is responsive to fulvestrant therapy comprising administering a fulvestrant inclusion complex or formulation thereof to an individual.
- an inclusion complex comprising a) a cyclodextrin; and b) a compound of the formula (I):
- the compound of formula (I) is also referred to herein as “fulvestrant”.
- the compound of the formula (I) is fulvestrant sulphoxide A, fulvestrant sulphoxide B, or a mixture of fulvestrant sulphoxide A and fulvestrant sulphoxide B.
- fulvestrant salts such as pharmaceutically acceptable salts, and solvates thereof, are also intended by the descriptions provided herein.
- all salt and non-salt forms of fulvestrant and solvates of the foregoing are embraced by the invention and descriptions of fulvestrant provided herein.
- the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD).
- the cyclodextrin for use in the inclusion complexes and formulations herein is a water soluble unsubstituted or substituted alpha-cyclodextrin (ACD), beta-cyclodextrin (BCD), or gamma-cyclodextrin (GCD).
- the beta-cyclodextrin is selected from the group consisting of methyl beta-cyclodextrin (MBCD), hydroxypropyl beta-cyclodextrin (HPBCD), and sulfobutylether beta-cyclodextrin (SBEBCD).
- the beta-cyclodextrin is methyl beta-cyclodextrin or hydroxypropyl beta-cyclodextrin.
- the gamma-cyclodextrin is hydroxypropyl gamma-cyclodextrin (HPGCD).
- the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD).
- provided are methods for improving the solubility of a compound of the formula (I) in water comprising combining the compound of the formula (I) with a cyclodextrin.
- a method of increasing the water solubility of a compound of formula (I) is provided, wherein the method comprises forming an inclusion complex of a cyclodextrin and a compound of the formula (I).
- the solubility of the compound of the formula (I), when present as an inclusion complex with a cyclodextrin in deionized water at 20° C. is increased by at least about or about 1.5-fold or 2-fold, when compared to the solubility of the compound of formula (I) in uncomplexed form under the same conditions.
- the solubility, such as the aqueous solubility, of fulvestrant in an inclusion complex may be increased by at least about or about any of 3, 4, 5, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 1,000, 2,000-fold or more over uncomplexed fulvestrant.
- the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD).
- a method of increasing the oral bioavailability of a compound of formula (I) comprises forming an inclusion complex of a cyclodextrin and a compound of the formula (I).
- the oral bioavailability of the compound of the formula (I), when present as an inclusion complex with a cyclodextrin is at least about 50% greater than the oral bioavailability of the compound of the formula (I) in uncomplexed form.
- Oral bioavailability, and comparisons thereof, may be assessed by methods known in the art, including any of the specific methods described herein.
- the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD).
- an inclusion complex of a compound of formula (I) and a cyclodextrin are provided, wherein the inclusion complex is capable of inducing a greater maximum concentration (Cm) of the compound systemically than what is achievable when the compound is administered alone in the same amount and under the same conditions.
- an inclusion complex of the compound of formula (I) is capable of inducing at least about or about 1.5 or 2 or more times greater C max for the compound systemically than what is achievable when the compound is administered alone in the same amount and under the same conditions.
- the C max of fulvestrant when administered to an individual as an inclusion complex with a cyclodextrin, is at least about 2 times greater than the C max of fulvestrant administered alone under the same conditions.
- the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD).
- an inclusion complex of a compound of formula (I) and a cyclodextrin is provided, wherein the inclusion complex is capable of inducing a greater area under the plasma concentration vs. time curve (AUC) of the compound than what is achievable when the compound is administered alone (in the absence of a cyclodextrin) in the same amount and under the same conditions.
- an inclusion complex of the compound of formula (I) is capable of inducing at least about or about 1 or 2 or more times greater AUC of compound than what is achievable when the compound is administered alone in the same amount and under the same conditions.
- the AUC of fulvestrant when administered to an individual as an inclusion complex with a cyclodextrin, is at least about 2 times greater than the AUC of fulvestrant administered alone in the same amount and under the same conditions.
- the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD).
- an inclusion complex of a compound of formula (I) and a cyclodextrin is provided, wherein the inclusion complex is capable of inducing a change in the time to reach the maximum plasma level (T max ) of the compound than what is achievable when the compound is administered alone (in the absence of a cyclodextrin) in the same amount and under the same conditions.
- T max is shorter with a fulvestrant inclusion complex.
- an inclusion complex of the compound of formula (I) is capable of reducing T max by about 0.5 or 1 or 2 fold over what is achievable when the compound is administered alone in the same amount and under the same conditions.
- the T max of fulvestrant when administered to an individual as an inclusion complex with a cyclodextrin, is at least about 2 times lower than the T max of fulvestrant administered alone in the same amount and under the same conditions.
- a fulvestrant inclusion complex reduces T max by at least about or about any of 1, 2, 3, 5, 10 and 12 hours or more.
- the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD).
- an orally, intranasally, sublingually, rectally, or vaginally administered inclusion complex of a compound of formula (I) and a cyclodextrin is provided, wherein the inclusion complex may be administered together with a long acting intramuscular fulvestrant formulation (e.g., FASLODEX®), compensating for the time required for the long acting intramuscular fulvestrant formulation alone to reach steady state fulvestrant plasma concentrations.
- the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD).
- a composition comprising a cyclodextrin and a compound of the formula (I) are provided, wherein the molar ratio of the compound of formula (I) to the cyclodextrin is from about 1:1 to about 1:300.
- the composition comprises an inclusion complex of a cyclodextrin and a compound of the formula (I).
- the composition comprises a physical mixture of a cyclodextrin and a compound of the formula (I), wherein the physical mixture does not comprise or is substantially free of an inclusion complex of a cyclodextrin and a compound of the formula (I).
- the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD).
- a formulation comprising a) a cyclodextrin; b) a compound of the formula (I), or a salt thereof or solvate of the foregoing; and c) a carrier.
- the formulation comprises an inclusion complex of the compound and a cyclodextrin.
- the carrier is a pharmaceutically acceptable carrier.
- the carrier may be in liquid, solid or semi-solid form. When the carrier is a liquid, it may be aqueous or an organic solvent, or a combination thereof in any amount.
- the carrier is selected from the group consisting of a solvent, a complexing agent, a filler, a diluent, a granulating agent, a disintegrant, a lubricant, a glidant, a pH-modifier, a tonicity modifier, an adjuvant, a dye, a polymer-based film coating, and a binder.
- the carrier is one or more of water for injection, microcrystalline cellulose, glucose, sodium lauryl sulphate, crosscarmellose sodium, colloidal silica, talc, magnesium stearate, sodium benzoate, aluminum magnesium silicate, lactose, methanol, ethanol, propanol, and acetone.
- the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD).
- Formulations comprising a cyclodextrin and fulvestrant may further comprise additional formulation components, also referred to herein as additional agents.
- the formulation further comprises an antioxidant.
- the antioxidant is a water-soluble antioxidant.
- the antioxidant is fully or partially water-insoluble.
- care may be taken to reduce or avoid displacement of fulvestrant in the inclusion complex by the antioxidant.
- formulations comprising a fulvestrant inclusion complex and a water-insoluble antioxidant may contain a relatively small amount of the antioxidant or take other precautions to reduce or avoid adverse consequences of the antioxidant on an inclusion complex of fulvestrant and a cyclodextrin.
- the formulation may include combinations of two or more of the antioxidants as described herein.
- the antioxidant is selected from the group consisting of ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, malic acid, propyl gallate, sodium bisulfite, sodium sulfite, sodium metabisulfite, potassium metabisulfite, potassium bisulfite, sodium thiosulfate, sodium formaldehyde sulfoxylate, L-ascorbic acid, D-ascorbic acid, acetylcysteine, cysteine, thioglycerol, thioglycoUic acid, thiolactic acid, thiourea, dithiothreitol, dithioeythreitol, glutathione, nordihydroguaiaretic acid, tocopherol, sodium ascorbate, hypophophorous acid, and fumaric acid.
- the antioxidant is selected from the group consisting of butylated hydroxyanisole, malic acid, sodium bisulfite, sodium sulfite, sodium metabisulfite, potassium metabisulfite, potassium bisulfite, sodium thiosulfate, sodium formaldehyde sulfoxylate, L-ascorbic acid, D-ascorbic acid, cysteine, thiolactic acid, glutathione, nordihydroguaiaretic acid, sodium ascorbate, hypophophorous acid and fumaric acid.
- the antioxidant is a dietary antioxidant, including, but not limited to, vitamin E, vitamin C, beta-carotene, and selenium. Other additional agents may be employed in the formulations.
- the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD).
- a formulation comprising (a) a cyclodextrin; (b) a compound of the formula (I), or a salt thereof, or solvate of the foregoing; and (c) a carrier, is a solid formulation.
- the formulation is a semi-solid.
- the formulation is a liquid.
- the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD).
- Unit dosage forms of fulvestrant inclusion complexes and formulations comprising fulvestrant and a cyclodextrin are also provided.
- the compound of the formula (I) is present in an amount of between about 0.1 mg and about 500 mg per unit solid or semi-solid dosage form or between about 0.1 mg/mL and about 50 mg/mL in a liquid dosage form.
- the compound of the formula (I) is present in an amount of about 250 mg per unit solid or semi-solid dosage form or about 25 mg/mL in a liquid dosage form.
- the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD).
- an inclusion complex described herein is in a substantially pure form.
- Methods of administering fulvestrant inclusion complexes and formulations to an individual are also provided, as are methods of using such complexes and formulations in therapy.
- methods of treating a disease or condition that is or is believed to be responsive to anti-estrogen therapy and/or ER-downregulation are provided, wherein the methods comprise administering to an individual in need thereof a fulvestrant inclusion complex or formulation comprising fulvestrant and a cyclodextrin, wherein fulvestrant is not complexed with the cyclodextrin.
- the disease or condition is cancer.
- the cancer may be early stage cancer, non-metastatic cancer, primary cancer, advanced cancer, locally advanced cancer, metastatic cancer, cancer in remission, recurrent cancer, cancer in an adjuvant setting, cancer in a neoadjuvant setting, or cancer substantially refractory to hormone therapy.
- the cancer is selected from the group consisting of breast cancer, endometrial cancer, prostate cancer, and lung cancer.
- the cancer is breast cancer, such as hormone receptor positive metastatic breast cancer.
- the disease or condition is systemic lupus erythematosus.
- the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD).
- a method of treating a cancer in an individual in need thereof comprises administering to the individual an effective amount of an inclusion complex of a) a cyclodextrin; and b) a compound of the formula (I), or a salt thereof, or solvate of the foregoing.
- the method may also employ a fulvestrant formulation described herein, such as a formulation comprising a) a cyclodextrin; b) a compound of the formula (I), or a salt thereof or solvate of the foregoing, and c) a carrier (e.g., a pharmaceutically acceptable carrier).
- the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD).
- the individual of the methods provided herein is a human, and may be male or female.
- the human has or is suspected of having a disease or condition that is or is believed to be responsive to anti-estrogen therapy and/or ER-downregulation, such as cancer.
- the individual is a post-menopausal woman who has or is suspected of having hormone receptor positive metastatic breast cancer.
- the individual is a post-menopausal woman who has or is suspected of having hormone receptor positive metastatic breast cancer with disease progression following hormone (e.g., anti-estrogen) therapy.
- the human has or is suspected of having systemic lupus erythematosus.
- the fulvestrant inclusion complex, or a fulvestrant formulation provided herein is intranasally, orally, sublingually, rectally, and/or vaginally administered to the individual in need thereof.
- the dosage of fulvestrant in the administered dose is between about 0.1 mg and about 500 mg per unit solid or semi-solid dosage form or between about 0.1 mg/mL and about 50 mg/mL in a liquid dosage form.
- the individual is administered a combination of an effective amount of a fulvestrant inclusion complex or formulation and one other pharmaceutical agent.
- the other pharmaceutical agent is an anti-cancer agent.
- the other pharmaceutical agent is selected from the group consisting of anastrozole (e.g., ARIMIDEX®), letrozole (e.g., FEMARA®), exemestane (e.g., AROMASIN®), aminoglutethimide (e.g., Cytadren®), vorozole (e.g., RIVIZOR®), formestane (e.g., LENTARON®), fadrozole (e.g., AFEMA®), testolactone (e.g., TESLAC®), gefitinib (e.g., IRESSA®), trastuzumab (e.g., HERCEPTIN®), crlotimnib (e.g., TARCEVA®), tipifanib (e.g., ZARNESTRA®), uncomplexed fulvestrant (e.g., FASLODEX® (AstraZeneca Pharmaceuticals LP)), and an antioxidant.
- two or more other pharmaceutical agents are intended for use in the methods, such as two or more of the anti-cancer agents provided herein.
- the inclusion complex and the other pharmaceutical agent are administered simultaneously or sequentially.
- the inclusion complex and the other pharmaceutical agent are administered concurrently.
- the inclusion complex and the other pharmaceutical agent may be administered, whether simultaneously, sequentially or otherwise, via the same or different routes.
- the methods comprise administering a) a composition comprising and/or an inclusion complex of a cyclodextrin and a compound of the formula (I), or a salt thereof or solvate of the foregoing, and b) a compound of the formula (I) in uncomplexed form.
- a composition comprising and/or an inclusion complex of a cyclodextrin and a compound of the formula (I), or a salt thereof, or solvate of the foregoing is administered orally, intranasally, sublingually, rectally, and/or vaginally and a compound of the formula (I) is administered intramuscularly.
- the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD).
- cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD).
- kits comprising an inclusion complex of a) a cyclodextrin; and b) a compound of the formula (I), or a salt thereof or solvate of the foregoing, or a formulation thereof.
- the kit may further comprise instructions for use, such as for use in the treatment of a disease or condition that is or is believed to be responsive to anti-estrogen therapy and/or ER-downregulation.
- a kit comprises instructions for use in the treatment of cancer or systemic lupus erythematosus.
- the kit may also comprise another pharmaceutical agent.
- a kit comprising a) a cyclodextrin; b) a compound of the formula (I), or a salt thereof, or solvate of the foregoing, or a formulation thereof; and c) an additional pharmaceutical agent selected from anastrozole (e.g., ARIMIDEX®), letrozole (e.g., FEMARA®), exemestane (e.g., AROMASIN®), aminoglutethimide (e.g., Cytadren®), vorozole (e.g., RIVIZOR®), formestane (e.g., LENTARON®), fadrozole (e.g., AFEMA®), testolactone (e.g., TESLAC®), gefitinib (e.g., IRESSA®), trastuzumab (e.g., HERCEPTIN®), edotinib (e.g., TARCEVA®), tip
- anastrozole
- uncomplexed fulvestrant when employed, in one aspect it is formulated in an oil-based carrier (e.g., arachis oil, sesame oil, castor oil, or neutral oil (e.g., MIGLYOL® 810 or MIGLYOL® 812)), or in a non-aqueous ester solvent (e.g., benzyl benzoate, ethyl oleate, isopropyl myristate, isopropyl palmitate, or a mixture or combination of any thereof) and an alcohol (e.g., ethanol, benzyl alcohol, or a mixture or combination of any thereof).
- the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD).
- an inclusion complex of a compound of the formula (I) and a cyclodextrin comprising admixing a compound of the formula (I), or salt thereof, or solvate of the foregoing, with a cyclodextrin.
- the method further comprises adding a solvent, mixed solvent, or buffer to the compound of the formula (I), the cyclodextrin, and/or a mixture thereof. If a solvent, mixed solvent or buffer is employed to form an inclusion complex, in one aspect the solvent, mixed solvent or buffer is removed after formulation of the inclusion complex to provide an inclusion complex free of or substantially free of solvent, mixed solvent or buffer.
- the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD).
- the step (a) further comprises admixing a suitable polymer.
- the method utilizes a suitable amount of solvent, such as water for injection (WFI).
- the method utilizes a suitable amount of a buffer, which in one aspect is a phosphate-citrate buffer.
- the method utilizes a suitable polymer, which in one aspect is selected from polyvinylpyrrolidone, hydroxypropyl methylcellulose, carboxymethylcellulose, and PLASDONE® Povidone.
- the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD).
- FIG. 1 shows a fulvestrant HPLC calibration data plot.
- FIG. 2 shows a fulvestrant aqueous solubility data plot in the presence and absence of various concentrations of alpha-cyclodextrin (ACD).
- ACD alpha-cyclodextrin
- FIG. 3 shows a fulvestrant aqueous solubility data plot in the presence and absence of various concentrations of beta-cyclodextrin (BCD).
- FIG. 4 shows a fulvestrant aqueous solubility data plot in the presence and absence of various concentrations of methyl beta-cyclodextrin (MBCD).
- MBCD methyl beta-cyclodextrin
- FIG. 5 shows a fulvestrant aqueous solubility data plot in the presence and absence of various concentrations of hydroxypropyl beta-cyclodextrin (HPBCD).
- FIG. 6 shows a fulvestrant aqueous solubility data plot in the presence and absence of various concentrations of sulfobutylether beta-cyclodextrin (SBEBCD).
- FIG. 7 shows a fulvestrant aqueous solubility data plot in the presence and absence of various concentrations of gamma-cyclodextrin (GCD).
- GCD gamma-cyclodextrin
- FIG. 8 shows a fulvestrant aqueous solubility data plot in the presence and absence of various concentrations of hydroxypropyl gamma-cyclodextrin (HPGCD).
- HPGCD hydroxypropyl gamma-cyclodextrin
- FIG. 9 shows a fulvestrant plasma concentration data plot generated for Experiment I (oral gavage of fulvestrant-HPBCD).
- FIG. 10 shows a fulvestrant plasma concentration data plot generated for Experiment II (oral gavage of fulvestrant-MBCD).
- FIG. 11 shows a fulvestrant plasma concentration data plot generated for Experiment II (oral gavage without cyclodextrin (CD)).
- FIG. 12 shows average fulvestrant plasma concentration data plot generated for Experiments I, II, and III (oral gavage of HPBCD, MBCD or without CD).
- FIG. 13 shows fulvestrant plasma concentration data plot generated for oral gavage of fulvestrant-HPBCD at the dose of 5 mg/kg.
- FIG. 14 shows a plot of the mean fulvestrant plasma concentrations over time.
- the present invention provides inclusion complexes, kits, formulations, and unit dosages comprising fulvestrant and a cyclodextrin. Also provided are methods of producing the inclusion complexes as well as methods of treatment.
- inclusion complexes comprising fulvestrant and a cyclodextrin strikingly enhance the aqueous solubility of fulvestrant as compared to fulvestrant in an uncomplexed form, suggesting that such inclusion complexes enhance the oral, intranasal and/or sublingual bioavailability of fulvestrant and may find particular use in administration of fulvestrant via these dosage routes.
- Fulvestrant inclusion complexes may also provide superior or complimentary pharmacokinetics as compared to uncomplexed fulvestrant delivered in the same amount and under the same conditions, including greater C max and AUC values and a reduction in T max .
- therapeutic plasma levels of fulvestrant may be achieved sooner with a fulvestrant inclusion complex as compared to long acting intra-muscular injectable formulations of uncomplexed fulvestrant, which can have a particular benefit to patients.
- inclusion complex is intended a complex wherein a moiety of a compound (e.g., a moiety of fulvestrant) is inserted, at least partially, into the cavity of a cyclodextrin (e.g., methyl beta-cyclodextrin (MBCD) or hydroxypropyl beta-cyclodextrin (HPBCD)).
- a cyclodextrin e.g., methyl beta-cyclodextrin (MBCD) or hydroxypropyl beta-cyclodextrin (HPBCD)
- MBCD methyl beta-cyclodextrin
- HPBCD hydroxypropyl beta-cyclodextrin
- solubility intends the solubility with reference to the total amount of compound (e.g., including the amount of compound in both complexed and uncomplexed form).
- treatment is an approach for obtaining beneficial or desired results, including clinical results.
- “delaying” means to defer, hinder, slow, retard, stabilize, and/or postpone development of one or more symptoms of the disease or condition (e.g., cancer or systemic lupus erythematosus).
- This delay can be of varying lengths of time, depending on the history of the disease and/or individual being treated.
- a sufficient or significant delay can, in effect, encompass prevention, in that the individual does not develop the condition (e.g., cancer or systemic lupus erythematosus).
- “pharmaceutically acceptable” with respect to a material refers to a material that is not biologically or otherwise unsuitable, e.g., the material may be incorporated (e.g., at the time of manufacturing or administration) into a pharmaceutical composition administered to an individual without causing significant undesirable biological effects.
- Pharmaceutically acceptable carriers or excipients have preferably met the required standards of toxicological and manufacturing testing and/or are included on the Inactive Ingredient Guide prepared by the U.S. Food and Drug administration.
- an effective amount intends such amount of a compound (e.g., fulvestrant) or an inclusion complex (e.g., an inclusion complex comprising fulvestrant and a cyclodextrin), or a combination therapy comprising at least one of the foregoing, which should be effective in a given therapeutic form.
- an effective amount may be in one or more doses, i.e., a single dose or multiple doses may be required to achieve the desired treatment endpoint.
- An effective amount may be considered in the context of administering one or more additional pharmaceutical agents in a combination therapy, and an inclusion complex may be considered to be given in an effective amount if, when administered sequentially, simultaneously, or continuously with one or more additional pharmaceutical agents, one or more desirable or beneficial result(s) may be or are achieved.
- “Combination therapy” intends a first therapy (e.g., fulvestrant or an inclusion complex thereof) used in conjunction with a second therapy (e.g., surgery and/or an additional pharmaceutical agent) for treating, stabilizing, preventing, and/or delaying a disease or condition.
- Administration in “conjunction with” another compound includes administration in the same or different composition(s), either sequentially, simultaneously, or continuously, through the same or different routes within a given time period.
- the combination therapy optionally includes one or more pharmaceutically acceptable carriers or excipients, non-pharmaceutically active compounds, and/or inert substances.
- a first therapy and second therapy in a combination therapy are administered with a time separation of no more than about 15 minutes, such as no more than about any of 10, 5, or 1 minutes.
- the first and second therapies may be contained in the same composition (e.g., a composition comprising both a first and second therapy) or in separate compositions (e.g., a first therapy in one composition and a second therapy is contained in another composition).
- a time separation in the context of simultaneous administration e.g., 5 minutes
- either the first therapy or the second therapy may be administered first.
- the term “sequential administration” means that the first therapy and second therapy in a combination therapy are administered with a time separation of more than about 15 minutes, such as more than about any of 20, 30, 40, 50, 60, or more minutes. Either the first therapy or the second therapy may be administered first.
- the first and second therapies are contained in separate compositions, which may be contained in the same or different packages or kits.
- the term “concurrent administration” means that the administration of the first therapy and that of a second therapy in a combination therapy overlap with each other.
- substantially pure in reference to an inclusion complex intends a preparation of the inclusion complex that contains about or less than about 15% impurity, wherein the impurity intends a compound other than an inclusion complex of fulvestrant and a cyclodextrin.
- substantially pure preparations include preparations that contain less than about 15% impurity, such as preparations that contain less than about any one of 15%, 12%, 10%, 8%, 5%, 3%, 2%, 1% and 0.5% impurity.
- references to “about” a value or parameter herein includes (and describes) variations that are directed to that value or parameter per se. For example, a description referring to “about X” includes the description of “X”.
- the present invention encompasses not only the entire group listed as a whole, but each member of the group individually and all possible subgroups of the main group, such as the main group absent one or more of the group members.
- the present invention also envisages the explicit exclusion of one or more of any of the group members.
- Cyclodextrins (“CDs”) are cyclic oligosaccharide structures composed of various glucopyranose units, such as 6, 7 and 8 units (alpha-, beta- and gamma-cyclodextrin, respectively) bound together to form a ring. Cyclodextrins characterized by a cone-like molecular shape and comprising a relatively hydrophobic central cavity and hydrophilic outer surface. The hydrophobic nature of the central cavity, in certain cases, endows the cyclodextrin with the ability to form inclusion complexes with a hydrophobic “guest” molecule. Polar and ionic groups are generally less likely to be included within the hydrophobic cavity than less-polar and non-ionic groups.
- a guest molecule is held within the hydrophobic cavity of the cyclodextrin “host” molecule.
- the inclusion complex may be stabilized by a number of forces, such as van der Waals attractive forces, electrostatics and hydrogen bonding.
- cyclodextrin molecule Although many factors affect the stability of an inclusion complex, the ability of a cyclodextrin molecule to form an inclusion complex with a guest molecule is a function of two key factors. The fast is steric and depends on the relative size of the cyclodextrin to the size of the guest molecule or certain key functional groups within the guest. The second factor is the thermodynamic interactions among different components of the system, such as the cyclodextrin, the guest, and the solvent, where present.
- Inclusion complexes may give rise to beneficial properties, which are not achievable otherwise, such as: solubility enhancement of highly insoluble guests; stabilization of labile guests against the degradative effects of oxidation, visible or UV light and heat; control of volatility and sublimation; physical isolation of incompatible compounds; chromatographic separations; taste modification by masking off flavors, unpleasant odors, and controlled release of drugs.
- Cyclodextrin inclusion complexes in some cases, may provide favorable flow, binding, and compaction properties to aid in drug formulation (e.g., in facilitating tablet compression).
- Inclusion complexes of fulvestrant as provided herein were discovered to notably enhance the aqueous solubility of fulvestrant as compared to fulvestrant in an uncomplexed form, suggesting that such inclusion complexes enhance the bioavailability of fulvestrant and may be used in the oral, intranasal, and/or sublingual administration of fulvestrant.
- Administration of fulvestrant via non-parenteral routes is significant and may offer patients more convenient, non-invasive treatment options, reducing the incidence of adverse side effects associated with parenteral fulvestrant therapy, and enhancing overall patient compliance.
- Non-parenteral fulvestrant formulations may also have a positive effect on overall therapeutic outcome.
- such formulations may be used alone, or together with parenteral administration of fulvestrant, to achieve steady-state drug levels sooner than with presently available fulvestrant parenteral formulations.
- higher dosing levels of fulvestrant may be achievable with such formulations, which can enhance ER downregulation and may provide an additional therapeutic benefit.
- Inclusion complexes provided herein comprise fulvestrant and a cyclodextrin, or a salt thereof, or a solvate (e.g., hydrate) of the foregoing.
- the inclusion complexes may be used alone, or together with an additional pharmaceutical agent, in the treatment of a disease or condition provided herein, such as cancer.
- Other agents may also be incorporated with the inclusion complex, where applicable.
- an inclusion complex may comprise a cyclodextrin and fulvestrant, with an antioxidant that is not itself a pharmaceutical agent but provides other benefits, such as stabilizing the complex over time, and which does not adversely effect the fulvestrant inclusion complex.
- Formulations comprising a fulvestrant inclusion complex, and optional additional pharmaceutical or other agents, together with a carrier, such as a pharmaceutically acceptable aqueous carrier, are also provided.
- an inclusion complex is an inclusion complex of a cyclodextrin and fulvestrant sulphoxide A, fulvestrant sulphoxide B, or a mixture of fulvestrant sulphoxide A and fulvestrant sulphoxide B.
- a preparation of an inclusion complex is a preparation of a cyclodextrin and substantially pure fulvestrant sulphoxide A or substantially pure fulvestrant sulphoxide B.
- a preparation of an inclusion complex is a preparation of a cyclodextrin and a mixture of fulvestrant sulphoxide A and fulvestrant sulphoxide B.
- Examples of a cyclodextrin for use in the inclusion complex include, but are not limited to, water soluble unsubstituted or substituted alpha-cyclodextrin (ACD), beta-cyclodextrin (BCD), and gamma-cyclodextrin (GCD).
- Examples of substituted beta-cyclodextrins that may be employed in the inclusion complexes herein include, but are not limited to, methyl beta-cyclodextrin (MBCD), hydroxypropyl beta-cyclodextrin (HPBCD), and sulfobutylether beta-cyclodextrin (SBEBCD).).
- substituted gamma-cyclodextrins examples include, but are not limited to, hydroxypropyl gamma-cyclodextrin (HPGCD). Mixtures of cyclodextrins may also be employed. For example, a formulation comprising fulvestrant and a mixture of two or three or four or more cyclodextrins is also provided.
- HPGCD hydroxypropyl gamma-cyclodextrin
- cyclodextrin may be of the same cyclodextrin class (e.g., two alpha-cyclodextrins) or different chemical classes (e.g., one alpha-cyclodextrin and one beta- or gamma-cyclodextrin).
- the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD).
- a cyclodextrin is obtained from a commercial source, including, but not limited to cyclodextrins sold under the following tradenames CAVASOL® W6 HP (Wacker Chemie AG, Kunststoff, Germany), CAVASOL® W6 HP TL (Wacker Chemie AG, Kunststoff, Germany), CAVAMAX® W6 Pharma (Wacker Chemie AG, Kunststoff, Germany), CAVASOL® W7 HP (Wacker Chemie AG, Kunststoff, Germany), CAVASOL® W7 HP Pharma (Wacker Chemie AG, Kunststoff, Germany), CAVASOL® W7 HP TL (Wacker Chemie AG, Kunststoff, Germany), CAVASOL® W7 M (Wacker Chemie AG, Kunststoff, Germany), CAVASOL® W7 M Pharma (Wacker Chemie AG, Kunststoff, Germany), CAVASOL® W7 M TL (Wacker Chemie AG, Kunststoff, Germany), CAVASOL® W8 HP (Wacker Chemie AG, Kunststoff, Germany), CAVASOLOL® W6
- the inclusion complex may comprise fulvestrant or a salt thereof or a solvate (e.g. a hydrate or alcoholate) of the foregoing that is partially or completely included into the cavity of a cyclodextrin molecule. Accordingly, one or more cyclodextrin molecules may be associated with each fulvestrant molecule.
- the complex may exist in a variety of molar ratios, which may be dependent on a variety of physical factors during the formation of the complex, and be transitional and vary during formation.
- fulvestrant is fully included into the cavity of a cyclodextrin molecule. In some embodiments, fulvestrant is partially included into the cavity of a cyclodextrin molecule. In some embodiments of the inclusion complex, the molar ratio of the fulvestrant to cyclodextrin is from any of about 1:1 to about 1:300; about 1:1 to about 1:150; about 1:1 to about 1:100; about 1:1 to about 1:50, about 1:1 to about 1:25; about 1:1 to about 1:10; about 1:1 to about 1:5; about 1:1 to about 1:4; about 1:1 to about 1:3; about 1:1 to about 1:2.5; and about 1:1 to about 1:2, or is about any of 1:1, 1:2, and 1:3.
- the inclusion complexes described herein may increase the solubility of fulvestrant.
- methods for improving the solubility of fulvestrant in water comprising complexing fulvestrant with a cyclodextrin.
- the solubility of fulvestrant in a fulvestrant inclusion complex, in deionized water at 20° C. is at least about 10-fold greater than the solubility of fulvestrant in uncomplexed form.
- a fulvestrant inclusion complex increases the solubility of fulvestrant by at least any of about or by about 10-, 25-, 50-, 75-, 100-, 250-, 500-, 750-, 1000-, 1500-, 2000-, 3000-, or 4000-fold compared to the solubility of fulvestrant in uncomplexed form.
- the uncomplexed fulvestrant is present in an oil-based carrier (e.g., arachis oil, sesame oil, castor oil, or neutral oil (e.g., MIGLYOLTM 810 or MIGLYOL® 812)), or in a non-aqueous ester solvent (e.g., benzyl benzoate, ethyl oleate, isopropyl myristate, isopropyl palmitate, or a mixture or combination of any thereof) and an alcohol (e.g., ethanol, benzyl alcohol, or a mixture or combination of any thereof).
- an uncomplexed fulvestrant is obtained from a commercial source, including, but not limited to, the fulvestrant formulation sold as the tradename FASLODEX®.
- the inclusion complexes described herein may provide improved pharmacokinetic properties for fulvestrant. Such changes in pharmacokinetic properties may result in desired therapeutic effects, such as a more rapid onset of therapeutic effect and/or less prolonged and/or reduced effects of a disease or condition for which fulvestrant treatment is obtained (e.g., cancer or systemic lupus erythematosus).
- desired therapeutic effects such as a more rapid onset of therapeutic effect and/or less prolonged and/or reduced effects of a disease or condition for which fulvestrant treatment is obtained (e.g., cancer or systemic lupus erythematosus).
- the inclusion complexes described herein may result in increased oral bioavailability of fulvestrant.
- the oral bioavailability of fulvestrant from an inclusion complex comprising fulvestrant and a cyclodextrin is at least any of about or about 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, or 90% greater than the oral bioavailability of fulvestrant alone under the same conditions.
- Methods of increasing oral bioavailability of fulvestrant by at least any of about or by about any of 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, or 90% as compared to administration of uncomplexed fulvestrant under the same conditions comprising administering fulvestrant in the form of an inclusion complex comprising fulvestrant and a cyclodextrin.
- Bioavailability assessments and comparisons may be determined using standard techniques known in the art (e.g., measuring AUC(fulvestrant inclusion complex)/AUC(uncomplexed fulvestrant) ⁇ 100).
- the conditions for assessing the amount of increase in bioavailability of an inclusion complex of fulvestrant as compared to fulvestrant in uncomplexed form include orally or intranasally administering any of about 5 mg/mL, about 10 mg/mL, about 15 mg/mL, about 20 mg/mL, about 25 mg/mL, about 30 mg/mL, about 35 mg/mL, about 40 mg/mL, or about 50 mg/mL of fulvestrant (in the appropriate complexed or uncomplexed form) in a carrier and at room temperature.
- the fulvestrant can be administered at room temperature in an aqueous solution (e.g., WFI) in the presence or absence of a buffer.
- the inclusion complexes described herein may result in an increased Cm of fulvestrant following administration of an amount of fulvestrant as an inclusion complex when compared to administering the same amount of fulvestrant, via the same route and under the same conditions, in uncomplexed form.
- the inclusion complexes described herein may also result in an increased C max of fulvestrant following administration of an amount of fulvestrant as an inclusion complex when compared to administering the same amount of fulvestrant via a different administration route, in uncomplexed form.
- C max of fulvestrant may be increased upon oral and/or intranasal administration of an amount of fulvestrant as an inclusion complex with a cyclodextrin when compared to administration of the same amount of uncomplexed fulvestrant as an intramuscular injection.
- the inclusion complexes described herein may result in an increased C max for fulvestrant within about 3 hours after oral administration of a fulvestrant inclusion complex to an individual.
- the C max of fulvestrant from an inclusion complex comprising fulvestrant and a cyclodextrin is at least about or about any of 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 40, 50, 60, 70, 80, 90, or 100 times greater than the C max of uncomplexed fulvestrant administered in the same amount and under the same conditions as the inclusion complex.
- the conditions comprise orally or intranasally administering any of about 5 mg/mL, about 10 mg/mL, about 15 mg/mL, about 20 mg/mL, about 25 mg/mL, about 30 mg/mL, about 35 mg/mL, about 40 mg/mL, or about 50 mg/mL of fulvestrant (in the appropriate complexed or uncomplexed form) at room temperature in an aqueous solution (e.g., WFI).
- aqueous solution e.g., WFI
- the inclusion complexes described herein may result in a decreased T max for fulvestrant following administration.
- the T max of fulvestrant from an inclusion complex comprising fulvestrant and a cyclodextrin is at least about or about any of 2%, 5/%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, or 90% lower than the T max of fulvestrant administered alone under the same conditions.
- the inclusion complexes described herein may also result in a decrease in T max following administration of an amount of fulvestrant as an inclusion complex when compared to administering the same amount of fulvestrant via a different administration route, in uncomplexed form.
- T max of fulvestrant may be decreased upon oral and/or intranasal administration of an amount of fulvestrant as an inclusion complex with a cyclodextrin when compared to administration of the same amount of fulvestrant as an intramuscular injection.
- the value of T max upon oral and/or intranasal administration of an amount of fulvestrant as an inclusion complex may be at least about or about any of 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, or 90% lower than the T max obtained by administration of the same amount of uncomplexed fulvestrant as an intramuscular injection.
- the conditions comprise orally or intranasally administering any of about 5 mg/mL, about 10 mg/mL, about 15 mg/mL, about 20 mg/mL, about 25 mg/mL, about 30 mg/mL, about 35 mg/mL, about 40 mg/mL, or about 50 mg/mL of fulvestrant (in the appropriate complexed or uncomplexed form) at room temperature in an aqueous solution (e.g., WFI).
- aqueous solution e.g., WFI
- the inclusion complexes described herein may result in decreasing the therapeutic time of onset for fulvestrant such that the therapeutic effect occurs sooner with a fulvestrant inclusion complex as compared to fulvestrant administered in an uncomplexed form.
- the therapeutic time of onset of fulvestrant from an inclusion complex comprising fulvestrant and a cyclodextrin is decreased by at least about or about any of 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, or 90% than the therapeutic time of onset of uncomplexed fulvestrant administered in the same amount and under the same conditions.
- an inclusion complex of fulvestrant decreases the therapeutic time of onset for fulvestrant by at least about or about any of 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, or 90% as compared to the therapeutic time of onset of uncomplexed fulvestrant administered in the same amount as an intramuscular injection.
- the fulvestrant inclusion complex is provided by oral or intranasal administration.
- the conditions comprise orally or intranasally administering any of about 5 mg/mL, about 10 mg/mL, about 15 mg/mL, about 20 mg/mL, about 25 mg/mL, about 30 mg/mL, about 35 mg/mL, about 40 mg/mL, or about 50 mg/mL of fulvestrant (in the appropriate complexed or uncomplexed form) at room temperature in an aqueous solution (e.g., WFI).
- aqueous solution e.g., WFI
- the inclusion complex comprising fulvestrant and a cyclodextrin is in substantially pure form.
- a preparation of substantially pure inclusion complex is provided wherein the preparation contains about or less than about any one of 15/%, 12%, 10%, 8%, 5%, 3%, 2%, 1% and 0.5% impurity.
- an inclusion complex may comprise a compound of formula (I) and/or a salt thereof.
- An inclusion complex may also comprise a solvate of a compound of formula (I) or a salt thereof.
- Solvates may contain either stoichiometric or non-stoichiametric amounts of a solvent, and are often formed during the process of crystallization.
- a solvent is water and the solvate is a hydrate.
- a solvent is an alcohol and the solvate is an alcoholate.
- the inclusion complexes described herein can exist in unsolvated forms as well as solvated forms.
- the inclusion complexes may also include hydrated forms or salt forms.
- inclusion complexes may be prepared on the basis of liquid state, solid state or semi-solid state reaction between the components. This may be accomplished by dissolving the cyclodextrin and fulvestrant in a suitable solvent or mixture of solvents. If desired, an inclusion complex so obtained may be subsequently isolated by crystallization, evaporation, spray drying or freeze drying.
- a solid state method the two components may be screened to uniform particle size and thoroughly mixed, at which point they may be ground in a high energy mill with optional heating, screening and homogenization.
- a semi-solid state the two components may be kneaded in the presence of small amounts of a suitable solvent, and the complex so-formed, is oven dried, screened and homogenized.
- the liquid state reaction generally provides optimum conditions for completeness of reaction.
- a method of producing an inclusion complex comprising fulvestrant and a cyclodextrin by admixing fulvestrant with a cyclodextrin.
- the method further comprises adding a solvent, mixed solvent, or buffer to fulvestrant, the cyclodextrin, and/or mixture thereof.
- the suitable amount of solvent, mixed solvent, or buffer may be added directly to a solid mixture of fulvestrant and the cyclodextrin.
- the solvent, mixed solvent, or buffer may be added to either fulvestrant or the cyclodextrin, and then added to the other of fulvestrant and the cyclodextrin.
- the solvent, mixed solvent, or buffer may be added independently to each of fulvestrant and cyclodextrin, followed by combining fulvestrant and the cyclodextrin.
- the method of producing an inclusion complex of fulvestrant and a cyclodextrin comprises the steps of: (a) admixing fulvestrant and a cyclodextrin; and (b) adding a suitable amount of solvent, mixed solvent, or buffer to the mixture of step (a) and mixing until a suspension or solution is formed.
- a buffer is employed.
- a formulation comprising a fulvestrant inclusion complex for intranasal administration in one aspect further comprises a buffer as detailed herein.
- Suitable buffers include, without limitation, phosphate buffers (e.g., phosphate-citrate), potassium hydrogen phthalate buffers, and acetate buffers.
- the buffer is a phosphate-citrate buffer.
- the added buffer and/or resulting suspension or solution has a pH between any of about 1.0, 2.0, and 3.0 and about 8.0, 9.0 or 10.0; about 3.0 and about 8.0, about 4.0 and about 6.0, about 4.5 and about 5.5; or a pH of greater than, less than, or about any of 1.0, 2.0, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 7.0, 7.5, 8.0, 9.0, or 10.0.
- a formulation comprising a fulvestrant inclusion complex for intranasal administration comprises a buffer and the formulation has a pH of between about 5.0 and about 8.0.
- a solvent is employed.
- a solvent in one aspect is an organic solvent or water.
- Suitable organic solvents are known to those of skill in the art and include, but are not limited to, low chain alcohols (e.g. methanol; ethanol; i-propanol) and acetone.
- the solvent is a polar solvent, such as water (e.g., ddH 2 0), methanol, ethanol, and i-propanol.
- a mixed solvent is employed.
- a mixed solvent in one aspect comprises an organic solvent or water.
- a mixed solvent is a mixture of water and an organic solvent.
- Suitable solvents, mixed solvents, or buffers include 100° % of ddH 2 0, or ddH 2 0 or buffer together with ethanol or methanol (1-99%).
- Various combinations of solvent, mixed solvent, or buffer for optimizing the production of an inclusion complex of fulvestrant and a cyclodextrin can be determined by persons skilled in the art in view of the methods described herein.
- fulvestrant may be admixed with the cyclodextrin at a molar ratio from about 0.2:1 to about 1:300.
- the molar ratio is about 0.5:1 to about 1:150, or about 1:1 to about 1:75, or about 1:1 to about 1:50, or about 1:1 to about 125, or about 1:1 to about 1:10, or about 1:1 to about 1:5, or about 1:1 to about 1:3, or about 1:1 to about 1:2, or any of about 1:1, 1:2, 13, 1:4, 1:5, 1:6, and 1:7.
- the solvent, mixed solvent, or buffer is heated to less than, greater than, or about any of 25° C., 30° C., 35° C., 40° C., 45° C., 50° C., 55° C., 60° C., 65° C., 75° C., or 80° C. (e.g., before, during and/or after mixing).
- the solvent, mixed solvent, or buffer may be heated prior to and/or after being added to fulvestrant and/or cyclodextrin.
- the solvent, mixed solvent, or buffer is heated greater than the preferred temperature for less than, greater than, or about any of 0.1 hr, 0.2 hr, 0.3 hr, 0.5 hr, 0.75 hr, 1 hr, 2 hr, 3 hr, 4 hr, 5 hr, 7 hr, 10 hr, 15 hr, 24 hr, 36 hr, or 48 hr.
- a suitable polymer may be added which may enhance the solubility and/or complexation ability of fulvestrant and cyclodextrin inclusion complex.
- a step of admixing fulvestrant and a cyclodextrin further comprises admixing a suitable polymer.
- suitable polymers include, for example, polyvinylpyrrolidone, hydroxypropyl methylcellulose, carboxymethylcellulose, and PLASDONE® Povidone, and derivatives thereof.
- the suitable polymer is a water-soluble polymer.
- the mixing is continued for at least any of about 0.1 hr, 02 hr, 0.3 hr, 0.5 hr, 0.75 hr, 1 hr, 2 hr, 4 hr, 10 hr, 24 hr, 36 hr, or 48 hr following formation of the suspension or solution. If heat is applied to the solvent, mixed solvent, or buffer during a method of producing an inclusion complex, the described mixing of the components may occur prior to, simultaneously with, and/or after the application of said heat.
- the method of producing an inclusion complex further comprises a step for drying the product obtained from the steps of a) admixing fulvestrant and a cyclodextrin and b) adding a suitable amount of a solvent, mixed solvent or buffer to the mixture.
- the drying comprises evaporation.
- the evaporation occurs for greater than, less than, or about any of 0.1 hr, 0.25 hr, 0.5 hr, 1 hr, 2 hr, 5 hr, 10 hr, 1 day, or 5 days.
- the evaporation is conducted under vacuum (e.g., less than any of about 0.75 atm, 0.5 atm, or 0.25 atm).
- the evaporation is conducted under atmospheric pressure.
- the drying comprises dry heat.
- the drying comprises spray-drying.
- the drying comprises freeze-drying.
- the drying comprises spray-granulation.
- a method of producing an inclusion complex between fulvestrant and a cyclodextrin comprising the steps of: (a) mixing the appropriate amount of fulvestrant and cyclodextrin with or without a suitable polymer; (b) adding a suitable amount of solvent, mixed solvent, and/or buffer to the mixture of step (a) with vigorous mixing until a paste or a slurry is formed; (c) continuing the mixing with further addition of solvent (e.g., water), mixed solvent, or buffer if necessary to maintain the paste or the slurry consistency, for a suitable period of time to form the inclusion complex; and (d) drying the product of step (c).
- solvent e.g., water
- the buffer is a phosphate-citrate buffer and the pH is about 5.
- the solvent added during steps (b) and (c) is heated.
- the solvent, mixed solvent, or buffer is deionized water and/or a buffer
- the deionized water and/or a buffer is heated to about 60° C.
- the mixing is preferably continued for a period of time greater than 0.2 hours.
- the vigorous mixing until a paste or a slurry is formed is conducted at about 60° C.
- a method of producing an inclusion complex between fulvestrant and a cyclodextrin comprising the steps of (a) mixing suitable amounts of fulvestrant and a cyclodextrin with or without a suitable polymer; (b) adding of a suitable solvent, mixed solvent, and/or buffer to the mixture of step (a) with mixing until a slurry, suspension or solution is formed; and (c) allowing the formation of the inclusion complex by evaporation of the water over a period of time.
- the buffer is a phosphate-citrate buffer and the buffer pH is about 5.
- the solvent added during step (b) is heated.
- the deionized water and/or a buffer is heated to about 60° C. In some embodiments of step (c), heat is applied to increase the evaporation rate. In some embodiments, the evaporation is conducted at 40° C. In some embodiment, evaporation in step (c) occurs for greater than about 1 hour. In some embodiments, the evaporation is conducted under vacuum.
- a method of producing an inclusion complex between fulvestrant and a cyclodextrin comprising the steps of: (a) mixing suitable amounts of fulvestrant and a cyclodextrin with or without a suitable polymer, (b) adding of a suitable solvent, mixed solvent, and/or buffer to the mixture of step (a) with mixing until a slurry, suspension or solution is formed; and (c) spray-drying the slurry, suspension or solution to obtain a solid drug-cyclodextrin inclusion complex.
- the buffer is a phosphate-citrate and the buffer pH is about 5.
- the suitable solvent, mixed solvent, and/or buffer added during step (b) is heated.
- the solvent, mixed solvent, or buffer is deionized water and/or a buffer
- the deionized water and/or a buffer is heated to about 60° C.
- a method of producing an inclusion complex between fulvestrant and a cyclodextrin comprising the steps of: (a) mixing suitable amounts of fulvestrant and a cyclodextrin with or without a suitable polymer, (b) adding of a suitable solvent, mixed solvent, and/or buffer to the mixture of step (a) with mixing until a solution is formed; and (c) freeze-drying the solution to obtain a solid drug-cyclodextrin inclusion complex.
- the buffer is a phosphate-citrate buffer and the buffer pH is about 5.
- the solvent, mixed solvent, and/or buffer added during step (b) is heated.
- the solvent, mixed solvent, or buffer is deionized water and/or a buffer, the deionized water and/or a buffer is heated to about 60° C.
- a method of producing an inclusion complex between fulvestrant and a cyclodextrin comprising the steps of (a) mixing suitable amounts of fulvestrant and a cyclodextrin with or without a suitable polymer, (b) adding of a suitable solvent, mixed solvent, and/or buffer to the mixture of step (a) with mixing until a slurry, suspension or solution is formed; (c) adding inactive pharmaceutical excipients to the slurry, suspension or solution, with continued mixing and (d) spray-granulating the slurry, suspension or solution to obtain solid particles, suitable for formulation into an oral formulation, containing a solid drug-cyclodextrin inclusion complex.
- the buffer is a phosphate-citrate buffer and the buffer pH is about 5.
- the solvent, mixed solvent, or buffer added during step (b) may be heated.
- the solvent, mixed solvent, or buffer is deionized water and/or a buffer
- the deionized water and/or a buffer is heated to about 60° C.
- the inactive pharmaceutical excipients included to produce an oral formulation according to step (c) may include commonly used pharmaceutical excipients commonly used in the art, and/or those described herein.
- a method of producing an inclusion complex between fulvestrant and a cyclodextrin comprising the steps of: (a) mixing suitable amounts of fulvestrant and cyclodextrin with or without a suitable polymer; (b) adding a suitable solvent, mixed solvent, and/or buffer to the mixture of step (a) with mixing until a solution is formed; (c) producing a liquid oral or intranasal formulation.
- Inactive pharmaceutical excipients may be added to the solution, containing the liquid drug-cyclodextrin inclusion complex.
- the buffer is a phosphate-citrate buffer and the buffer pH is about 5.
- the solvent, mixed solvent, and/or buffer added during step (d) is heated.
- the solvent, mixed solvent, or buffer is deionized water and/or a buffer
- the deionized water and/or a buffer is heated to about 60° C.
- the inactive pharmaceutical excipients included to produce a liquid oral or intranasal formulation according to step (c) may include commonly used pharmaceutical excipients commonly used in the art, and/or those described herein.
- fulvestrant in some embodiments of the methods for producing an inclusion complex between fulvestrant and a cyclodextrin described above, greater than any of about 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% of fulvestrant is in complexed form.
- a product obtained by any of the preceding processes is also provided for herein.
- inclusion complexes described herein may be used in the preparation of a composition or formulation, such as a pharmaceutical composition or formulation, by combining an inclusion complex described with at least one or any combination of more than one of a pharmaceutical acceptable carrier, excipient, stabilizing agent and/or other agent, which are known in the art, for use in the methods of treatment, methods of administration, and dosage regimes described herein.
- a pharmaceutically acceptable carrier may include, for example, solvents, mixed solvents, complexing agents, fillers, stabilizers, diluents, granulating agents, disintegrants, lubricants, glidants, pH-modifiers, tonicity modifiers, adjuvants, binders, etc., known to the skilled artisan that are suitable for administration to an individual (e.g., a human). Combinations of two or more carriers are also contemplated.
- the pharmaceutically acceptable carrier(s) and any additional components, as described herein, should be compatible for use in the intended route of administration (e.g., oral, parenteral, intranasal, or sublingal) for a particular dosage form. Such suitability will be recognized by the skilled artisan, particularly in view of the teaching provided herein.
- the formulations may vary or be tailored according to the condition to be treated, the amount of compound to be administered, the condition of the individual, and other variables that will readily be apparent to one of ordinary skill in the art in view of the teachings provided herein.
- inclusion complexes may be formulated, for example, as solid, semi-solid, and liquid dosage forms, such as tablets, pills, powders, liquid solutions or suspensions, suppositories, injectable and infusible solutions, and sprays.
- solid dosage forms such as tablets, pills, powders, liquid solutions or suspensions, suppositories, injectable and infusible solutions, and sprays.
- the preferred form depends on the intended mode of administration and therapeutic application.
- the following formulations, additives, and methods are merely exemplary and are in no way limiting.
- Fulvestrant described herein may be formulated with a cyclodextrin and may comprise one or more of the favorable properties described for the inclusion complexes herein (e.g., increased solubility). In some embodiments, fulvestrant is in the uncomplexed form in the presence of a cyclodextrin.
- a mixture of fulvestrant in both complexed and uncomplexed form with a cyclodextrin e.g., a molar ratio mixture of greater than, less than, or any of about 1:300, 1:150, 1:75, 1:50, 1:25, 1:20, 1:15 1:10, 1:7.5, 1:5, 1:3, 12, 1:1, 2:1, 3:1, 4:1, 5:1, 7.5:1, 10:1, 15:1, 25:1, 50:1, 100:1, 150:1 or 300:1 of complexed fulvestrant to uncomplexed fulvestrant, respectively).
- a formulation comprising fulvestrant, a cyclodextrin, and a carrier.
- the formulation comprises an effective amount of fulvestrant, cyclodextrin, and a carrier.
- the formulation may comprise a molar ratio of cyclodextrin to fulvestrant that is greater than, less than, or any of about 1:1, 2:1, 3:1, 4:1, 5:1, 7.5:1, 10:1, 15:1, 25:1, 50:1, 75:1, 100:1, 150:1 or 300:1.
- the formulation comprising the fulvestrant, a cyclodextrin, and a carrier may be further formulated in any manner described herein for the inclusion complex formulations, and may be used in any of the methods described herein, as well as at any dosage described herein, for the inclusion complexes and/or inclusion complex formulations (e.g., to treat a condition, such as cancer or systemic lupus erythematosus).
- These formulations also may provide improved pharmacokinetic properties as described herein (e.g., bioavailability, C max , T max , and time of onset) when compared to uncomplexed fulvestrant administered under the same conditions.
- the formulation comprising fulvestrant and a cyclodextrin, a complex of fulvestrant with a cyclodextrin, or a mixture thereof is a sterile formulation.
- Additives used with the inclusion complexes described herein include, for example, one or more excipients (e.g., one or more excipients), antioxidants (e.g., one or more antioxidants), stabilizers (e.g., one or more stabilizers), preservatives (e.g., one or more preservatives, including antimicrobial preservatives), pH adjusting and buffering agents (e.g., one or more pH adjusting and/or buffering agents), tonicity adjusting agents (e.g., one or more tonicity adjusting agents), thickening agents (e.g., one or more thickening agents), suspending agents (e.g., one or more suspending agents), binding agents (e.g., one or more binding agents), viscosity enhancing agents (e.g., one or more viscosity enhancing agents), sweetening agent (e.g., one or more sweetening agent (e.g., one or more sweet).
- excipients e.g
- antioxidants include, but are not limited to, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, malic acid, propyl gallate, sodium bisulfite, sodium sulfite, sodium metabisulfite, potassium metabisulfite, potassium bisulfite, sodium thiosulfate, sodium formaldehyde sulfoxylate, L-ascorbic acid, D-ascorbic acid, acetylcysteine, cysteine, thioglycerol, thioglycoUic acid, thiolactic acid, thiourea, dithiothreitol, dithioerythreitol, glutathione, nordihydroguaiaretic acid, tocophcrol, sodium ascorbate, hypophophorous acid, and fumaric acid.
- the antioxidant is selected from the group consisting of sodium bisulfite, sodium sulfite, sodium metabisulfite, potassium metabisulfite, potassium bisulfite, sodium thiosulfate, sodium formaldehyde sulfoxylate, L-ascorbic acid, D-ascorbic acid, acetylcysteine, thioglycerol, thioglycoUic acid, thiolactic acid, thiourea, dithiothreitol, dithiocrythreitol, glutathione, nordihydroguaiaretic acid, sodium ascorbate and hypophophorous acid.
- the antioxidant is a dietary antioxidant, including, but not limited to, vitamin E, vitamin C, beta-carotene, and selenium.
- the additives include processing agents and drug delivery modifiers and enhancers, such as, for example, calcium phosphate, magnesium stearate, talc, monosaccharides, disaccharides, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, dextrose, polyvinylpyrrolidinone, low melting waxes, ion exchange resins, and the like, as well as combinations of any two or more thereof.
- processing agents and drug delivery modifiers and enhancers such as, for example, calcium phosphate, magnesium stearate, talc, monosaccharides, disaccharides, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, dextrose, polyvinylpyrrolidinone, low melting waxes, ion exchange resins, and the like, as well as combinations of any two or more thereof.
- drug delivery modifiers and enhancers such as, for example, calcium phosphate, magnesium stearate, talc, monos
- Formulations suitable for oral administration may comprise, for example, (a) liquid solutions, such as an effective amount of fulvestrant or cyclodextrin inclusion complex thereof dissolved in diluents, such as water, saline, er other ingestable liquid such as orange juice, (b) capsules, sachets or tablets, each containing a predetermined amount of fulvestrant or inclusion complex thereof, as solids or granules, (c) suspensions in an appropriate liquid, (d) suitable emulsions, and (e) powders.
- liquid solutions such as an effective amount of fulvestrant or cyclodextrin inclusion complex thereof dissolved in diluents, such as water, saline, er other ingestable liquid such as orange juice
- capsules, sachets or tablets each containing a predetermined amount of fulvestrant or inclusion complex thereof, as solids or granules
- suspensions in an appropriate liquid such as water, saline, er
- Tablet forms can include one or more of lactose, mannitol, corn starch, potato starch, microcrystalline cellulose, acacia, gelatin, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, stearic acid, and other excipients, colorants, diluents, buffering agents, moistening agents, preservatives, flavoring agents, and pharmacologically compatible excipients.
- Lozenge forms can comprise fulvestrant or an inclusion complex thereof in a flavor, usually sucrose and acacia or tragacanth, as well as pastilles comprising fulvestrant or an inclusion complex thereof in an inert base, such as gelatin and glycerin, or sucrose and acacia, emulsions, gels, and the like containing, in addition to the active ingredient, such excipients as are known in the art.
- Oral formulations may include any suitable dosage, including those described herein, such as any of about 0.1 mg, 1 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 250 mg, 275 mg, 300 mg, 350 mg, 400 mg, 450 mg, or 500 mg of fulvestrant per unit dose.
- the formulations may be used for the treatment of a condition (e.g., cancer or systemic lupus erythematosus). Solid dosage forms for oral administration may be particularly useful for the treatment of cancer.
- the inclusion complexes can be enclosed in a hard or soft capsule, can be compressed into tablets, or can be incorporated with beverages or food or otherwise incorporated into the diet.
- Capsules can be formulated by mixing the inclusion complex with an inert pharmaceutical diluent and inserting the mixture into a hard gelatin capsule of the appropriate size. If soft capsules are desired, a slurry, suspension or solution of the inclusion complex may be encapsulated by machine into a gelatin capsule.
- Liquid dosage forms for oral administration may include pharmaceutically acceptable solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water or buffers. Such formulations may also comprise adjuvants, such as wetting, emulsifying, suspending, antioxidants, preservatives (e.g., antimicrobial preservative), enhancing (e.g., viscosity-enhancing), sweetening, flavoring, and perfuming agents. Liquid dosage forms of the inclusion complexes for oral administration may be particularly useful for the treatment of cancer.
- the formulation further comprises an additional agent, which may be an additional pharmaceutical or other agent
- the additional agent may be employed in a manner that reduces the number or severity of adverse effects that the additional agent may have on the fulvestrant cyclodextrin inclusion complex.
- an additional agent may confer a benefit on a formulation comprising a fulvestrant cyclodextrin inclusion complex
- such an agent may also have the potential to displace fulvestrant in the inclusion complex or otherwise prevent or reduce the quality of fulvestrant inclusion.
- agents may still confer a benefit but their adverse consequences may be reduced or avoided if used in reduced amounts.
- additional agents may be selected such that the additional agent or combination thereof is less likely to adversely affect the inclusion complex.
- Formulations suitable for parenteral administration include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain anti-oxidants, buffers, bacteriostats, and solutes that render the formulation compatible with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizing agents, and preservatives.
- the formulations can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid for reconstitution (e.g., water for injection), immediately prior to use.
- Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described.
- Injectable preparations may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
- the sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in propylene glycol.
- the sterile injectable preparation may also be a sterile powder to be reconstituted using acceptable vehicles prior to administration.
- acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution.
- sterile, fixed oils may be employed as a solvent or suspending medium.
- any bland fixed oil may be employed including synthetic mono- or diglycerides.
- fatty acids such as oleic acid may be used in the preparation of injectables.
- Formulation of the inclusion complex in liquid form may have a pH in the range of about 1.0 to about 10.0, including for example pH ranges of any of about 5.0 to about 8.0, about 5.0 to about 7.0, about 5.0 to about 6.0, about 6.5 to about 7.5, and about 6.5 to about 7.0.
- the pH of the composition is formulated to no less than about 6, 5, or 4, including for example a pH of any of about 8, 7.5, 7, 6.5, 6, 5.5, 5, 4.5, or 4.
- the formulation can also be made to be isotonic with blood by the addition of a suitable tonicity modifier, such as glycerol.
- the inclusion complexes may also be formulated for administration by inhalation.
- Formulations suitable for aerosol administration which comprise the inclusion complex may include, for example, aqueous and non-aqueous, isotonic sterile solutions, which can contain anti-oxidants, buffers, bacteriostats, and solutes, as well as aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizing agents, and preservatives, alone or in combination with other suitable components, which can be made into aerosol formulations to be administered via inhalation.
- These aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like. They also can be formulated as pharmaceuticals for non-pressured preparations, such as in a nebulizer or an atomizer.
- the inclusion complexes may also be formulated in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.
- the inclusion complexes may also be formulated for topical administration, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.
- Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-applied transdermal patches may also be used.
- unit dosage forms comprising the inclusion complexes and formulations described herein. These unit dosage forms can be stored in a suitable packaging in single or multiple unit dosages and may also be further sterilized and sealed.
- the pharmaceutical formulation e.g., a dosage or unit dosage form of a pharmaceutical formulation
- the amount of fulvestrant within the formulation is in any of the following ranges: about 0.1 to about 50 mg, about 1 to about 50 mg, about 5 to about 50 mg, about 20 to about 50 mg, about 50 to about 100 mg, about 100 to about 125 mg, about 125 to about 150 mg, about 150 to about 175 mg, about 175 to about 200 mg, about 200 to about 225 mg, about 225 to about 250 mg, about 250 to about 300 mg, about 300 to about 350 mg, about 350 to about 400 mg, about 400 to about 450 mg, about 450 to about 500 mg, about 500 mg to about 550 mg, about 550 mg to about 600 mg, about 600 mg to about 650 mg, about 650 mg to about 700 mg, about 700 mg to about 750 mg, about 750 mg to about 800 mg.
- the amount of fulvestrant within the formulation is in the range of about 1 mg to about 500 mg, such as any of about 5 mg to about 250 mg, about 20 mg to about 400 mg, or about 50 mg, 100 mg, 150 m, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, or 800 mg.
- the formulation may comprise a molar ratio of a cyclodextrin to fulvestrant that is greater than, less than, or any of about 1:1, 2:1, 3:1, 4:1, 5:1, 7.5:1, 10:1, 15:1, 25:1, 50:1, 75:1, 100:1, 150:1 or 300:1.
- the amount of the amount of fulvestrant within the formulation is in the range of about 1 mg to about 800 mg, such as any of about 5 mg to about 700 mg, 20 mg to about 500 mg, or about 20 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, or 800 mg
- the amount of a cyclodextrin in the formulation may be any of about 5 mg to about 2500 mg, such as any of about 15 mg to about 1500 mg, about 30 mg to about 750 mg, about 60 mg to about 300 mg, about 100 mg to about 200 mg, or about 60 mg, 75 mg, 100 mg, 125 mg, 150 mg, 200 mg, 225 mg, 250 mg, 275 mg or 300 mg.
- the carrier is suitable for parental administration (e.g., intravenous administration). In some embodiments, the carrier is suitable for intramuscular administration. In some embodiments, the carrier is suitable for oral administration. In some embodiments, the carrier is suitable for intranasal administration. In some embodiments, the carrier is suitable for sublingual, rectal or vaginal administration. In some embodiments, fulvestrant of the inclusion complex is the only pharmaceutically active agent for the treatment of the condition (e.g., cancer or systemic lupus erythematosus) that is contained in the formulation.
- the condition e.g., cancer or systemic lupus erythematosus
- dosage forms for the treatment of cancer or systemic lupus erythematosus, comprising (i) a mixture of a fulvestrant with a cyclodextrin, and/or an inclusion complex thereof wherein the amount of fulvestrant is in the range of about 0.1 mg to about 500 mg per unit dose, and (ii) a pharmaceutically acceptable carrier.
- the amount of fulvestrant in the unit dosage form includes any of about 0.1 mg, 1 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 250 mg, 275 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, or 800 mg of fulvestrant.
- formulations of the inclusion complexes described herein comprising one or more of a complexing agent, a filler, a diluent, a granulating agent, a disintegrant, a lubricant, or a glidant.
- the complexing agent, filler, diluent, granulating agent, disintegrant, lubricant, or glidant may be chosen from among the ingredient listed in Table 1.
- formulations may contain zero, one, or more than one ingredient from each use category in Table 1.
- Formulations may additionally contain other complexing agents, fillers, diluents, granulating agents, disintegrants, lubricants, or glidants not listed in Table 1.
- Formulations may also contain additional ingredients that are not complexing agents, fillers, diluents, granulating agents, disintegrants, lubricants, or glidants.
- Formulation 1 Formulation 2
- Formulation 3 Formulation 4
- Formulation 5 Complexing Sodium Ethanol None Methanol None agent hydrogen carbonate Filler/diluent Glucose Mannitol; Microcrystalline Sodium Glucose; sucrose modified starch cellulose; lactose chloride; dextrates Granulating None Acacia mucilage None Starch mucilage Tragacanth agent mucilage Disintegrant Alginic acid; Aluminum Crosscarmellose Microcrystalline Sodium lauryl carbon dioxide magnesium sodium cellulose sulphate silicate Lubricant Calcium stearate Fumaric acid Magnesium Liquid paraffin Sodium stearate benzoate Glidant Colloidal silica Talc Colloidal silica Talc Talc Other Dye Dye Dye; PVA-based PVA-based film None ingredients film coating coating coating
- the complexing agent, filler, diluent, granulating agent, disintegrant, lubricant, or glidant is present in the amount per tablet indicated in Table 3.
- the inclusion complex is formulated as a tablet comprising fulvestrant and a cyclodextrin in amounts per tablet as indicated in Table 4 and one or more additional ingredients listed in Table 4 in an amount per tablet as indicated in Table 4.
- formulations of the inclusion complexes described herein comprising one or more of a vehicle, a suspending agent, antimicrobial preservatives, antioxidants, viscosity enhancing agents, sweetening agents, flavoring agents or coloring agents.
- the vehicle, suspending agent, antimicrobial preservatives, antioxidants, viscosity enhancing agents, sweetening agents, flavoring agents or coloring agents may be chosen from among the ingredients listed in Table 5.
- formulations may contain zero, one, or more than one ingredient from each use category in Table 5.
- Formulations may additionally contain another vehicle, a suspending agent, antimicrobial preservatives, antioxidants, viscosity enhancing agents, sweetening agents, flavoring agents or coloring agents not listed in Table 5.
- Formulations may also contain additional ingredients that are not vehicles, suspending agents, antimicrobial preservatives, antioxidants, viscosity enhancing agents, sweetening agents, flavoring agents, or coloring agents.
- the formulations described herein are oral formulations.
- Vehicle Water distilled water, purified water, water for injection, aromatic water, juices, syrups, spirits
- Suspending agent Agar, alginic acid, bentonite, calcium stearate, carbomers, carboxymethylcellulose calcium, carboxymethylcellulose sodium, carrageenan, cellulose, ceratonia, colloidal silicon dioxide, dextrin, gelatin, guar gum, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose, hypromellose, kaolin, magnesium aluminum silicate, maltitol, medium-chain triglycerides, methylcellulose, microcrystalline cellulose, polycarbophil, polyethylene glycol, potassium alginate, povidone, propylene glycol alginate, sesame oil, sodium alginate, sodium starch glycolate, sorbitan esters, sucrose, tragacanth, xanthan gum.
- Antimicrobial Alcohol benzalkonium chloride, benzethonium chloride, benzoic acid, preservative benzyl alcohol, boric acid, bronopol, butylated hydroxyanisole, butylparaben, cetrimide, cetylpyridinium chloride, chlorbutanol, chlorhexidine, chlorobutanol, chlorocresol, chloroform, chloroxylenol, cresol, dimethyl ether, ethylparaben, glycerin, hexetidine, imidurea, isopropyl alcohol, lactic acid, methylparaben, monothioglycerol, parabens, alkyl chain length, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric acetate, phenylmercuric borate, phenylmercuric nitrate, potassium benzoate, potassium metabisulfite, potassium sorbate, propionic acid, propyl gallate
- Exemplary formulations are shown in Table 6.
- Formulation 1 Formulation 2
- Formulation 3 Formulation 4
- Vehicle Water for Aromatic water Syrup Water for Water for injection injection injection Suspending None None None None None None None None None None
- Microcrystalline agent cellulose Antimicrobial None Benzoic acid Chloroform Benzoic acid Benzoic acid preservative Antioxidant None Thioglycerol Acetyl cysteine Thioglycerol Ascorbic acid Viscosity None None None None Carboxymethyl enhancing cellulose agent Sweetening Aspartame Acesulfame Fructose Saccharin Aspartame agent potassium Other Flavouring & Flavouring & Flavouring & Flavouring & Flavouring & Flavouring & Flavouring & ingredients coloring agent coloring agent coloring agent coloring agent coloring agent coloring agent coloring agent coloring agent coloring agent coloring agent coloring agent coloring agent coloring agent coloring agent coloring agent coloring agent coloring agent coloring agent coloring agent coloring agent coloring agent coloring agent coloring agent coloring agent coloring agent coloring agent coloring agent coloring agent coloring agent coloring agent coloring agent coloring agent coloring agent coloring agent
- formulations of the inclusion complexes described herein comprising one or more of a vehicle, suspending agents, antimicrobial preservatives, antioxidants, viscosity enhancing agents.
- the vehicle, suspending agents, antimicrobial preservatives, antioxidants, viscosity enhancing agents may be chosen from among the ingredients listed in Table 7.
- formulations may contain zero, one, or more than one ingredient from each use category in Table 7.
- Formulations may additionally contain other vehicles, suspending agents, antimicrobial preservatives, antioxidants and viscosity enhancing agents not listed in Table 7.
- Formulations may also contain additional ingredients that are not vehicles, suspending agents, antimicrobial preservatives, antioxidants or viscosity enhancing agents.
- the formulations described herein are intranasal formulations.
- Formulation 1 Formulation 2
- Formulation 3 Formulation 4
- Vehicle Water for Water for Water for pH 6 Buffered Water for injection injection injection water for injection injection Suspending None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None Microcrystalline agent cellulose Antimicrobial None Benzoic acid Benzalkonium Benzoic acid Benzoic acid preservative chloride Antioxidant None Thioglycerol Acetyl cysteine Thioglycerol Ascorbic acid Viscosity None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None None
- kits containing materials useful for the treatment of a condition that is responsive to fulvestrant e.g., cancer or systemic lupus erythematosus.
- the kits may contain an inclusion complex of fulvestrant and a cyclodextrin, and optionally contain instructions for use (e.g., instructions for preparation and/or administration of a formulation comprising the complex).
- instructions for use e.g., instructions for preparation and/or administration of a formulation comprising the complex.
- Information detailing possible side effects of the formulation, and any other relevant information may also be enclosed.
- the instructions may be in any suitable format, including, but not limited to, printed matter, videotape, computer readable disk, optical disc or directions to internet-based instructions.
- kits for treating an individual who suffers from or is susceptible to one or more of the conditions described herein comprising a first container comprising a dosage amount of a formulation containing an inclusion complex as disclosed herein, and instructions for use.
- the container may be any of those known in the art and appropriate for storage and delivery of intravenous, intranasal or oral formulations.
- the kit further comprises a second container comprising a pharmaceutically acceptable carrier, diluent, adjuvant, etc. for preparation of the formulation to be administered to the individual.
- kits comprise a container with a label.
- Suitable containers include, for example, bottles, vials, and test tubes.
- the containers may be formed from a variety of materials such as glass or plastic.
- the containers may hold an inclusion complex comprising fulvestrant and a cyclodextrin.
- the containers may further comprise one or more additional pharmaceutical agents (e.g., an anti-cancer agent).
- the label on the container may indicate that the inclusion complex or the formulation is used for treating or suppressing a condition that is responsive to fulvestrant (e.g., cancer or systemic lupus erythematosus), and may also indicate directions for in vivo use, such as those described herein.
- the kit may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for performing any methods described herein.
- the kit comprises the container described above and a second container comprising a buffer.
- kits may include additional pharmaceutical agents for use in conjunction with the formulation described herein.
- the additional pharmaceutical agent is fulvestrant in uncomplexed form, such as in the product FASLODEX® (AstraZeneca Pharmaceuticals LP).
- the additional pharmaceutical agent(s) may be one or more drug(s) for the treatment of conditions responsive to fulvestrant (e.g., cancer or systemic lupus erythematosus).
- the additional pharmaceutical agent(s) may be one or more drug(s) for the treatment of one or more side effects from the use of the inclusion complexes described herein.
- kits may include additional agents for adjunctive therapy or other agents known to the skilled artisan as effective in the treatment or prevention of the conditions described herein.
- the additional pharmaceutical agent is an anti-cancer agent.
- the anti-cancer agent is an aromatase inhibitor (AI), including, but not limited to, anastrozole (e.g., ARIMIDEX®), letrozole (e.g., FEMARA®), exemestane (e.g., AROMASIN®), aminoglutethimide (Cytadren®), vorozole (e.g., RIVIZOR®), formestane (e.g., LENTARON®), fadrozole (e.g. AFEMA®), or testolactone (e.g., TESLAC®).
- AI aromatase inhibitor
- the anti-cancer agent is an epidermal growth factor receptor (EGFR) inhibitor, including, but not limited to, gefitinib (e.g., IRESSA®), trastuzumab (e.g., HERCEPTIN®), or erlotinib (e.g., TARCEVA®).
- EGFR epidermal growth factor receptor
- the anti-cancer agent is a farnesyl transferase inhibitor, including, but not limited to tipifarnib (e.g., ZARNESTRA®).
- the anti-cancer agent is uncomplexed fulvestrant, such as uncomplexed fulvestrant administered as an intramuscular injection (e.g., FASLODEX®).
- the anti-cancer agent is an antioxidant, including, but not limited to vitamin E, vitamin C, beta-carotene, and selenium.
- the anti-cancer agent is selected from the group consisting of anastrozole (e.g., ARIMIDEX®), letrozole (e.g., FEMARA®), exemestane (e.g., AROMASIN®), aminoglutethimide (e.g., Cytadren®), vorozole (e.g., RIVIZOR®), formestane (e.g., LENTARON®), fadrozole (e.g., AFEMA®), testolactone (e.g., TESLAC®), gefitinib (e.g., IRESSA®), trastuzumab (e.g., HERCEPTIN®), erlotinib (e.g., TARCEVA®), tipifarnib (e.g., ZARNESTRA®), uncomplexed fulvestrant (e.g., FASLODEX®), and an antioxidant (e.g., vitamin E, vitamin C,
- Kits may also be provided that contain sufficient dosages of the compounds described herein (including formulations thereof) to provide effective treatment for an individual, such as a human in need of such treatment, for an extended period, such as any of 1-3 days, 1-5 days, a week, 2 weeks, 3, weeks, 4 weeks, 6 weeks, 8 weeks, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months or more.
- kits may include the composition as described herein packaged in either a unit dosage form or in a multi-use form.
- the kits may also include multiple units of the unit dose form.
- the kits may be used for any of the methods described herein, including, for example, to treat an individual with a condition described herein, or to delay a condition described herein.
- the kits may include a dosage amount of at least one formulation as disclosed herein. Kits may also comprise a means for the delivery of the formulation thereof, such as a syringe, inhaler, intranasal spray, patch or other such device.
- inclusion complexes described herein comprising fulvestrant and a cyclodextrin, formulations thereof, and formulations comprising an uncomplexed fulvestrant and a cyclodextrin, or mixtures thereof, may be used for the treatment of indications that are believed to be or are responsive to fulvestrant therapy (e.g., cancer and systemic lupus erythematosus).
- fulvestrant therapy e.g., cancer and systemic lupus erythematosus.
- a method of treating a cancer in an individual in need thereof comprising administering to the individual an effective amount of an inclusion complex comprising fulvestrant and a cyclodextrin, or a formulation thereof.
- beneficial or desired results in a treatment include, but are not limited to, one or more of the following: decreasing one or more symptoms resulting from the condition (e.g., cancer or systemic lupus erythematosus), diminishing the extent of the disease, stabilizing the condition, delaying or slowing the progression of the condition, reversing the progression or severity of the condition, ameliorating the condition, decreasing the dose of one or more other medications required to treat the condition, and/or increasing the quality of life of an individual who has been or is suspected of having the condition.
- the methods described herein contemplate any one or more of these aspects of treatment.
- a method of delaying the development of a condition wherein the method reduces the probability of developing the condition in a given time frame and/or reduces the extent of the condition in a given time-frame, when compared to not using the method. Such comparisons may be based on clinical studies, using a statistically significant number of subjects.
- a method of delaying the development of a condition is provided, wherein the method encompasses preventing a recurrence of the condition in a given time frame, such as 3 months, 6 months, 1 year, 2 years, 3 years, 5 years, 10 years or more.
- the methods and/or inclusion complex formulations used herein reduce the severity of one or more symptoms associated with the condition (e.g., cancer or systemic lupus erythematosus) by at least any of about 10%, 20%, 30%, 400/%, 50%, 60%, 70%, 80%, 90%, 95%, or 100% compared to the corresponding symptom in the same individual prior to treatment or compared to the corresponding symptom in other individuals not receiving the methods and/or inclusion complex formulations.
- the condition e.g., cancer or systemic lupus erythematosus
- the individual being treated for a condition described herein has been identified as having one or more of the symptoms described herein.
- Identification of the conditions as described herein by a skilled physician is routine in the art such as routine physical exams or clinical detection.
- the cancer is early stage cancer, non-metastatic cancer, primary cancer, advanced cancer, locally advanced cancer, metastatic cancer, cancer in remission, recurrent cancer, cancer in an adjuvant setting, cancer in a neoadjuvant setting, or cancer substantially refractory to hormone therapy.
- the cancer includes, but is not limited to, breast cancer, endometrial cancer, prostate cancer, and lung cancer.
- the methods detailed herein may be applicable to an individual in need thereof, which may be an individual who has been diagnosed with, previously treated for, and/or suspected of having the condition to be treated (e.g., cancer or systemic lupus erythematosus).
- the individual in need thereof may also be an individual who is at risk for a condition (e.g., age, a family or self history of the condition, life-style factors indicative of risk for the condition, etc.).
- an individual is an individual who has previously had the condition and is at risk fir recurrence of the condition.
- the individual is a mammal, including, but not limited to human, bovine, horse, feline, rabbit, canine, rodent, or primate.
- the mammal is a primate.
- the primate is a human.
- the individual is human, including adults and children. The human may be of either sex and the methods may be applicable to either a man or a woman.
- the individual is a human who is believed to be or is in need of treatment.
- the individual is a pre-menopausal, per-menopausal or post-menopausal woman.
- the individual is a post-menopausal woman with disease (e.g., breast cancer) progression following hormone (e.g., antiestrogen) therapy.
- the individual is a pre-menopausal woman with disease (e.g., breast cancer) progression following hormone (e.g., anti-estrogen) therapy.
- the individual is a non-mammal.
- the primate is a non-human primate such as chimpanzees and other apes and monkey species.
- the mammal is a farm animal such as cattle, horses, sheep, goats, and swine; pets such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice, and guinea pigs; and the like.
- the individual is a non-mammal, including, but not limited to, birds, and the like.
- the term “individual” does not denote a particular age or sex.
- a method of treating breast cancer in an individual in need thereof comprising administering to the individual an effective amount of an inclusion complex comprising fulvestrant and a cyclodextrin (e.g., MBCD or HPBCD), or a formulation thereof.
- the individual is a pre- or peri-menopausal individual with breast cancer progression following anti-estrogen therapy.
- the individual is a post-menopausal individual with breast cancer progression following anti-estrogen therapy.
- the breast cancer is early stage breast cancer, non-metastatic breast cancer, advanced breast cancer, stage IV breast cancer, locally advanced breast cancer, metastatic breast cancer, hormone receptor positive metastatic breast cancer, advanced breast cancer, breast cancer in remission, breast cancer in an adjuvant setting, ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC), or breast cancer in a neoadjuvant setting.
- the breast cancer is hormone receptor positive metastatic breast cancer.
- the breast cancer is advanced breast cancer.
- the breast cancer is ductal carcinoma in situ.
- breast cancer which may be HER2 positive or HER2 negative
- the individual may be a human who has a gene, geneticmutation, or polymorphism associated with breast cancer (e.g., BRCA1, BRCA2, ATM, CHEK2, RAD51, AR, DIRAS3, ERBB2, TP53, AKT, PTEN, and/or PI3K) or has one or more extra copies of a gene (e.g., one or more extra copies of the HER2 gene) associated with breast cancer.
- the method further comprises identifying a cancer patient population (e.g., breast cancer population) based on a hormone receptor status of patients having tumor tissue not expressing both ER and PgR and administering to the patient population an effective amount of the inclusion complex comprising fulvestrant and a cyclodextrin.
- a cancer patient population e.g., breast cancer population
- a method of treating endometrial cancer in an individual in need thereof, comprising administering to the individual an effective amount of an inclusion complex comprising fulvestrant and a cyclodextrin (e.g., MBCD or HPBCD), or a formulation thereof.
- the individual is a pre- or peri-menopausal woman.
- the individual is a post-menopausal woman.
- the endometrial cancer is endometrial stromal sarcoma, uterine carcinosarcoma, endometrial adenocarcinoma, Type I endometrial carcinoma, or Type II endometrial carcinoma.
- the endometrial carcinoma is stage IA, stage IB, stage IC, stage IIA, stage IIB, stage IIIA, stage IIB, stage IIIC, stage IVA, or stage IVB endometrial carcinoma.
- a method of treating prostate cancer in an individual in need thereof comprising administering to the individual an effective amount of an inclusion complex comprising fulvestrant and a cyclodextrin (e.g., MBCD or HPBCD), or a formulation thereof.
- the prostate cancer is an adenocarcinoma.
- the prostate cancer is a sarcoma, neuroendocrine tumor, small cell cancer, ductal cancer, or a lymphoma.
- the prostate cancer is stage A prostate cancer (the cancer cannot be felt during a rectal exam.).
- the prostate cancer is stage B prostate cancer (the tumor involves more tissue within the prostate, it can be felt during a rectal exam, or it is found with a biopsy that is done because of a high PSA level.).
- the prostate cancer is stage C prostate cancer (the cancer has spread outside the prostate to nearby tissues.).
- the prostate cancer is stage D prostate cancer.
- the prostate cancer may be androgen independent prostate cancer (AIPC).
- the prostate cancer may be androgen dependent prostate cancer.
- the prostate cancer may be refractory to hormone therapy.
- the prostate cancer may be substantially refractory to hormone therapy.
- the individual may be a human who has a gene, genetic mutation, or polymorphism associated with prostate cancer (e.g., RNASEL/HPC1, ELAC2/HPC2, SR-A/MSR1, CHEK2, BRCA2, PON1, OGG1, MIC-1, TLR4, and/or PTEN) or has one or more extra copies of a gene associated with prostate cancer.
- a gene, genetic mutation, or polymorphism associated with prostate cancer e.g., RNASEL/HPC1, ELAC2/HPC2, SR-A/MSR1, CHEK2, BRCA2, PON1, OGG1, MIC-1, TLR4, and/or PTEN
- a method of treating lung cancer in an individual in need thereof comprising administering to the individual an effective amount of an inclusion complex comprising fulvestrant and a cyclodextrin (e.g., MBCD or HPBCD), or a formulation thereof.
- the hmg cancer is a non-small cell lung cancer (NSCLC).
- NSCLC neuroendocrine lung tumors
- large-cell carcinoma e.g., large-cell neuroendocrine carcinoma, combined large-cell neuroendocrine carcinoma, basaloid carcinoma, lymphoepithelioma-like carcinoma, clear cell carcinoma, and large-cell carcinoma with rhabdoid phenotype
- adenocarcinoma e.g., acinar, papillary (e.g., bronchioloalveolar carcinoma, nonmucinous, mucinous, mixed mucinous and nonmucinous and indeterminate cell type
- solid adenocarcinoma with mucin adenocarcinoma with mixed subtypes
- well-differentiated fetal adenocarcinoma mucinous (colloid) adenocarcinoma, mucinous cystadenocarcinoma, signet ring adenocarcinoma, and clear cell adenocarcinoma
- neuroendocrine lung tumors and s
- the NSCLC may be, according to TNM classifications, a stage T tumor (primary tumor), a stage N tumor (regional lymph nodes), or a stage M tumor (distant metastasis).
- the lung cancer is a carcinoid (typical or atypical), adenosquamous carcinoma, cylindroma, or carcinoma of the salivary gland (e.g., adenoid cystic carcinoma or mucoepidermoid carcinoma).
- the lung cancer is a carcinoma with pleomorphic, sarcomatoid, or sarcomatous elements (e.g., carcinomas with spindle and/or giant cells, spindle cell carcinoma, giant cell carcinoma, carcinosarcoma, or pulmonary blastoma).
- the cancer is small cell lung cancer (SCLC; also called oat cell carcinoma).
- SCLC small cell lung cancer
- the small cell lung cancer may be limited-stage, extensive stage or recurrent small cell lung cancer.
- the individual may be a human who has a gene, genetic mutation, or polymorphism suspected or shown to be associated with lung cancer (e.g., SASH1, LATS1, IGF2R, PARK2, KRAS, PTEN, Kras2, Krag, Pas1, ERCC1, XPD, IL8RA, EGFR, a f AD, EPHX, MMP1, MMP2, MMP3, MMP12, IL1p ⁇ RAS, and/or AKT) or has one or more extra copies of a gene associated with lung cancer.
- a gene, genetic mutation, or polymorphism suspected or shown to be associated with lung cancer e.g., SASH1, LATS1, IGF2R, PARK2, KRAS, PTEN, Kras2, Krag, Pas1, ERCC1, XPD, IL8RA, EGFR, a f AD, EPHX, MMP1, MMP2, MMP3, MMP12, IL1p ⁇ RAS, and/or AKT
- lung cancer e.g
- inclusion complexes described herein may be used for the treatment of systemic lupus erythematosus.
- a method of treating systemic lupus erythematosus in an individual comprising administering to the individual an effective amount of an inclusion complex comprising fulvestrant and a cyclodextrin, or a formulation thereof.
- the method detailed herein may use any inclusion complex or composition detailed herein.
- the inclusion complex may be administered via any route (e.g., orally, intranasally, sublingually, parenterally, such as intravenously, rectally, intravaginally).
- a method of treating a cancer in an individual in need thereof comprising administering to the individual an effective amount of an inclusion complex comprising fulvestrant and a cyclodextrin, or a formulation thereof, and one other pharmaceutical agent.
- a method of treating systemic lupus erythematosus in an individual in need thereof comprising administering to the individual an effective amount of an inclusion complex comprising fulvestrant and a cyclodextrin, or a formulation thereof and one other pharmaceutical agent.
- the additional pharmaceutical agent in one aspect refers to an active agent other than complexed fulvestrant, for example, an anti-cancer agent other than fulvestrant, which is administered to elicit a therapeutic effect or fulvestrant in an uncomplexed form.
- the additional pharmaceutical agent is an anti-cancer agent other than fulvestrant. More than one additional pharmaceutical agent may be employed.
- An additional pharmaceutical agent may be directed to a therapeutic effect related to one or more conditions that fulvestrant is intended to treat or prevent (e.g., cancer or systemic lupus erythematosus) or the pharmaceutical agent may be intended to treat or prevent a symptom of the underlying condition (e.g., pain, swelling, warmth and redness throughout the breast, Paget's disease of the breast, malar rash, fatigue, loss of appetite, inflammation (e.g., pericarditis, myocarditis, or endocarditis), bone or joint pain, arthritis, anemia and iron deficiency, pleuritis, pleural effusion, lupus pneumonitis, pulmonary hypertension, pulmonary emboli, pulmonary hemorrhage, chronic diffuse interstitial lung disease, hematuria, headache, or proteinuria, etc.) or to further reduce the appearance or severity of side effects of fulvestrant (e.g., asthenia, pain, headache, back pain, vasodilatation
- the pharmaceutical agent is an anti-cancer agent.
- the anti-cancer agent is an aromatase inhibitor (AI), including, but not limited to, anastrozole (e.g., ARIMIDEX®), letrozole (e.g., FEMARA®), exemestane (e.g., AROMASIN®), aminoglutethimide (Cytadren®), vorozole (e.g., RIVIZOR®), formestane (e.g., LENTARON®), fadrozole (e.g., AFEMA®), or testolactone (e.g., TESLAC®).
- AI aromatase inhibitor
- the anti-cancer agent is an epidermal growth factor receptor (EGFR) inhibitor, including, but not limited to, gefitinib (e.g., IRESSA®), trastuzumab (e.g., HERCEPTIN®), or erlotinib (e.g., TARCEVA®).
- EGFR epidermal growth factor receptor
- the anti-cancer agent is a farnesyl transferase inhibitor, including, but not limited to tipifamib (e.g., ZARNESTRA®).
- the anti-cancer agent is fulvestrant in uncomplexed form (e.g., FASLODEX®).
- the anti-cancer agent is an antioxidant, including, but not limited to vitamin E, vitamin C, beta-carotene, and selenium.
- the formulation may include combinations of two or more of the anti-cancer agents as described herein (e.g., any of 2, 3, or more anti-cancer agents).
- the antioxidant includes, but is not limited to, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, malic acid, propyl gallate, sodium bisulfite, sodium sulfite, sodium metabisulfite, potassium metabisulfite, potassium bisulfite, sodium thiosulfate, sodium formaldehyde sulfoxylate, L-ascorbic acid, D-ascorbic acid, acetylcysteine, cysteine, thioglycerol, thioglycoUic acid, thiolactic acid, thiourea, dithiothreitol, dithiocrythreitol, glutathione, nordihydroguaiaretic acid, tocopherol, sodium ascorbate, hypophophorous acid, and fumaric acid.
- the anti-cancer agent is selected from the group consisting of anastrozole (e.g., ARIMIDEX®), letrozole (e.g., FEMARA®), exemestane (e.g., AROMASIN®), aminoglutethimide (Cytadren®), vorozole (e.g., RIVIZOR®), formestane (e.g., LENTARON®), fadrozole (e.g., AFEMA®), testolactone (e.g., TESLAC®), gefitinib (e.g., IRESSA®), trastuzumab (e.g., HERCEPTIN®), erlotinib (e.g., TARCEVA®), tipifarnib (e.g., ZARNESTRA®), fulvestrant in uncomplexed form (e.g., FASLODEX®), and an antioxidant (e.g., vitamin E, vitamin C, beta-
- a method of treating a hormone receptor positive metatstatic breast cancer in an individual in need thereof comprising administering to the individual an effective amount of an inclusion complex comprising fulvestrant and a cyclodextrin, or a formulation thereof, and anastrozole.
- a method of treating a hormone receptor positive metatstatic breast cancer in an individual in need thereof comprising administering to the individual an effective amount of an inclusion complex comprising fulvestrant and a cyclodextrin, or a formulation thereof, and exemestane.
- a method of treating a hormone receptor positive metatstatic breast cancer in an individual in need thereof comprising administering to the individual an effective amount of an inclusion complex comprising fulvestrant and a cyclodextrin, or a formulation thereof, and uncomplexed fulvestrant (e.g., FASLODEX®).
- an inclusion complex comprising fulvestrant and a cyclodextrin, or a formulation thereof, and uncomplexed fulvestrant (e.g., FASLODEX®).
- a method of treating a hormone receptor positive metatstatic breast cancer in an individual in need thereof comprising administering to the individual an effective amount of an inclusion complex comprising fulvestrant and a cyclodextrin, or a formulation thereof and gefitinib.
- a method of treating a hormone receptor positive metatstatic breast cancer in an individual in need thereof comprising administering to the individual an effective amount of an inclusion complex comprising fulvestrant and a cyclodextrin, or a formulation thereof and lapatinib.
- a method of treating a hormone receptor positive metatstatic breast cancer in an individual in need thereof comprising administering to the individual an effective amount of an inclusion complex comprising fulvestrant and a cyclodextrin, or a formulation thereof and tipifarnib.
- the inclusion complex comprising fulvestrant and a cyclodextrin, or a formulation thereof, and the other pharmaceutical agent are administered simultaneously. In some embodiments, the inclusion complex comprising fulvestrant and a cyclodextrin, or a formulation thereof, and the other pharmaceutical agent are administered sequentially. Either the inclusion complex or the other pharmaceutical agent may be administered first. The inclusion complex and the other pharmaceutical agent may be contained in the same or different packages or compositions.
- the amount of the inclusion complex administered to an individual may vary based on a variety of factors, including, for example, the particular condition being treated, the frequency of administration, the particular formulation being administered, the severity of the condition being treated and the age, weight and general health of the individual, the adverse effects experienced by the individual being treated, etc.
- a pharmaceutical unit dosage chosen may be fabricated and administered to provide a defined final concentration of drug in the blood, tissues, organs, or other targeted region of the body. Determination of an effective amount for a given situation can be readily determined by routine experimentation (e.g., using in vivo animal models) and is within the skill and judgment of the ordinary clinician, particularly in view of the teachings provided herein.
- an effective amount of the inclusion complex or therapy may do any one or more of the following: (i) reduce the number of cancer cells; (ii) reduce tumor size; (iii) inhibit, retard, slow to some extent, and preferably stop cancer cell infiltration into peripheral organs; (iv) inhibit (e.g., slow to some extent and preferably stop) tumor metastasis; (v) inhibit tumor growth; (vi) prevent or delay occurrence and/or recurrence of a tumor, and (vii) relieve to some extent one or more of the symptoms associated with the cancer.
- the amount is sufficient to ameliorate, palliate, lessen, and/or delay one or more of symptoms of cancer.
- an effective amount of the inclusion complex or therapy may inhibit, retard, slow to some extent, prevent, delay occurrence and/or recurrence of; or relieve to some extent one or more of the symptoms associated with systemic lupus erythematosus.
- the effective amount may vary depending on the composition being administered, the condition being treated/prevented, the severity of the condition being treated/prevented, the age, body size, weight, and relative health of the individual, the route and form of administration, the judgement of the attending medical or veterinary practitioner (if applicable), and other factors appreciated by the skilled artisan in view of the teaching provided herein.
- An effective amount may be assessed, for example, by using data from one or more clinical, physiological, biochemical, histological, electrophysiological, and/or behavioral evaluations.
- the amount of the inclusion complex comprising fulvestrant and a cyclodextrin is effective to result in an objective response (such as a partial response or a complete response). In some embodiments, the amount of inclusion complex is sufficient to result in a complete response in the individual. In some embodiments, the amount of the inclusion complex is sufficient to result in a partial response in the individual. In some embodiments, the amount of the inclusion complex administered alone is sufficient to produce an overall response rate of more than about any of about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% among a population of individuals treated with the complex. Responses of an individual to treatment can be determined by the skilled artisan using, for example routine physical exams and/or clinical detection known in the art and/or described herein.
- the amount of the inclusion complex is below the level that induces a toxicological effect (where the toxicological effect in one aspect is an effect above a clinically acceptable level of toxicity) or is at a level where a potential side effect can be controlled or tolerated when the complex is administered to the individual.
- the amount of the inclusion complex is close to a maximum tolerated dose (MTD) of the complex following the same dosing regime.
- the amount of the inclusion complex is more than any of about 80%, 90%, 95%, or 98% of the MTD.
- the amount of fulvestrant from an inclusion complex comprising fulvestrant and a cyclodextrin is included in any of the following ranges: about 0.1 to about 5 mg, about 1 to about 10 mg, about 5 to about 10 mg, about 10 to about 15 mg, about 15 to about 20 mg, about 20 to about 25 mg, about 20 to about 50 mg, about 25 to about 50 mg, about 50 to about 75 mg, about 50 to about 100 mg, about 75 to about 100 mg, about 100 to about 125 mg, about 125 to about 150 mg, about 150 to about 175 mg, about 175 to about 200 mg, about 200 to about 225 mg, about 225 to about 250 mg, about 250 to about 300 mg, about 300 to about 350 mg, about 350 to about 400 mg, about 400 to about 450 mg, about 450 to about 500 mg, about 550 to about 600 mg, about 650 to about 700 mg, or about 750 to about 800 mg.
- the amount of fulvestrant from an inclusion complex is in the range of about 1 mg to about 800 mg, such as about 5 mg to about 700 mg, 10 mg to about 500 mg, 20 mg to about 250 mg, or about 25 mg, 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 500 mg, 600 mg, 700 mg, or 800 mg.
- the concentration of fulvestrant from an inclusion complex comprising fulvestrant and cyclodextrin as inclusion complex is dilute (about 0.1 mg/ml) or concentrated (about 200 mg/ml), including for example any of about 0.1 to about 200 mg/ml, about 0.1 to about 100 mg/ml, about 1 to about 50 mg/ml, about 2 mg/ml to about 25 mg/ml, about 4 to about 10 mg/ml, about 5 mg/ml.
- the concentration of fulvestrant of the inclusion complex is at least about any of 0.5 mg/ml, 1.3 mg/ml, 1.5 mg/ml, 2 mg/ml, 3 mg/ml, 4 mg/ml, 5 mg/ml, 6 mg/ml, 7 mg/ml, 8 mg/ml, 9 mg/ml, 10 mg/ml, 15 mg/ml, 20 mg/ml, 25 mg/ml, 30 mg/ml, 40 mg/ml, 50 mg/ml, 60 mg/ml, 70 mg/ml, 80 mg/ml, 90 mg/ml, 100 mg/ml, 150 mg/ml, or 200 mg/ml.
- Exemplary effective amounts of fulvestrant from an inclusion complex comprising fulvestrant and a cyclodextrin include, but are not limited to, any of about 2.5 mg/m 2 , 5 mg/m 2 , 10 mg/m 2 , 15 mg/m 2 , 20 mg/m 2 , 25 mg/m 2 , 30 mg/m 2 , 50 mg/m 2 , 60 mg/m 2 , 75 mg/m 2 , 80 mg/m 2 , 90 mg/m 2 , 100 mg/m 2 , 120 mg/m 2 , 160 mg/m 2 , 175 mg/m 2 , 180 mg/m 2 , 200 mg/m 2 , 210 mg/m 2 , 220 mg/m 2 , 250 mg/m 2 , 260 mg/m 2 , 300 mg/m 2 , 350 mg/m 2 , 400 mg/m 2 , 500 mg/m 2 , 540 mg/m 2 , 750 mg/m 2 , 1000 mg/m 2 , or 1080 mg/
- a formulation includes less than about any of 350 mg/m 2 , 300 mg/m 2 , 250 mg/m 2 , 200 mg/m 2 , 150 mg/m 2 , 120 mg/m 2 , 100 mg/m 2 , 90 mg/m 2 , 50 mg/m 2 , or 30 mg/m 2 of fulvestrant.
- the amount of fulvestrant within the inclusion complex per administration is less than any of about 25 m/m, 22 m/m 2 , 20 mg/m 2 , 18 mg/m 2 , 15 mg/m 2 , 14 mg/m 2 , 13 mg/m 2 , 12 mg/m 2 , 11 mg/m 2 , 10 mg/m 2 , 9 mg/m 2 , 8 mg/m 2 , 7 mg/m 2 , 6 mg/m 2 , 5 mg/m 2 , 4 mg/m 2 , 3 mg/m 2 , 2 mg/m 2 , or 1 mg/m.
- the effective amount of fulvestrant from the inclusion complex is included in any of the following ranges: about 1 to about 5 mg/m, about 5 to about 10 mg/m 2 , about 10 to about 25 mg/m 2 , about 25 to about 50 mg/m 2 , about 50 to about 75 mg/m 2 , about 75 to about 100 mg/m 2 , about 100 to about 125 mg/m 2 about 125 to about 156 mg/m 2 , about 150 to about 175 mg/m 2 , about 175 to about 200 mg/m 2 , about 200 to about 225 mg/m 2 , about 225 to about 250 mg/m 2 , about 250 to about 300 mg/m 2 , about 300 to about 350 mg/m 2 , or about 350 to about 400 mg/m 2 .
- the effective amount of fulvestrant from an inclusion complex comprising fulvestrant and a cyclodextrin includes at least any of about 0.01 mg/kg, 0.05 mg/kg, 0.1 mg/kg, 0.25 mg/kg, 0.5 mg/kg, 1 mg/kg, 1.5 mg/kg, 2 mg/kg, 2.5 mg/kg, 3.5 mg/kg, 5 mg/kg, 6.5 mg/kg, 7.5 mg/kg, 10 mg/kg, 15 mg/kg, or 20 mg/kg.
- the effective amount of fulvestrant includes less than any of about 350 mg/kg, 300 mg/kg, 250 mg/kg, 200 mg/kg, 150 mg/kg, 100 mg/kg, 50 mg/kg, 25 mg/kg, 20 mg/kg, 10 mg/kg, 7.5 mg/kg, 6.5 mg/kg, 5 mg/kg, 3.5 mg/kg, 2.5 mg/kg, 2 mg/kg, 1.5 mg/kg, 1 mg/kg, 0.75 mg/kg, 0.5 mg/kg, 0.25 mg/kg, 0.1 mg/kg, 0.05 mg/kg.
- Exemplary dosing frequencies include, but are not limited to, weekly without break; weekly, three out of four weeks; once every three weeks; once every two weeks; weekly, two out of three weeks.
- the inclusion complex is administered any of about once every 2 weeks, once every 3 weeks, once every 4 weeks, once every 6 weeks, or once every 8 weeks.
- the composition is administered at least any of about 1 ⁇ , 2 ⁇ , 3 ⁇ , 4 ⁇ , 5 ⁇ , 6 ⁇ , or 7 ⁇ (i.e., daily) a week.
- the intervals between each administration are less than any of about 6 months, 3 months, 1 month, 20 days, 15, days, 12 days, 10 days, 9 days, 8 days, 7 days, 6 days, 5 days, 4 days, 3 days, 2 days, or 1 day. In some embodiments, the intervals between each administration are more than any of about 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 8 months, or 12 months. In some embodiments, there is no break in the dosing schedule. In some embodiments, the interval between each administration is no more than about a week.
- the administration of the inclusion complex can be extended over an extended period of time, such as from about a month up to about seven years.
- the composition is administered over a period of at least any of about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 18, 24, 30, 36, 48, 60, 72, or 84 months.
- the dosing frequency of the inclusion complex may be adjusted over the course of the treatment based on the judgment of the administering physician. For example, a multiple daily dosage routine of the inclusion complex may be included.
- the inclusion complexes described herein allow, in some embodiments, infusion of the complex to an individual over an infusion time that is shorter than about 24 hours.
- the inclusion complex is administered over an infusion period of less than any of about 24 hours, 12 hours, 8 hours, 5 hours, 3 hours, 2 hours, 1 hour, 30 minutes, 20 minutes, or 10 minutes. In some embodiments, the inclusion complex is administered over an infusion period of about 30 minutes.
- inclusion complexes described herein can be administered to an individual (such as human) via various routes, including, for example, intravenous, intra-arterial, intraperitoneal, intrapulmonary, oral, inhalation, intravesicular, intramuscular, intra-tracheal, subcutaneous, intraocular, intrathecal, transmucosal, intranasal, rectal, intravaginal and transdermal.
- routes including, for example, intravenous, intra-arterial, intraperitoneal, intrapulmonary, oral, inhalation, intravesicular, intramuscular, intra-tracheal, subcutaneous, intraocular, intrathecal, transmucosal, intranasal, rectal, intravaginal and transdermal.
- sustained continuous release formulation of the composition may be used.
- inclusion complex is administered by any acceptable route including, but not limited to, orally, intramuscularly, transdermally, intravenously, intranasally, rectally, intravaginally through an inhaler or other air borne delivery systems and the like. Additional methods of administration are known in the art.
- the inclusion complexes described herein are administered parenterally (e.g., intravenously).
- parenterally e.g., intravenously
- methods of treating a cancer in an individual comprising intranasally administering an inclusion complex comprising fulvestrant and a cyclodextrin.
- inclusion complexes described herein may allow the complexes to be taken orally or sublingually.
- the inclusion complexes or formulations comprising the complexes are suitable for oral or sublingual administration.
- the inclusion complexes may be administered with an additional therapeutic agent and/or an additional treatment modality.
- the dosing frequency of the inclusion complex and the additional pharmaceutical agent may be adjusted over the course of the treatment based on the judgment of the administering physician.
- the inclusion complex and the additional therapeutic agent can be administered at different dosing frequency or intervals.
- the inclusion complex can be administered weekly, while the additional therapeutic agent can be administered more or less frequently.
- sustained continuous release formulation of the inclusion complex and/or the additional therapeutic agent may be used.
- Various formulations and devices for achieving sustained release are known in the art. A combination of the administration configurations described herein can be used.
- the inclusion complex (e.g., the inclusion complex comprising fulvestrant and a cyclodextrin) can be administered daily and the additional therapeutic agent (e.g., FASLODEX®) can be administered monthly.
- the inclusion complex e.g., the inclusion complex comprising fulvestrant and a cyclodextrin
- the additional therapeutic agent e.g., FASLODEX®
- the inclusion complex can be administered weekly and the additional therapeutic agent (e.g., FASLODEX®) can be administered monthly.
- the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD). In some embodiments, the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD), wherein HPBCD or MBCD is used in a formulation for intravascular administration.
- the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD), wherein HPBCD or MBCD is used in a formulation for slow intravascular administration.
- HPBCD hydroxypropyl beta-cyclodextrin
- MBCD methyl beta-cyclodextrin
- the commercial product e.g., FASLODEX®
- the commercial product e.g., FASLODEX®
- excellent stability at room temperature may be attained by the inclusion complex of the present invention: an inclusion complex of the invention has been found to be stable at temperatures of over 25° C. and at 40° C. for over 24 months.
- the fulvestrant used in the Examples was obtained from Hangzhou Hysen Pharma Co., Ltd., Hangzhou, China.
- the HPLC system used for the chromatographic determination of fulvestrant consisted of a Waters 600E quaternary gradient pump, a Waters 717plus WISP autosampler and a Waters 2487 Dual A, Absorbance detector. Separation was performed using a Phenomenex Luna C18 column (250 ⁇ 4.6 mm; 5 urn) (Phenomenex, Torrance, Calif.) (supplied by Separations, South Africa) and a mobile phase consisting of 50% MeCN:22.5% ddH 2 0:27.5% MeOH. The mobile phase was degassed and filtered prior to use.
- the fulvestrant used for preparation of standard solutions was of pharmaceutical grade.
- the acetonitrile used as mobile phase was of HPLC grade (Merck Chemicals, South Africa). Double distilled water (ddH 2 0) was used at all times during the assay.
- Stock fulvestrant solution was prepared according to the following steps: 1) 10 mg of fulvestrant powder was accurately weighed into a 10 mL volumetric flask; 2) the fulvestrant powder was dissolved and made to volume in mobile phase; 3) this solution was then vortexed for at least 20 seconds to ensure complete dissolution of the analyte. A concentration range of 10-500 ⁇ g/mL fulvestrant was prepared in the mobile phase. Calibration data generated during the fulvestrant aqueous solubility study for one of the fulvestrant calibration plots is presented in Table 10, with the graphical presentation of the data presented in FIG. 1 . The method, which produced a linear plot, is suitable for the evaluation of fulvestrant.
- Fulvestrant HPLC calibration data TABLE 10 Fulvestrant HPLC calibration data. Fulvestrant Concentration ( ⁇ g/mL) Peak Area 10 6017.79 20 11356.84 50 29814.88 100 57946.34 200 114870.10 300 173177.22 400 229736.60 500 287091.62
- ACD Alpha-Cyclodextrin
- aqueous solubility of fulvestrant was evaluated in the presence of increasing concentrations of ACD and the absence thereof.
- aqueous solubility of fulvestrant was evaluated in the presence of increasing concentrations of BCD and the absence thereof.
- aqueous solubility of fulvestrant was evaluated in the presence of increasing concentrations of MBCD and the absence thereof.
- aqueous solubility of fulvestrant was evaluated in the presence of increasing concentrations of HPBCD and the absence thereof.
- aqueous solubility of fulvestrant was evaluated in the presence of increasing concentrations of SBEBCD and the absence thereof.
- aqueous solubility of fulvestrant was evaluated in the presence of increasing concentrations of GCD and the absence thereof.
- aqueous solubility of fulvestrant was evaluated in the presence of increasing concentrations of HPGCD and the absence thereof.
- fulvestrant forms inclusion complexes with cyclodextrins to greater and lesser extents, depending on the specific cyclodextrin.
- Fulvestrant aqueous solubility enhancements with ACD; SBEBCD and HPGCD yielded fulvestrant aqueous solubilities of between 1 to 2 mg/mL, which was a significant enhancement over the aqueous solubility of fulvestrant in the absence of these cyclodextrins.
- the aqueous solubility enhancements of fulvestrant with BCD and GCD were lower.
- aqueous solubility of fulvestrant in the presence of HPBCD was enhanced from below 0.010 mg/mL to 5.5 mg/mL in 400 mg/mL HPBCD.
- the greatest aqueous solubility enhancement of fulvestrant was, however, achieved with MBCD, whereby the fulvestrant aqueous solubility was significantly enhanced from below 0.010 mg/mL to 35.9 mg/mL in 400 mg/mL MBCD.
- the test articles were considered to be >99% pure and contained 5 mg/mL of fulvestrant.
- the vehicles used to prepare the two novel batches comprised 400 mg/mL hydroxypropyl beta-cyclodextrin (HPBCD) (Batch 1) and 400 mg/mL methyl beta-cyclodextrin (MBCD) (Batch 2).
- the control fulvestrant formulation comprised of a 5 mg/mL fulvestrant suspension in ddH 2 0 (Batch 3). All animals were fasted for approximately 24 hours prior to dose administration. Water was available ad libitum. Pre-dose, and 1 h and 2 h post dose blood sampling was conducted by means of the tail snip procedure, whereby 0.5 mL was collected at each sampling point.
- rats Five minutes prior to the final (3 h) blood sampling point, rats were anaesthetised with 0.5 ml 6% sodium pentobarbitone and 5 mL blood was collected. Prior to drug administration by means of gavage, each of the rats was anaesthetized with halothane gas, following which a gavage tube was inserted through the mouth and through which the various solutions were administered. 0.5 mL saline was administered through the gavage tubes immediately following drug administration.
- mice All of the animals that were dosed by means of oral gavage were bled pre-dose, and at 1 hour (h) and 2 h post dose, with blood sampling having been conducted by means of the tail snip procedure, whereby 0.5 mL was collected at each sampling point.
- rats Five minutes prior to the terminal blood sampling point (3 h), rats were anaesthetised with 0.5 ml 6% sodium pentobarbitone and 5 mL blood was collected from each, after which the rats were sacrificed.
- the tail snip blood was collected in 1 mL K3E (K 3 EDTA) MINICOLLECT® (Greiner Bio-one; Lot 090319; Exp. 2010-08) blood collection tubes, with the terminal samples having been collected in 9 mL K3E (K 3 EDTA) VACUETTE® (Greiner Bio-one; Lot A090602D; Exp. 2010-12) blood collection tubes. Following collection, the samples were placed on ice and then centrifuged at 4° C. for 15 minutes. 0.2 mL and 2 mL plasma aliquots were obtained from the tail snip and terminal sampling points respectively. These samples were frozen ( ⁇ 60° C. to ⁇ 80° C.) prior to being shipped on dry ice to a facility for analysis of fulvestrant concentrations.
- test article fulvestrant
- LC-MS liquid chromatography-mass spectroscopy
- LC-MS/MS method was developed and used to determine fulvestrant in rat plasma.
- rat plasma samples were thawed at room temperature, briefly vortexed, after which 100 uL plasma was pipetted into 1.5 ml Eppendorf® Safe-Lock® microcentrifuge tubes. Samples were then precipitated with methanol (200 uL) containing the internal standard, doxepin (245 ng/mL). These samples were vortexed for 30 seconds and centrifuged for 5 minutes at 15 000 rpm. The supernatant (200 uL) was transferred to 96 well plates and 5 uL was injected onto the HPLC column.
- Calibration standards were prepared in rat plasma (anticoagulant lithium heparinate), whereby a stock solutions of fulvestrant in methanol was used to spike a pool of blank rat plasma which was serially diluted with blank rat plasma to attain the desired concentrations, spanning a range of 4.5 ng/mL to 1149 ng/mL (STD 1-STD 9).
- both of the cyclodextrin based fulvestrant formulations presented with fulvestrant being recovered from all post-dose samples collected from these two groups of animals, thus indicating that the two cyclodextrin based formulations do enhance oral bioavailability of fulvestrant significantly.
- HPBCD and MBCD based formulations presented with similar fulvestrant plasma concentrations over time, as may be evidenced by the data presented in FIG. 12 , whereby the mean C max values for the HPBCD and MBCD formulations were measured at 86.1 ng/mL and 96.6 ng/mL respectively and T max occurring for both formulations at the 1 hour sampling point.
- aqueous formulations of fulvestrant complexed with HPBCD or MBCD offer viable opportunities as oral formulations.
- Oral formulations present with distinct advantages over the currently marketed long acting IM fulvestrant formulations, which present with pain upon injection, owing to the 5 mL injection volume.
- long acting IM fulvestrant 250 mg/5 mL
- a viable oral formulation can achieve the desired plasma levels immediately, thus replacing the need for an IM formulation, or can be used together with the IM formulation as part of a loading-dose regimen.
- Example 3 Oral Fulvestrant Absorption Study Using Fulvestrant and Hydroxypropyl Beta-Cyclodextrin (HPBCD) in Whistar Rats
- Fulvestrant was administered at a dose of 5 mg/kg by oral gavage to each animal, with blood concentrations measured hourly over a 4-hour period.
- the vehicle used to prepare the novel batch comprised 450 mg/mL hydroxypropyl beta-cyclodextrin (HPBCD) (Batch 7_4). All animals were fasted for approximately 24 hours prior to dose administration. Water was available ad libitum. Pre-dose, and 1, 2 and 3 hour post dose blood sampling for the oral gavage group was conducted by means of the tail snip procedure, whereby 0.5 mL was collected at each sampling point.
- mice Five minutes prior to the final (4-hour) blood sampling point, rats were anaesthetised with 0.5 ml 6% sodium pentobarbitone and 5 mL blood was collected. Prior to drug administration by means of gavage, each of the rats were anaesthetized with halothane gas, following which a gavage tube was inserted through the mouth and through which the various solutions were administered. 0.5 mL saline was administered through the gavage tubes immediately following drug administration. The information for this example is summarized in Table 25.
- the tail snip blood was collected in 1 mL K3E (K 3 EDTA) MINICOLLECT® (Greiner Bio-one; Lot 090319; Exp. 2010-08) blood collection tubes, with the terminal samples having been collected in 4 mL K3E (K 3 EDTA) VACUETTE® (Greiner Bio-one; Lot L020902; Exp. 2010-08) blood collection tubes. Following collection, these samples were placed on ice and then centrifuged at 4° C. for 15 minutes. 0.2 mL and 2 mL plasma aliquots were obtained from the tail-snip and terminal sampling points respectively. These samples were frozen ( ⁇ 60° C.
- fulvestrant was measured in adult Whistar rat plasma by via an LC-MS method. Individual and mean plasma fulvestrant concentration-time profiles following oral administration by gavage in this example are presented in FIG. 13 and Table 26.
- fulvestrant-HPBCD novel fulvestrant-hydroxypropyl-beta-cyclodextrin
- the oral fulvestrant solutions contained 5 mg/mL of fulvestrant in 450 mg/mL HPBCD.
- the fulvestrant SA IM control fulvestrant formulation was a short acting formulation, developed, described and used by AstraZeneca (20 mg/mL fulvestrant).
- Venous blood samples (1 ml) were obtained from each animal at pr-dose and the following times post-dose (in minutes): 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 210, 240, 300, 360, 480, 720, 1080 and 1440.
- Samples were collected via implanted vascular ports in the jugular veins of the dogs and into tubes containing K 2 EDTA anticoagulant. Following collection, the blood samples were placed on ice and then centrifuged for 15 minutes. The plasma was harvested and approximately 0.5 mL aliquots were stored frozen ( ⁇ 18° C.) prior to being shipped on dry ice to a contract laboratory for the determination of fulvestrant in the plasma samples.
- the same liquid chromatography-mass spectroscopy (LC-MS) analytical method was employed as that described in Example 3.
- Mean values for these parameters are: Absorption halftime—19 min; Estimated bioavailability—6.5% (relative to and assuming 100% bioavailability for the LA IM fulvestrant formulation); T max ⁇ 74 min; MRT—258 min; elimination halftime—55 min.
- FIG. 15 illustrates a simulation of oral dosing to an “average” beagle dog, employing a regimen of 5 mg/kg every eight hours for 24 hours. It is postulated that similar rapid absorption may be achieved in humans.
- Samples were assayed via HPLC for fulvestrant content following manufacture and at each evaluation point (3; 6; 9; 12; 18 and 24-months post manufacture).
- the HPLC method used was also specific to the detection of the presence of the principle fulvestrant degradation product, fulvestrant sulphone.
- the HPLC method employed is the same as that described in Example 1. At each sampling point, three vials were selected for fulvestrant quantification; evaluation for the presence of fulvestrant sulphone and pH determination.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- Physiology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Nanotechnology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
- This patent application claims priority from U.S. 61/383,660, the content of which is incorporated herein by reference.
- The present invention relates to inclusion complexes between fulvestrant and a cyclodextrin, and formulations thereof. Methods of preparing fulvestrant inclusion complexes are also provided. Moreover, the present invention relates to the use of inclusion complexes of, and pharmaceutical formulations comprising, fulvestrant and a cyclodextrin in the treatment of a disease or condition that is or is believed to be responsive to anti-estrogen therapy and/or ER-downregulation, such as cancer.
- Fulvestrant (7-alpha-[9-(4,4,5,5,5-penta fluoropentylsulphinyl)nonyl]estra-1,3,5-(10)-trien-3,17-beta-diol), has the structural formula (I):
- and is commercially available as an oily parenteral formulation for monthly intramuscular administration under the tradename FASTODEX® (AstraZeneca Pharmaceuticals LP). Fulvestrant contains 6 asymmetric carbon atoms and a stereogenic sulphoxide in the side chain. The active ingredient of FASLODEX™ is a mixture of 2 diastereoisomers:fulvestrant sulphoxide A and B, having the same absolute configuration at each of the stereogenic centers in the steroid system but different absolute configurations at the sulphur atom. Commercially available Fulvestrant is a mixture of two diastereoisomers, Fulvestrant Sulphoxide A and Fulvestrant Sulphoxide B. Fulvestrant formulations have been described in, for example, U.S. Pat. Nos. 6,774,122 and 7,456,160.
- Fulvestrant acts as an estrogen receptor antagonist without agonist properties, blocking the trophic actions of estrogens without itself having any partial agonist (estrogen-like) activity on the endometrium. Fulvestrant binds to estrogen receptors (ERs) in a competitive manner with affinity comparable with that of estradiol and downregulates the ER protein in human breast cancer cells. Data from pro-clinical studies indicated that fulvestrant is effective against human breast cancer cells and xenografts displaying acquired resistance to tamoxifen or letrozole. See, Osborne et al, Cancer Chemother. Pharmacol., 134(2): 89-95 (1994); Osborne et al, Journal of the National Cancer Institute, 87(10) 746-750 (1995); and Long and Jelovac, Clinical Cancer Research, 8:2378-2388 (2002). FASLODEX® is currently indicated for use in the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Bross et al., The Oncologist, 7:477-480 (2002).
- Fulvestrant's characteristics, such as having a very high lipophilicity, extremely low aqueous solubility and the fact that it is only ionized at very high pH, present formulation challenges and account for its administration as an oily intramuscular injection. Commercially available FASLODEX® is an intramuscular injection of 250 mg fulvestrant in a sterile oily solution in either a single 5 ml pre-filled syringe or two 2.5 ml pre-filled syringes, as long acting injection(s). The long acting FASLODEX® intramuscular depot formulation contains benzyl alcohol and castor oil as solvents and is designed to deliver the dose of 250 mg of fulvestrant over a 1 month period from a single 5 ml intramuscular injection in the buttock or two 2.5 ml intramuscular injection into the buttocks. Bross et al., The Oncologist, 7:477-480 (2002). While this required monthly dose of 250 mg or bi-monthly dose of 125 mg of fulvestrant is effective, it takes approximately 3-6 months to achieve steady-state plasma levels of fulvestrant. See, e.g., Chia and Gradishar, The Breast 17:S16-S21 (2008); and William et al., Clinical Breast Cancer, 6(1):S23-S29 (2005). Decreasing the time in which steady-state plasma levels are reached following administration of fulvestrant may reduce the time taken to achieve a therapeutic response, which can be particularly beneficial for patients who would otherwise experience disease progression early during endocrine treatment Robertson, J. F. R, The Oncologist 12:744-784 (2007). In addition, increasing ER downregulation with higher doses of fulvestrant may provide a better treatment response. Id.
- Alternative dosing regimens of FASLODEX® have been suggested as a way to enhance the efficacy of fulvestrant therapy. However, even if alternative dosing regimens of FASLODEX® were to provide a therapeutic benefit, administration of fulvestrant as an intramuscular injection still has various disadvantages. For example, injection-site reaction, including transient pain and inflammation, is one of the most common drug-related events reported for FASLODEX®. Bross, The Oncologist, 7:477-480 (2002). Other disadvantages associated with intramuscular administration include nerve/bone damage during needle insertion, pain and tissue damage, accidental injection of air into artery or vein, extreme pain and/or tissue damage. Such events would only increase if new dosing regimens require more frequent injections. Intramuscular injections may also be inconvenient to the patient and be a source of anxiety, which can adversely impact patient compliance. In one study of patient preference for administration of endocrine therapy by injection or oral tablets, the majority of respondants generally preferred administration via daily tablets. L. Fallowfield, et ah, Annals of Oncology, 17: 205-210 (2006). Given the importance of patient compliance to therapeutic outcome, patient preference is an important consideration. In addition, intramuscular injections are not suitable for all patients. For example, patients with certain blood disorders (e.g., bleeding diatheses, thrombocytopenia) or receiving anticoagulants may not be suitable candidates for administration of fulvestrant by intramuscular injection.
- Delivery of fulvestrant via non-invasive formulations, such as oral delivery, have been explored, but adequate bioavailability, aqueous solubility, and target formulation concentration could not be achieved, presumably due to the high lipophilicity and low aqueous solubility of fulvestrant. See, e.g., Harrison M., et al., (2003) Proc. ASCO, 22: 45, abstract 311.
- There therefore remains a need for additional fulvestrant formulations, such as formulations that render fulvestrant suitable for oral, intranasal and/or sublingual administration.
- The present invention provides inclusion complexes, kits, formulations, and unit dosages comprising fulvestrant and a cyclodextrin. Also provided are methods of producing fulvestrant inclusion complexes and methods of treating a disease or indication that is responsive to fulvestrant therapy comprising administering a fulvestrant inclusion complex or formulation thereof to an individual.
- In one aspect, an inclusion complex comprising a) a cyclodextrin; and b) a compound of the formula (I):
- or a salt thereof or a solvate of the foregoing, is provided. The compound of formula (I) is also referred to herein as “fulvestrant”. In some embodiments of any of the aspects of the invention, the compound of the formula (I) is fulvestrant sulphoxide A, fulvestrant sulphoxide B, or a mixture of fulvestrant sulphoxide A and fulvestrant sulphoxide B. It is understood that fulvestrant salts, such as pharmaceutically acceptable salts, and solvates thereof, are also intended by the descriptions provided herein. Thus, all salt and non-salt forms of fulvestrant and solvates of the foregoing are embraced by the invention and descriptions of fulvestrant provided herein. In some embodiments, the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD).
- In some embodiments of any of the aspects of the invention, the cyclodextrin for use in the inclusion complexes and formulations herein is a water soluble unsubstituted or substituted alpha-cyclodextrin (ACD), beta-cyclodextrin (BCD), or gamma-cyclodextrin (GCD). In some embodiments, the beta-cyclodextrin is selected from the group consisting of methyl beta-cyclodextrin (MBCD), hydroxypropyl beta-cyclodextrin (HPBCD), and sulfobutylether beta-cyclodextrin (SBEBCD). In some embodiments, the beta-cyclodextrin is methyl beta-cyclodextrin or hydroxypropyl beta-cyclodextrin. In some embodiments, the gamma-cyclodextrin is hydroxypropyl gamma-cyclodextrin (HPGCD). In one preferred embodiment, the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD).
- In one aspect, provided are methods for improving the solubility of a compound of the formula (I) in water comprising combining the compound of the formula (I) with a cyclodextrin. In another aspect, a method of increasing the water solubility of a compound of formula (I) is provided, wherein the method comprises forming an inclusion complex of a cyclodextrin and a compound of the formula (I). In some embodiments, the solubility of the compound of the formula (I), when present as an inclusion complex with a cyclodextrin in deionized water at 20° C., is increased by at least about or about 1.5-fold or 2-fold, when compared to the solubility of the compound of formula (I) in uncomplexed form under the same conditions. In other embodiments, the solubility, such as the aqueous solubility, of fulvestrant in an inclusion complex may be increased by at least about or about any of 3, 4, 5, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 1,000, 2,000-fold or more over uncomplexed fulvestrant. Solubility comparisons may be assessed by methods known to the skilled artisan, such as any of the specific methods and conditions detailed herein. In one preferred embodiment, the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD).
- A method of increasing the oral bioavailability of a compound of formula (I) is provided, wherein the method comprises forming an inclusion complex of a cyclodextrin and a compound of the formula (I). In some embodiments, the oral bioavailability of the compound of the formula (I), when present as an inclusion complex with a cyclodextrin, is at least about 50% greater than the oral bioavailability of the compound of the formula (I) in uncomplexed form. Oral bioavailability, and comparisons thereof, may be assessed by methods known in the art, including any of the specific methods described herein. In one preferred embodiment, the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD).
- In some embodiments, an inclusion complex of a compound of formula (I) and a cyclodextrin are provided, wherein the inclusion complex is capable of inducing a greater maximum concentration (Cm) of the compound systemically than what is achievable when the compound is administered alone in the same amount and under the same conditions. In one aspect, an inclusion complex of the compound of formula (I) is capable of inducing at least about or about 1.5 or 2 or more times greater Cmax for the compound systemically than what is achievable when the compound is administered alone in the same amount and under the same conditions. In some embodiments, the Cmax of fulvestrant, when administered to an individual as an inclusion complex with a cyclodextrin, is at least about 2 times greater than the Cmax of fulvestrant administered alone under the same conditions. In one preferred embodiment, the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD).
- In some embodiments, an inclusion complex of a compound of formula (I) and a cyclodextrin is provided, wherein the inclusion complex is capable of inducing a greater area under the plasma concentration vs. time curve (AUC) of the compound than what is achievable when the compound is administered alone (in the absence of a cyclodextrin) in the same amount and under the same conditions. In one aspect, an inclusion complex of the compound of formula (I) is capable of inducing at least about or about 1 or 2 or more times greater AUC of compound than what is achievable when the compound is administered alone in the same amount and under the same conditions. In some embodiments, the AUC of fulvestrant, when administered to an individual as an inclusion complex with a cyclodextrin, is at least about 2 times greater than the AUC of fulvestrant administered alone in the same amount and under the same conditions. In one preferred embodiment, the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD).
- In some embodiments, an inclusion complex of a compound of formula (I) and a cyclodextrin is provided, wherein the inclusion complex is capable of inducing a change in the time to reach the maximum plasma level (Tmax) of the compound than what is achievable when the compound is administered alone (in the absence of a cyclodextrin) in the same amount and under the same conditions. In one aspect, Tmax is shorter with a fulvestrant inclusion complex. In one aspect, an inclusion complex of the compound of formula (I) is capable of reducing Tmax by about 0.5 or 1 or 2 fold over what is achievable when the compound is administered alone in the same amount and under the same conditions. In some embodiments, the Tmax of fulvestrant, when administered to an individual as an inclusion complex with a cyclodextrin, is at least about 2 times lower than the Tmax of fulvestrant administered alone in the same amount and under the same conditions. In one aspect, a fulvestrant inclusion complex reduces Tmax by at least about or about any of 1, 2, 3, 5, 10 and 12 hours or more. In one preferred embodiment, the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD).
- In some embodiments, an orally, intranasally, sublingually, rectally, or vaginally administered inclusion complex of a compound of formula (I) and a cyclodextrin is provided, wherein the inclusion complex may be administered together with a long acting intramuscular fulvestrant formulation (e.g., FASLODEX®), compensating for the time required for the long acting intramuscular fulvestrant formulation alone to reach steady state fulvestrant plasma concentrations. In one preferred embodiment, the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD).
- In some embodiments, a composition comprising a cyclodextrin and a compound of the formula (I) are provided, wherein the molar ratio of the compound of formula (I) to the cyclodextrin is from about 1:1 to about 1:300. In one aspect, the composition comprises an inclusion complex of a cyclodextrin and a compound of the formula (I). In another aspect, the composition comprises a physical mixture of a cyclodextrin and a compound of the formula (I), wherein the physical mixture does not comprise or is substantially free of an inclusion complex of a cyclodextrin and a compound of the formula (I). In one preferred embodiment, the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD).
- In another aspect, a formulation comprising a) a cyclodextrin; b) a compound of the formula (I), or a salt thereof or solvate of the foregoing; and c) a carrier, are provided. In one aspect, the formulation comprises an inclusion complex of the compound and a cyclodextrin. In one variation, the carrier is a pharmaceutically acceptable carrier. The carrier may be in liquid, solid or semi-solid form. When the carrier is a liquid, it may be aqueous or an organic solvent, or a combination thereof in any amount. In one aspect, the carrier is selected from the group consisting of a solvent, a complexing agent, a filler, a diluent, a granulating agent, a disintegrant, a lubricant, a glidant, a pH-modifier, a tonicity modifier, an adjuvant, a dye, a polymer-based film coating, and a binder. In some embodiments, the carrier is one or more of water for injection, microcrystalline cellulose, glucose, sodium lauryl sulphate, crosscarmellose sodium, colloidal silica, talc, magnesium stearate, sodium benzoate, aluminum magnesium silicate, lactose, methanol, ethanol, propanol, and acetone. More than one carrier may be employed and combinations of carriers provided herein are intended. In one preferred embodiment, the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD).
- Formulations comprising a cyclodextrin and fulvestrant may further comprise additional formulation components, also referred to herein as additional agents. In some embodiments of the formulations described herein, the formulation further comprises an antioxidant. In one aspect, the antioxidant is a water-soluble antioxidant. In another aspect, the antioxidant is fully or partially water-insoluble. When a water-insoluble antioxidant is employed, care may be taken to reduce or avoid displacement of fulvestrant in the inclusion complex by the antioxidant. For example, formulations comprising a fulvestrant inclusion complex and a water-insoluble antioxidant may contain a relatively small amount of the antioxidant or take other precautions to reduce or avoid adverse consequences of the antioxidant on an inclusion complex of fulvestrant and a cyclodextrin. In some embodiments, the formulation may include combinations of two or more of the antioxidants as described herein. In some embodiments, the antioxidant is selected from the group consisting of ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, malic acid, propyl gallate, sodium bisulfite, sodium sulfite, sodium metabisulfite, potassium metabisulfite, potassium bisulfite, sodium thiosulfate, sodium formaldehyde sulfoxylate, L-ascorbic acid, D-ascorbic acid, acetylcysteine, cysteine, thioglycerol, thioglycoUic acid, thiolactic acid, thiourea, dithiothreitol, dithioeythreitol, glutathione, nordihydroguaiaretic acid, tocopherol, sodium ascorbate, hypophophorous acid, and fumaric acid. In some embodiments, the antioxidant is selected from the group consisting of butylated hydroxyanisole, malic acid, sodium bisulfite, sodium sulfite, sodium metabisulfite, potassium metabisulfite, potassium bisulfite, sodium thiosulfate, sodium formaldehyde sulfoxylate, L-ascorbic acid, D-ascorbic acid, cysteine, thiolactic acid, glutathione, nordihydroguaiaretic acid, sodium ascorbate, hypophophorous acid and fumaric acid. In some embodiments, the antioxidant is a dietary antioxidant, including, but not limited to, vitamin E, vitamin C, beta-carotene, and selenium. Other additional agents may be employed in the formulations. In one preferred embodiment, the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD).
- In some embodiments, a formulation comprising (a) a cyclodextrin; (b) a compound of the formula (I), or a salt thereof, or solvate of the foregoing; and (c) a carrier, is a solid formulation. In some embodiments, the formulation is a semi-solid. In some embodiments, the formulation is a liquid. In one preferred embodiment, the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD).
- Unit dosage forms of fulvestrant inclusion complexes and formulations comprising fulvestrant and a cyclodextrin are also provided. In some embodiments, the compound of the formula (I) is present in an amount of between about 0.1 mg and about 500 mg per unit solid or semi-solid dosage form or between about 0.1 mg/mL and about 50 mg/mL in a liquid dosage form. In some embodiments, the compound of the formula (I) is present in an amount of about 250 mg per unit solid or semi-solid dosage form or about 25 mg/mL in a liquid dosage form. In one preferred embodiment, the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD).
- In another aspect, an inclusion complex described herein is in a substantially pure form.
- Methods of administering fulvestrant inclusion complexes and formulations to an individual are also provided, as are methods of using such complexes and formulations in therapy. For example, methods of treating a disease or condition that is or is believed to be responsive to anti-estrogen therapy and/or ER-downregulation are provided, wherein the methods comprise administering to an individual in need thereof a fulvestrant inclusion complex or formulation comprising fulvestrant and a cyclodextrin, wherein fulvestrant is not complexed with the cyclodextrin. In one aspect, the disease or condition is cancer. The cancer may be early stage cancer, non-metastatic cancer, primary cancer, advanced cancer, locally advanced cancer, metastatic cancer, cancer in remission, recurrent cancer, cancer in an adjuvant setting, cancer in a neoadjuvant setting, or cancer substantially refractory to hormone therapy. In some embodiments, the cancer is selected from the group consisting of breast cancer, endometrial cancer, prostate cancer, and lung cancer. In one variation, the cancer is breast cancer, such as hormone receptor positive metastatic breast cancer. In another aspect, the disease or condition is systemic lupus erythematosus. In one preferred embodiment, the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD).
- In a particular aspect, a method of treating a cancer in an individual in need thereof is provided, wherein the method comprises administering to the individual an effective amount of an inclusion complex of a) a cyclodextrin; and b) a compound of the formula (I), or a salt thereof, or solvate of the foregoing. The method may also employ a fulvestrant formulation described herein, such as a formulation comprising a) a cyclodextrin; b) a compound of the formula (I), or a salt thereof or solvate of the foregoing, and c) a carrier (e.g., a pharmaceutically acceptable carrier). In one preferred embodiment, the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD).
- In some embodiments, the individual of the methods provided herein is a human, and may be male or female. In some embodiments the human has or is suspected of having a disease or condition that is or is believed to be responsive to anti-estrogen therapy and/or ER-downregulation, such as cancer. In some embodiments, the individual is a post-menopausal woman who has or is suspected of having hormone receptor positive metastatic breast cancer. In some embodiments, the individual is a post-menopausal woman who has or is suspected of having hormone receptor positive metastatic breast cancer with disease progression following hormone (e.g., anti-estrogen) therapy. In some embodiments the human has or is suspected of having systemic lupus erythematosus.
- In one aspect of the methods, the fulvestrant inclusion complex, or a fulvestrant formulation provided herein, is intranasally, orally, sublingually, rectally, and/or vaginally administered to the individual in need thereof. In some embodiments, the dosage of fulvestrant in the administered dose is between about 0.1 mg and about 500 mg per unit solid or semi-solid dosage form or between about 0.1 mg/mL and about 50 mg/mL in a liquid dosage form.
- In another aspect of the therapeutic methods, such as a method of treating a cancer in an individual in need thereof, the individual is administered a combination of an effective amount of a fulvestrant inclusion complex or formulation and one other pharmaceutical agent. In some embodiments, the other pharmaceutical agent is an anti-cancer agent. In some embodiments, the other pharmaceutical agent is selected from the group consisting of anastrozole (e.g., ARIMIDEX®), letrozole (e.g., FEMARA®), exemestane (e.g., AROMASIN®), aminoglutethimide (e.g., Cytadren®), vorozole (e.g., RIVIZOR®), formestane (e.g., LENTARON®), fadrozole (e.g., AFEMA®), testolactone (e.g., TESLAC®), gefitinib (e.g., IRESSA®), trastuzumab (e.g., HERCEPTIN®), crlotimnib (e.g., TARCEVA®), tipifanib (e.g., ZARNESTRA®), uncomplexed fulvestrant (e.g., FASLODEX® (AstraZeneca Pharmaceuticals LP)), and an antioxidant. It is understood that in some variations of the methods provided herein, two or more other pharmaceutical agents are intended for use in the methods, such as two or more of the anti-cancer agents provided herein. In some embodiments, the inclusion complex and the other pharmaceutical agent are administered simultaneously or sequentially. In some embodiments, the inclusion complex and the other pharmaceutical agent are administered concurrently. The inclusion complex and the other pharmaceutical agent may be administered, whether simultaneously, sequentially or otherwise, via the same or different routes.
- In one variation, the methods comprise administering a) a composition comprising and/or an inclusion complex of a cyclodextrin and a compound of the formula (I), or a salt thereof or solvate of the foregoing, and b) a compound of the formula (I) in uncomplexed form. In a particular variation, a composition comprising and/or an inclusion complex of a cyclodextrin and a compound of the formula (I), or a salt thereof, or solvate of the foregoing, is administered orally, intranasally, sublingually, rectally, and/or vaginally and a compound of the formula (I) is administered intramuscularly. In one preferred embodiment, the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD).
- In another aspect, provided is the use of an inclusion complex of a) a cyclodextrin; and b) a compound of the formula (I), or a salt thereof, or solvate of the foregoing, for the manufacture of a medicament for use in a method provided herein, such as a method of treating a cancer, such as breast cancer, in an individual. In one preferred embodiment, the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD).
- In another aspect, provided is a kit comprising an inclusion complex of a) a cyclodextrin; and b) a compound of the formula (I), or a salt thereof or solvate of the foregoing, or a formulation thereof. The kit may further comprise instructions for use, such as for use in the treatment of a disease or condition that is or is believed to be responsive to anti-estrogen therapy and/or ER-downregulation. In a particular variation, a kit comprises instructions for use in the treatment of cancer or systemic lupus erythematosus. The kit may also comprise another pharmaceutical agent. In one such aspect, a kit is provided comprising a) a cyclodextrin; b) a compound of the formula (I), or a salt thereof, or solvate of the foregoing, or a formulation thereof; and c) an additional pharmaceutical agent selected from anastrozole (e.g., ARIMIDEX®), letrozole (e.g., FEMARA®), exemestane (e.g., AROMASIN®), aminoglutethimide (e.g., Cytadren®), vorozole (e.g., RIVIZOR®), formestane (e.g., LENTARON®), fadrozole (e.g., AFEMA®), testolactone (e.g., TESLAC®), gefitinib (e.g., IRESSA®), trastuzumab (e.g., HERCEPTIN®), edotinib (e.g., TARCEVA®), tipifarnib (e.g., ZARNESTRA®), uncomplexed fulvestrant (e.g., FASLODEX® (AstraZeneca Pharmaceuticals LP)), and an antioxidant. When uncomplexed fulvestrant is employed, in one aspect it is formulated in an oil-based carrier (e.g., arachis oil, sesame oil, castor oil, or neutral oil (e.g., MIGLYOL® 810 or MIGLYOL® 812)), or in a non-aqueous ester solvent (e.g., benzyl benzoate, ethyl oleate, isopropyl myristate, isopropyl palmitate, or a mixture or combination of any thereof) and an alcohol (e.g., ethanol, benzyl alcohol, or a mixture or combination of any thereof). In one preferred embodiment, the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD).
- In another aspect, provided are methods of producing an inclusion complex of a compound of the formula (I) and a cyclodextrin, comprising admixing a compound of the formula (I), or salt thereof, or solvate of the foregoing, with a cyclodextrin. In some embodiments, the method further comprises adding a solvent, mixed solvent, or buffer to the compound of the formula (I), the cyclodextrin, and/or a mixture thereof. If a solvent, mixed solvent or buffer is employed to form an inclusion complex, in one aspect the solvent, mixed solvent or buffer is removed after formulation of the inclusion complex to provide an inclusion complex free of or substantially free of solvent, mixed solvent or buffer. In one preferred embodiment, the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD).
- In another aspect, provided are methods of producing an inclusion complex of a cyclodextrin and a compound of the formula (I), or a salt thereof, or solvate of the foregoing, comprising the steps of a) admixing the compound of the formula (I) and the cyclodextrin; and b) adding a suitable amount of solvent, mixed solvent, or buffer to the mixture of step (a) and mixing until a suspension or solution is formed. In some embodiments, the step (a) further comprises admixing a suitable polymer. In some embodiments, the method utilizes a suitable amount of solvent, such as water for injection (WFI). In some embodiments, the method utilizes a suitable amount of a buffer, which in one aspect is a phosphate-citrate buffer. In some embodiments, the method utilizes a suitable polymer, which in one aspect is selected from polyvinylpyrrolidone, hydroxypropyl methylcellulose, carboxymethylcellulose, and PLASDONE® Povidone. In one preferred embodiment, the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD).
-
FIG. 1 shows a fulvestrant HPLC calibration data plot. -
FIG. 2 shows a fulvestrant aqueous solubility data plot in the presence and absence of various concentrations of alpha-cyclodextrin (ACD). -
FIG. 3 shows a fulvestrant aqueous solubility data plot in the presence and absence of various concentrations of beta-cyclodextrin (BCD). -
FIG. 4 shows a fulvestrant aqueous solubility data plot in the presence and absence of various concentrations of methyl beta-cyclodextrin (MBCD). -
FIG. 5 shows a fulvestrant aqueous solubility data plot in the presence and absence of various concentrations of hydroxypropyl beta-cyclodextrin (HPBCD). -
FIG. 6 shows a fulvestrant aqueous solubility data plot in the presence and absence of various concentrations of sulfobutylether beta-cyclodextrin (SBEBCD). -
FIG. 7 shows a fulvestrant aqueous solubility data plot in the presence and absence of various concentrations of gamma-cyclodextrin (GCD). -
FIG. 8 shows a fulvestrant aqueous solubility data plot in the presence and absence of various concentrations of hydroxypropyl gamma-cyclodextrin (HPGCD). -
FIG. 9 shows a fulvestrant plasma concentration data plot generated for Experiment I (oral gavage of fulvestrant-HPBCD). -
FIG. 10 shows a fulvestrant plasma concentration data plot generated for Experiment II (oral gavage of fulvestrant-MBCD). -
FIG. 11 shows a fulvestrant plasma concentration data plot generated for Experiment II (oral gavage without cyclodextrin (CD)). -
FIG. 12 shows average fulvestrant plasma concentration data plot generated for Experiments I, II, and III (oral gavage of HPBCD, MBCD or without CD). -
FIG. 13 shows fulvestrant plasma concentration data plot generated for oral gavage of fulvestrant-HPBCD at the dose of 5 mg/kg. -
FIG. 14 shows a plot of the mean fulvestrant plasma concentrations over time. -
FIG. 15 shows a simulation of blood concentrations resulting from oral dosing of fulvestrant-HPBCD 5 mg/kg 8-hourly to an “average dog” (Average concentration at steady state based on exponentials=26 ng/mL. A dotted line is drawn at the level of the purported therapeutic target concentration). -
FIG. 16 shows a plot of Fulvestrant-HPBCD stability data (Batch 1_1 stored at 25° C. and 40° C.; T=0 to T=24 months). -
FIG. 17 shows a plot of Fulvestrant-HPBCD stability data (Batch 1_2 stored at 25° C. and 40° C.; T=0 to T=24 months). -
FIG. 18 shows a plot of Fulvestrant-HPBCD stability data (Batch 1_3 stored at 2° C.; T=0 to T=18 months). -
FIG. 19 shows a plot of Fulvestrant-HPBCD stability data (Batch 1_4 stored at 2° C.; T=0 to T=18 months). -
FIG. 20 shows a plot of Fulvestrant-RAMEB stability data (Batch 2_1 stored at 2° C.; 25° C. and 40° C.; T=0 to T=18 months). -
FIG. 21 shows a plot of Fulvestrant-RAMEB stability data (Batch 2_2 stored at 2° C.; 25° C. and 40° C.; T=0 to T=18 months). - The present invention provides inclusion complexes, kits, formulations, and unit dosages comprising fulvestrant and a cyclodextrin. Also provided are methods of producing the inclusion complexes as well as methods of treatment.
- The inventors have discovered that inclusion complexes comprising fulvestrant and a cyclodextrin strikingly enhance the aqueous solubility of fulvestrant as compared to fulvestrant in an uncomplexed form, suggesting that such inclusion complexes enhance the oral, intranasal and/or sublingual bioavailability of fulvestrant and may find particular use in administration of fulvestrant via these dosage routes. Fulvestrant inclusion complexes may also provide superior or complimentary pharmacokinetics as compared to uncomplexed fulvestrant delivered in the same amount and under the same conditions, including greater Cmax and AUC values and a reduction in Tmax. In addition, therapeutic plasma levels of fulvestrant may be achieved sooner with a fulvestrant inclusion complex as compared to long acting intra-muscular injectable formulations of uncomplexed fulvestrant, which can have a particular benefit to patients.
- Unless defined otherwise or clearly indicated by context, all technical and scientific terms and abbreviations used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
- As used herein, the term “inclusion complex” or “IC” is intended a complex wherein a moiety of a compound (e.g., a moiety of fulvestrant) is inserted, at least partially, into the cavity of a cyclodextrin (e.g., methyl beta-cyclodextrin (MBCD) or hydroxypropyl beta-cyclodextrin (HPBCD)). The inserted compound of the inclusion complex is considered “complexed” with the cyclodextrin. A compound that is not part of an inclusion complex is considered “alone” or “uncomplexed.”
- As used herein, the term “solubility” intends the solubility with reference to the total amount of compound (e.g., including the amount of compound in both complexed and uncomplexed form).
- As used herein, “treatment”, “treating”, or “treat” is an approach for obtaining beneficial or desired results, including clinical results.
- With respect to a disease or condition, “delaying” means to defer, hinder, slow, retard, stabilize, and/or postpone development of one or more symptoms of the disease or condition (e.g., cancer or systemic lupus erythematosus). This delay can be of varying lengths of time, depending on the history of the disease and/or individual being treated. As is evident to one skilled in the art, a sufficient or significant delay can, in effect, encompass prevention, in that the individual does not develop the condition (e.g., cancer or systemic lupus erythematosus).
- As used herein, “pharmaceutically acceptable” with respect to a material, refers to a material that is not biologically or otherwise unsuitable, e.g., the material may be incorporated (e.g., at the time of manufacturing or administration) into a pharmaceutical composition administered to an individual without causing significant undesirable biological effects. Pharmaceutically acceptable carriers or excipients have preferably met the required standards of toxicological and manufacturing testing and/or are included on the Inactive Ingredient Guide prepared by the U.S. Food and Drug administration.
- The term “effective amount” intends such amount of a compound (e.g., fulvestrant) or an inclusion complex (e.g., an inclusion complex comprising fulvestrant and a cyclodextrin), or a combination therapy comprising at least one of the foregoing, which should be effective in a given therapeutic form. As is understood in the art, an effective amount may be in one or more doses, i.e., a single dose or multiple doses may be required to achieve the desired treatment endpoint. An effective amount may be considered in the context of administering one or more additional pharmaceutical agents in a combination therapy, and an inclusion complex may be considered to be given in an effective amount if, when administered sequentially, simultaneously, or continuously with one or more additional pharmaceutical agents, one or more desirable or beneficial result(s) may be or are achieved.
- “Combination therapy” intends a first therapy (e.g., fulvestrant or an inclusion complex thereof) used in conjunction with a second therapy (e.g., surgery and/or an additional pharmaceutical agent) for treating, stabilizing, preventing, and/or delaying a disease or condition. Administration in “conjunction with” another compound includes administration in the same or different composition(s), either sequentially, simultaneously, or continuously, through the same or different routes within a given time period. In some embodiments, the combination therapy optionally includes one or more pharmaceutically acceptable carriers or excipients, non-pharmaceutically active compounds, and/or inert substances.
- The term “simultaneous administration,” as used herein, means that a first therapy and second therapy in a combination therapy are administered with a time separation of no more than about 15 minutes, such as no more than about any of 10, 5, or 1 minutes. When the first and second therapies are administered simultaneously, the first and second therapies may be contained in the same composition (e.g., a composition comprising both a first and second therapy) or in separate compositions (e.g., a first therapy in one composition and a second therapy is contained in another composition). When there is a time separation in the context of simultaneous administration (e.g., 5 minutes), either the first therapy or the second therapy may be administered first.
- As used herein, the term “sequential administration” means that the first therapy and second therapy in a combination therapy are administered with a time separation of more than about 15 minutes, such as more than about any of 20, 30, 40, 50, 60, or more minutes. Either the first therapy or the second therapy may be administered first. The first and second therapies are contained in separate compositions, which may be contained in the same or different packages or kits.
- As used herein, the term “concurrent administration” means that the administration of the first therapy and that of a second therapy in a combination therapy overlap with each other.
- Unless otherwise stated, “substantially pure” in reference to an inclusion complex intends a preparation of the inclusion complex that contains about or less than about 15% impurity, wherein the impurity intends a compound other than an inclusion complex of fulvestrant and a cyclodextrin. Substantially pure preparations include preparations that contain less than about 15% impurity, such as preparations that contain less than about any one of 15%, 12%, 10%, 8%, 5%, 3%, 2%, 1% and 0.5% impurity.
- Reference to “about” a value or parameter herein includes (and describes) variations that are directed to that value or parameter per se. For example, a description referring to “about X” includes the description of “X”.
- As used herein, the singular forms “a,” “or,” and “the” include plural referents unless the context clearly dictates otherwise.
- It is understood that wherever embodiments are described herein with the language “comprising,” otherwise analogous embodiments described in terms of “consisting of and/or “consisting essentially of are also provided.
- Where aspects or embodiments of the invention are described in terms of a Markush group or other grouping of alternatives, the present invention encompasses not only the entire group listed as a whole, but each member of the group individually and all possible subgroups of the main group, such as the main group absent one or more of the group members. The present invention also envisages the explicit exclusion of one or more of any of the group members.
- Cyclodextrins (“CDs”) are cyclic oligosaccharide structures composed of various glucopyranose units, such as 6, 7 and 8 units (alpha-, beta- and gamma-cyclodextrin, respectively) bound together to form a ring. Cyclodextrins characterized by a cone-like molecular shape and comprising a relatively hydrophobic central cavity and hydrophilic outer surface. The hydrophobic nature of the central cavity, in certain cases, endows the cyclodextrin with the ability to form inclusion complexes with a hydrophobic “guest” molecule. Polar and ionic groups are generally less likely to be included within the hydrophobic cavity than less-polar and non-ionic groups. In these complexes, a guest molecule is held within the hydrophobic cavity of the cyclodextrin “host” molecule. The inclusion complex may be stabilized by a number of forces, such as van der Waals attractive forces, electrostatics and hydrogen bonding.
- Although many factors affect the stability of an inclusion complex, the ability of a cyclodextrin molecule to form an inclusion complex with a guest molecule is a function of two key factors. The fast is steric and depends on the relative size of the cyclodextrin to the size of the guest molecule or certain key functional groups within the guest. The second factor is the thermodynamic interactions among different components of the system, such as the cyclodextrin, the guest, and the solvent, where present.
- The binding of guest molecules within host cyclodextrins is not fixed or permanent but rather is a dynamic equilibrium. See, e.g., Valle, Process Biochemistry. 2004, 39(9): 1033-46 and Loftsson et al., Journal of Pharmaceutical Sciences, 1996, 85(10): 1017-25. Inclusion of a guest molecule in a cyclodextrin host may exert a profound effect on the physicochemical properties of the guest molecule that is temporarily locked or caged within the host cavity. Inclusion complexes may give rise to beneficial properties, which are not achievable otherwise, such as: solubility enhancement of highly insoluble guests; stabilization of labile guests against the degradative effects of oxidation, visible or UV light and heat; control of volatility and sublimation; physical isolation of incompatible compounds; chromatographic separations; taste modification by masking off flavors, unpleasant odors, and controlled release of drugs. Cyclodextrin inclusion complexes, in some cases, may provide favorable flow, binding, and compaction properties to aid in drug formulation (e.g., in facilitating tablet compression).
- Importantly, however, the effect of inclusion of a guest molecule in a cyclodextrin host remains unpredictable. For example, although various cyclodextrin complexes have been reported to enhance the bioavailability of small molecule drugs, cyclodextrin inclusion complexes have also been reported to have either no effect on host bioavailability or in fact decrease the bioavailability of certain guest compounds. R. Carrier, et al., Journal of Controlled Release, 123(2):78-99. The interaction of cyclodextrins with labile compounds can also result in several outcomes: cyclodextrins can retard degradation, can have no effect on reactivity, or can accelerate drug degradation. Loftsson et al., supra. In addition, the unpredictability of thermodynamic quantities related to inclusion complex formation have also been reported. A. Steffen et al., Chemistry Central Journal, 2007, 1:29.
- Inclusion complexes of fulvestrant as provided herein were discovered to notably enhance the aqueous solubility of fulvestrant as compared to fulvestrant in an uncomplexed form, suggesting that such inclusion complexes enhance the bioavailability of fulvestrant and may be used in the oral, intranasal, and/or sublingual administration of fulvestrant. Administration of fulvestrant via non-parenteral routes is significant and may offer patients more convenient, non-invasive treatment options, reducing the incidence of adverse side effects associated with parenteral fulvestrant therapy, and enhancing overall patient compliance. Non-parenteral fulvestrant formulations may also have a positive effect on overall therapeutic outcome. For example, such formulations may be used alone, or together with parenteral administration of fulvestrant, to achieve steady-state drug levels sooner than with presently available fulvestrant parenteral formulations. In addition, higher dosing levels of fulvestrant may be achievable with such formulations, which can enhance ER downregulation and may provide an additional therapeutic benefit.
- Inclusion complexes provided herein comprise fulvestrant and a cyclodextrin, or a salt thereof, or a solvate (e.g., hydrate) of the foregoing. The inclusion complexes may be used alone, or together with an additional pharmaceutical agent, in the treatment of a disease or condition provided herein, such as cancer. Other agents may also be incorporated with the inclusion complex, where applicable. For example, an inclusion complex may comprise a cyclodextrin and fulvestrant, with an antioxidant that is not itself a pharmaceutical agent but provides other benefits, such as stabilizing the complex over time, and which does not adversely effect the fulvestrant inclusion complex. Formulations comprising a fulvestrant inclusion complex, and optional additional pharmaceutical or other agents, together with a carrier, such as a pharmaceutically acceptable aqueous carrier, are also provided.
- In some embodiments, an inclusion complex is an inclusion complex of a cyclodextrin and fulvestrant sulphoxide A, fulvestrant sulphoxide B, or a mixture of fulvestrant sulphoxide A and fulvestrant sulphoxide B. In a particular variation, a preparation of an inclusion complex is a preparation of a cyclodextrin and substantially pure fulvestrant sulphoxide A or substantially pure fulvestrant sulphoxide B. In another variation, a preparation of an inclusion complex is a preparation of a cyclodextrin and a mixture of fulvestrant sulphoxide A and fulvestrant sulphoxide B.
- Examples of a cyclodextrin for use in the inclusion complex include, but are not limited to, water soluble unsubstituted or substituted alpha-cyclodextrin (ACD), beta-cyclodextrin (BCD), and gamma-cyclodextrin (GCD). Examples of substituted beta-cyclodextrins that may be employed in the inclusion complexes herein include, but are not limited to, methyl beta-cyclodextrin (MBCD), hydroxypropyl beta-cyclodextrin (HPBCD), and sulfobutylether beta-cyclodextrin (SBEBCD).). Examples of substituted gamma-cyclodextrins that may be employed in the inclusion complexes herein include, but are not limited to, hydroxypropyl gamma-cyclodextrin (HPGCD). Mixtures of cyclodextrins may also be employed. For example, a formulation comprising fulvestrant and a mixture of two or three or four or more cyclodextrins is also provided. Where a more than one cyclodextrin is employed, it may be of the same cyclodextrin class (e.g., two alpha-cyclodextrins) or different chemical classes (e.g., one alpha-cyclodextrin and one beta- or gamma-cyclodextrin). In one preferred embodiment, the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD).
- In some embodiments, a cyclodextrin is obtained from a commercial source, including, but not limited to cyclodextrins sold under the following tradenames CAVASOL® W6 HP (Wacker Chemie AG, Munich, Germany), CAVASOL® W6 HP TL (Wacker Chemie AG, Munich, Germany), CAVAMAX® W6 Pharma (Wacker Chemie AG, Munich, Germany), CAVASOL® W7 HP (Wacker Chemie AG, Munich, Germany), CAVASOL® W7 HP Pharma (Wacker Chemie AG, Munich, Germany), CAVASOL® W7 HP TL (Wacker Chemie AG, Munich, Germany), CAVASOL® W7 M (Wacker Chemie AG, Munich, Germany), CAVASOL® W7 M Pharma (Wacker Chemie AG, Munich, Germany), CAVASOL® W7 M TL (Wacker Chemie AG, Munich, Germany), CAVASOL® W8 HP (Wacker Chemie AG, Munich, Germany), CAVASOL® W8 HP Pharma (Wacker Chemie AG, Munich, Germany), KLEPTOSE® HPB (Roquette Pharma, Geneva, Ill.), and CAPTISOL® (Cydex Pharmaceuticals, Inc. Lenexa, Kans.). In some embodiments, the cyclodextrin is CAVASOL® W7 M Pharma. In some embodiments, the cyclodextrin is KLEPTOSE® HPB.
- The inclusion complex may comprise fulvestrant or a salt thereof or a solvate (e.g. a hydrate or alcoholate) of the foregoing that is partially or completely included into the cavity of a cyclodextrin molecule. Accordingly, one or more cyclodextrin molecules may be associated with each fulvestrant molecule. The complex may exist in a variety of molar ratios, which may be dependent on a variety of physical factors during the formation of the complex, and be transitional and vary during formation.
- In some embodiments, fulvestrant is fully included into the cavity of a cyclodextrin molecule. In some embodiments, fulvestrant is partially included into the cavity of a cyclodextrin molecule. In some embodiments of the inclusion complex, the molar ratio of the fulvestrant to cyclodextrin is from any of about 1:1 to about 1:300; about 1:1 to about 1:150; about 1:1 to about 1:100; about 1:1 to about 1:50, about 1:1 to about 1:25; about 1:1 to about 1:10; about 1:1 to about 1:5; about 1:1 to about 1:4; about 1:1 to about 1:3; about 1:1 to about 1:2.5; and about 1:1 to about 1:2, or is about any of 1:1, 1:2, and 1:3.
- The inclusion complexes described herein may increase the solubility of fulvestrant. In one aspect, are provided methods for improving the solubility of fulvestrant in water comprising complexing fulvestrant with a cyclodextrin. In some embodiments, the solubility of fulvestrant in a fulvestrant inclusion complex, in deionized water at 20° C., is at least about 10-fold greater than the solubility of fulvestrant in uncomplexed form. In some embodiments, a fulvestrant inclusion complex increases the solubility of fulvestrant by at least any of about or by about 10-, 25-, 50-, 75-, 100-, 250-, 500-, 750-, 1000-, 1500-, 2000-, 3000-, or 4000-fold compared to the solubility of fulvestrant in uncomplexed form.
- In some embodiments, the uncomplexed fulvestrant is present in an oil-based carrier (e.g., arachis oil, sesame oil, castor oil, or neutral oil (e.g., MIGLYOL™ 810 or MIGLYOL® 812)), or in a non-aqueous ester solvent (e.g., benzyl benzoate, ethyl oleate, isopropyl myristate, isopropyl palmitate, or a mixture or combination of any thereof) and an alcohol (e.g., ethanol, benzyl alcohol, or a mixture or combination of any thereof). In some embodiments, an uncomplexed fulvestrant is obtained from a commercial source, including, but not limited to, the fulvestrant formulation sold as the tradename FASLODEX®.
- The inclusion complexes described herein may provide improved pharmacokinetic properties for fulvestrant. Such changes in pharmacokinetic properties may result in desired therapeutic effects, such as a more rapid onset of therapeutic effect and/or less prolonged and/or reduced effects of a disease or condition for which fulvestrant treatment is obtained (e.g., cancer or systemic lupus erythematosus).
- The inclusion complexes described herein may result in increased oral bioavailability of fulvestrant. In some embodiments, the oral bioavailability of fulvestrant from an inclusion complex comprising fulvestrant and a cyclodextrin is at least any of about or about 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, or 90% greater than the oral bioavailability of fulvestrant alone under the same conditions. Methods of increasing oral bioavailability of fulvestrant by at least any of about or by about any of 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, or 90% as compared to administration of uncomplexed fulvestrant under the same conditions are provided, such methods comprising administering fulvestrant in the form of an inclusion complex comprising fulvestrant and a cyclodextrin.
- Bioavailability assessments and comparisons may be determined using standard techniques known in the art (e.g., measuring AUC(fulvestrant inclusion complex)/AUC(uncomplexed fulvestrant)×100). In some of these embodiments, the conditions for assessing the amount of increase in bioavailability of an inclusion complex of fulvestrant as compared to fulvestrant in uncomplexed form include orally or intranasally administering any of about 5 mg/mL, about 10 mg/mL, about 15 mg/mL, about 20 mg/mL, about 25 mg/mL, about 30 mg/mL, about 35 mg/mL, about 40 mg/mL, or about 50 mg/mL of fulvestrant (in the appropriate complexed or uncomplexed form) in a carrier and at room temperature. In some embodiments, the fulvestrant can be administered at room temperature in an aqueous solution (e.g., WFI) in the presence or absence of a buffer.
- The inclusion complexes described herein may result in an increased Cm of fulvestrant following administration of an amount of fulvestrant as an inclusion complex when compared to administering the same amount of fulvestrant, via the same route and under the same conditions, in uncomplexed form. The inclusion complexes described herein may also result in an increased Cmax of fulvestrant following administration of an amount of fulvestrant as an inclusion complex when compared to administering the same amount of fulvestrant via a different administration route, in uncomplexed form. For example, Cmax of fulvestrant may be increased upon oral and/or intranasal administration of an amount of fulvestrant as an inclusion complex with a cyclodextrin when compared to administration of the same amount of uncomplexed fulvestrant as an intramuscular injection. In some embodiments, the inclusion complexes described herein may result in an increased Cmax for fulvestrant within about 3 hours after oral administration of a fulvestrant inclusion complex to an individual. In some embodiments, the Cmax of fulvestrant from an inclusion complex comprising fulvestrant and a cyclodextrin is at least about or about any of 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 40, 50, 60, 70, 80, 90, or 100 times greater than the Cmax of uncomplexed fulvestrant administered in the same amount and under the same conditions as the inclusion complex. In some of these embodiments, the conditions comprise orally or intranasally administering any of about 5 mg/mL, about 10 mg/mL, about 15 mg/mL, about 20 mg/mL, about 25 mg/mL, about 30 mg/mL, about 35 mg/mL, about 40 mg/mL, or about 50 mg/mL of fulvestrant (in the appropriate complexed or uncomplexed form) at room temperature in an aqueous solution (e.g., WFI). Methods of increasing Cmax in accordance with the descriptions herein are also provided.
- The inclusion complexes described herein may result in a decreased Tmax for fulvestrant following administration. In some embodiments, the Tmax of fulvestrant from an inclusion complex comprising fulvestrant and a cyclodextrin is at least about or about any of 2%, 5/%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, or 90% lower than the Tmax of fulvestrant administered alone under the same conditions. The inclusion complexes described herein may also result in a decrease in Tmax following administration of an amount of fulvestrant as an inclusion complex when compared to administering the same amount of fulvestrant via a different administration route, in uncomplexed form. For example, Tmax of fulvestrant may be decreased upon oral and/or intranasal administration of an amount of fulvestrant as an inclusion complex with a cyclodextrin when compared to administration of the same amount of fulvestrant as an intramuscular injection. The value of Tmax upon oral and/or intranasal administration of an amount of fulvestrant as an inclusion complex may be at least about or about any of 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, or 90% lower than the Tmax obtained by administration of the same amount of uncomplexed fulvestrant as an intramuscular injection. In some of these embodiments, the conditions comprise orally or intranasally administering any of about 5 mg/mL, about 10 mg/mL, about 15 mg/mL, about 20 mg/mL, about 25 mg/mL, about 30 mg/mL, about 35 mg/mL, about 40 mg/mL, or about 50 mg/mL of fulvestrant (in the appropriate complexed or uncomplexed form) at room temperature in an aqueous solution (e.g., WFI). Methods of decreasing Tmax in accordance with the descriptions herein are also provided.
- The inclusion complexes described herein may result in decreasing the therapeutic time of onset for fulvestrant such that the therapeutic effect occurs sooner with a fulvestrant inclusion complex as compared to fulvestrant administered in an uncomplexed form. In one embodiment, the therapeutic time of onset of fulvestrant from an inclusion complex comprising fulvestrant and a cyclodextrin is decreased by at least about or about any of 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, or 90% than the therapeutic time of onset of uncomplexed fulvestrant administered in the same amount and under the same conditions. In other embodiments an inclusion complex of fulvestrant decreases the therapeutic time of onset for fulvestrant by at least about or about any of 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, or 90% as compared to the therapeutic time of onset of uncomplexed fulvestrant administered in the same amount as an intramuscular injection. In one aspect, the fulvestrant inclusion complex is provided by oral or intranasal administration. In some of these embodiments, the conditions comprise orally or intranasally administering any of about 5 mg/mL, about 10 mg/mL, about 15 mg/mL, about 20 mg/mL, about 25 mg/mL, about 30 mg/mL, about 35 mg/mL, about 40 mg/mL, or about 50 mg/mL of fulvestrant (in the appropriate complexed or uncomplexed form) at room temperature in an aqueous solution (e.g., WFI). Methods of decreasing therapeutic time of onset for fulvestrant in accordance with the descriptions herein are also provided.
- In some embodiments, the inclusion complex comprising fulvestrant and a cyclodextrin is in substantially pure form. In one variation, a preparation of substantially pure inclusion complex is provided wherein the preparation contains about or less than about any one of 15/%, 12%, 10%, 8%, 5%, 3%, 2%, 1% and 0.5% impurity.
- The inclusion complexes described herein, formulations thereof, and methods include all salt and solvate forms. For example, an inclusion complex may comprise a compound of formula (I) and/or a salt thereof. An inclusion complex may also comprise a solvate of a compound of formula (I) or a salt thereof. Solvates may contain either stoichiometric or non-stoichiametric amounts of a solvent, and are often formed during the process of crystallization. In one aspect, a solvent is water and the solvate is a hydrate. In another aspect, a solvent is an alcohol and the solvate is an alcoholate. In some embodiments, the inclusion complexes described herein can exist in unsolvated forms as well as solvated forms. The inclusion complexes may also include hydrated forms or salt forms.
- Also provided are methods of preparing the inclusion complexes described herein. In some instances inclusion complexes may be prepared on the basis of liquid state, solid state or semi-solid state reaction between the components. This may be accomplished by dissolving the cyclodextrin and fulvestrant in a suitable solvent or mixture of solvents. If desired, an inclusion complex so obtained may be subsequently isolated by crystallization, evaporation, spray drying or freeze drying. In a solid state method, the two components may be screened to uniform particle size and thoroughly mixed, at which point they may be ground in a high energy mill with optional heating, screening and homogenization. In a semi-solid state, the two components may be kneaded in the presence of small amounts of a suitable solvent, and the complex so-formed, is oven dried, screened and homogenized. The liquid state reaction generally provides optimum conditions for completeness of reaction.
- In one aspect is provided a method of producing an inclusion complex comprising fulvestrant and a cyclodextrin by admixing fulvestrant with a cyclodextrin. In some embodiments, the method further comprises adding a solvent, mixed solvent, or buffer to fulvestrant, the cyclodextrin, and/or mixture thereof.
- In the preparation of a fulvestrant inclusion complex, the suitable amount of solvent, mixed solvent, or buffer may be added directly to a solid mixture of fulvestrant and the cyclodextrin. Alternatively, the solvent, mixed solvent, or buffer may be added to either fulvestrant or the cyclodextrin, and then added to the other of fulvestrant and the cyclodextrin. In some embodiments, the solvent, mixed solvent, or buffer may be added independently to each of fulvestrant and cyclodextrin, followed by combining fulvestrant and the cyclodextrin.
- In one aspect, the method of producing an inclusion complex of fulvestrant and a cyclodextrin comprises the steps of: (a) admixing fulvestrant and a cyclodextrin; and (b) adding a suitable amount of solvent, mixed solvent, or buffer to the mixture of step (a) and mixing until a suspension or solution is formed.
- In some embodiments, a buffer is employed. For example, a formulation comprising a fulvestrant inclusion complex for intranasal administration in one aspect further comprises a buffer as detailed herein. Suitable buffers include, without limitation, phosphate buffers (e.g., phosphate-citrate), potassium hydrogen phthalate buffers, and acetate buffers. In some embodiments, the buffer is a phosphate-citrate buffer. In some embodiments, the added buffer and/or resulting suspension or solution has a pH between any of about 1.0, 2.0, and 3.0 and about 8.0, 9.0 or 10.0; about 3.0 and about 8.0, about 4.0 and about 6.0, about 4.5 and about 5.5; or a pH of greater than, less than, or about any of 1.0, 2.0, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 7.0, 7.5, 8.0, 9.0, or 10.0. In one aspect, a formulation comprising a fulvestrant inclusion complex for intranasal administration comprises a buffer and the formulation has a pH of between about 5.0 and about 8.0. In some embodiments, a solvent is employed. A solvent in one aspect is an organic solvent or water. Suitable organic solvents are known to those of skill in the art and include, but are not limited to, low chain alcohols (e.g. methanol; ethanol; i-propanol) and acetone. In some embodiments, the solvent is a polar solvent, such as water (e.g., ddH20), methanol, ethanol, and i-propanol. In some embodiments, a mixed solvent is employed. A mixed solvent in one aspect comprises an organic solvent or water. In one aspect, a mixed solvent is a mixture of water and an organic solvent. Suitable solvents, mixed solvents, or buffers include 100° % of
ddH 20, orddH 20 or buffer together with ethanol or methanol (1-99%). Various combinations of solvent, mixed solvent, or buffer for optimizing the production of an inclusion complex of fulvestrant and a cyclodextrin can be determined by persons skilled in the art in view of the methods described herein. - For the methods of producing an inclusion complex of fulvestrant and a cyclodextrin, fulvestrant may be admixed with the cyclodextrin at a molar ratio from about 0.2:1 to about 1:300. In some embodiments, the molar ratio is about 0.5:1 to about 1:150, or about 1:1 to about 1:75, or about 1:1 to about 1:50, or about 1:1 to about 125, or about 1:1 to about 1:10, or about 1:1 to about 1:5, or about 1:1 to about 1:3, or about 1:1 to about 1:2, or any of about 1:1, 1:2, 13, 1:4, 1:5, 1:6, and 1:7.
- In some embodiments of the methods of producing an inclusion complex, the solvent, mixed solvent, or buffer is heated to less than, greater than, or about any of 25° C., 30° C., 35° C., 40° C., 45° C., 50° C., 55° C., 60° C., 65° C., 75° C., or 80° C. (e.g., before, during and/or after mixing). The solvent, mixed solvent, or buffer may be heated prior to and/or after being added to fulvestrant and/or cyclodextrin. In some embodiments, the solvent, mixed solvent, or buffer is heated greater than the preferred temperature for less than, greater than, or about any of 0.1 hr, 0.2 hr, 0.3 hr, 0.5 hr, 0.75 hr, 1 hr, 2 hr, 3 hr, 4 hr, 5 hr, 7 hr, 10 hr, 15 hr, 24 hr, 36 hr, or 48 hr.
- During the formation of the inclusion complex between fulvestrant and a cyclodextrin, a suitable polymer may be added which may enhance the solubility and/or complexation ability of fulvestrant and cyclodextrin inclusion complex. Accordingly, in some embodiments of the methods of producing an inclusion complex, a step of admixing fulvestrant and a cyclodextrin further comprises admixing a suitable polymer. Suitable polymers include, for example, polyvinylpyrrolidone, hydroxypropyl methylcellulose, carboxymethylcellulose, and PLASDONE® Povidone, and derivatives thereof. In some embodiments, the suitable polymer is a water-soluble polymer.
- In some embodiments of the methods of producing an inclusion complex, the mixing is continued for at least any of about 0.1 hr, 02 hr, 0.3 hr, 0.5 hr, 0.75 hr, 1 hr, 2 hr, 4 hr, 10 hr, 24 hr, 36 hr, or 48 hr following formation of the suspension or solution. If heat is applied to the solvent, mixed solvent, or buffer during a method of producing an inclusion complex, the described mixing of the components may occur prior to, simultaneously with, and/or after the application of said heat.
- In some embodiments, the method of producing an inclusion complex further comprises a step for drying the product obtained from the steps of a) admixing fulvestrant and a cyclodextrin and b) adding a suitable amount of a solvent, mixed solvent or buffer to the mixture. In some embodiments, the drying comprises evaporation. In some embodiments, the evaporation occurs for greater than, less than, or about any of 0.1 hr, 0.25 hr, 0.5 hr, 1 hr, 2 hr, 5 hr, 10 hr, 1 day, or 5 days. In some embodiments, the evaporation is conducted under vacuum (e.g., less than any of about 0.75 atm, 0.5 atm, or 0.25 atm). In some embodiments, the evaporation is conducted under atmospheric pressure. In some embodiments, the drying comprises dry heat. In some embodiments, the drying comprises spray-drying. In some embodiments, the drying comprises freeze-drying. In some embodiments, the drying comprises spray-granulation.
- In one aspect, is provided a method of producing an inclusion complex between fulvestrant and a cyclodextrin comprising the steps of: (a) mixing the appropriate amount of fulvestrant and cyclodextrin with or without a suitable polymer; (b) adding a suitable amount of solvent, mixed solvent, and/or buffer to the mixture of step (a) with vigorous mixing until a paste or a slurry is formed; (c) continuing the mixing with further addition of solvent (e.g., water), mixed solvent, or buffer if necessary to maintain the paste or the slurry consistency, for a suitable period of time to form the inclusion complex; and (d) drying the product of step (c). In some embodiments of step (b), the buffer is a phosphate-citrate buffer and the pH is about 5. In some embodiments, the solvent added during steps (b) and (c) is heated. In some embodiments, wherein the solvent, mixed solvent, or buffer is deionized water and/or a buffer, the deionized water and/or a buffer is heated to about 60° C. In some embodiments, the mixing is preferably continued for a period of time greater than 0.2 hours. In some embodiments, the vigorous mixing until a paste or a slurry is formed is conducted at about 60° C.
- In another aspect, is provided a method of producing an inclusion complex between fulvestrant and a cyclodextrin comprising the steps of (a) mixing suitable amounts of fulvestrant and a cyclodextrin with or without a suitable polymer; (b) adding of a suitable solvent, mixed solvent, and/or buffer to the mixture of step (a) with mixing until a slurry, suspension or solution is formed; and (c) allowing the formation of the inclusion complex by evaporation of the water over a period of time. In some embodiments of step (b), the buffer is a phosphate-citrate buffer and the buffer pH is about 5. In some embodiments, the solvent added during step (b) is heated. In some embodiments, wherein the solvent, mixed solvent, or buffer is deionized water and/or a buffer, the deionized water and/or a buffer is heated to about 60° C. In some embodiments of step (c), heat is applied to increase the evaporation rate. In some embodiments, the evaporation is conducted at 40° C. In some embodiment, evaporation in step (c) occurs for greater than about 1 hour. In some embodiments, the evaporation is conducted under vacuum.
- In another aspect, is provided a method of producing an inclusion complex between fulvestrant and a cyclodextrin comprising the steps of: (a) mixing suitable amounts of fulvestrant and a cyclodextrin with or without a suitable polymer, (b) adding of a suitable solvent, mixed solvent, and/or buffer to the mixture of step (a) with mixing until a slurry, suspension or solution is formed; and (c) spray-drying the slurry, suspension or solution to obtain a solid drug-cyclodextrin inclusion complex. In some embodiments, the buffer is a phosphate-citrate and the buffer pH is about 5. In some embodiments, the suitable solvent, mixed solvent, and/or buffer added during step (b) is heated. In some embodiments, wherein the solvent, mixed solvent, or buffer is deionized water and/or a buffer, the deionized water and/or a buffer is heated to about 60° C.
- In another aspect, is provided a method of producing an inclusion complex between fulvestrant and a cyclodextrin comprising the steps of: (a) mixing suitable amounts of fulvestrant and a cyclodextrin with or without a suitable polymer, (b) adding of a suitable solvent, mixed solvent, and/or buffer to the mixture of step (a) with mixing until a solution is formed; and (c) freeze-drying the solution to obtain a solid drug-cyclodextrin inclusion complex. In some embodiments, the buffer is a phosphate-citrate buffer and the buffer pH is about 5. In some embodiments, the solvent, mixed solvent, and/or buffer added during step (b) is heated. In some embodiments, wherein the solvent, mixed solvent, or buffer is deionized water and/or a buffer, the deionized water and/or a buffer is heated to about 60° C.
- In another aspect, is provided a method of producing an inclusion complex between fulvestrant and a cyclodextrin comprising the steps of (a) mixing suitable amounts of fulvestrant and a cyclodextrin with or without a suitable polymer, (b) adding of a suitable solvent, mixed solvent, and/or buffer to the mixture of step (a) with mixing until a slurry, suspension or solution is formed; (c) adding inactive pharmaceutical excipients to the slurry, suspension or solution, with continued mixing and (d) spray-granulating the slurry, suspension or solution to obtain solid particles, suitable for formulation into an oral formulation, containing a solid drug-cyclodextrin inclusion complex. In some embodiments, the buffer is a phosphate-citrate buffer and the buffer pH is about 5. In some embodiments, the solvent, mixed solvent, or buffer added during step (b) may be heated. In some embodiments, wherein the solvent, mixed solvent, or buffer is deionized water and/or a buffer, the deionized water and/or a buffer is heated to about 60° C. The inactive pharmaceutical excipients included to produce an oral formulation according to step (c) may include commonly used pharmaceutical excipients commonly used in the art, and/or those described herein.
- In another aspect, is provided a method of producing an inclusion complex between fulvestrant and a cyclodextrin comprising the steps of: (a) mixing suitable amounts of fulvestrant and cyclodextrin with or without a suitable polymer; (b) adding a suitable solvent, mixed solvent, and/or buffer to the mixture of step (a) with mixing until a solution is formed; (c) producing a liquid oral or intranasal formulation. Inactive pharmaceutical excipients may be added to the solution, containing the liquid drug-cyclodextrin inclusion complex. In some embodiments, the buffer is a phosphate-citrate buffer and the buffer pH is about 5. In some embodiments, the solvent, mixed solvent, and/or buffer added during step (d) is heated. In some embodiments, wherein the solvent, mixed solvent, or buffer is deionized water and/or a buffer, the deionized water and/or a buffer is heated to about 60° C. The inactive pharmaceutical excipients included to produce a liquid oral or intranasal formulation according to step (c) may include commonly used pharmaceutical excipients commonly used in the art, and/or those described herein.
- In some embodiments of the methods for producing an inclusion complex between fulvestrant and a cyclodextrin described above, greater than any of about 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% of fulvestrant is in complexed form.
- A product obtained by any of the preceding processes is also provided for herein.
- The inclusion complexes described herein (e.g., an inclusion complex of fulvestrant with a cyclodextrin) may be used in the preparation of a composition or formulation, such as a pharmaceutical composition or formulation, by combining an inclusion complex described with at least one or any combination of more than one of a pharmaceutical acceptable carrier, excipient, stabilizing agent and/or other agent, which are known in the art, for use in the methods of treatment, methods of administration, and dosage regimes described herein. A pharmaceutically acceptable carrier may include, for example, solvents, mixed solvents, complexing agents, fillers, stabilizers, diluents, granulating agents, disintegrants, lubricants, glidants, pH-modifiers, tonicity modifiers, adjuvants, binders, etc., known to the skilled artisan that are suitable for administration to an individual (e.g., a human). Combinations of two or more carriers are also contemplated.
- The pharmaceutically acceptable carrier(s) and any additional components, as described herein, should be compatible for use in the intended route of administration (e.g., oral, parenteral, intranasal, or sublingal) for a particular dosage form. Such suitability will be recognized by the skilled artisan, particularly in view of the teaching provided herein. The formulations may vary or be tailored according to the condition to be treated, the amount of compound to be administered, the condition of the individual, and other variables that will readily be apparent to one of ordinary skill in the art in view of the teachings provided herein. The inclusion complexes may be formulated, for example, as solid, semi-solid, and liquid dosage forms, such as tablets, pills, powders, liquid solutions or suspensions, suppositories, injectable and infusible solutions, and sprays. The preferred form depends on the intended mode of administration and therapeutic application. The following formulations, additives, and methods are merely exemplary and are in no way limiting.
- Fulvestrant described herein may be formulated with a cyclodextrin and may comprise one or more of the favorable properties described for the inclusion complexes herein (e.g., increased solubility). In some embodiments, fulvestrant is in the uncomplexed form in the presence of a cyclodextrin. In some embodiments, is provided a mixture of fulvestrant in both complexed and uncomplexed form with a cyclodextrin (e.g., a molar ratio mixture of greater than, less than, or any of about 1:300, 1:150, 1:75, 1:50, 1:25, 1:20, 1:15 1:10, 1:7.5, 1:5, 1:3, 12, 1:1, 2:1, 3:1, 4:1, 5:1, 7.5:1, 10:1, 15:1, 25:1, 50:1, 100:1, 150:1 or 300:1 of complexed fulvestrant to uncomplexed fulvestrant, respectively). Accordingly, in one aspect is provided a formulation comprising fulvestrant, a cyclodextrin, and a carrier. In some embodiments, the formulation comprises an effective amount of fulvestrant, cyclodextrin, and a carrier. The formulation may comprise a molar ratio of cyclodextrin to fulvestrant that is greater than, less than, or any of about 1:1, 2:1, 3:1, 4:1, 5:1, 7.5:1, 10:1, 15:1, 25:1, 50:1, 75:1, 100:1, 150:1 or 300:1. Additionally, the formulation comprising the fulvestrant, a cyclodextrin, and a carrier may be further formulated in any manner described herein for the inclusion complex formulations, and may be used in any of the methods described herein, as well as at any dosage described herein, for the inclusion complexes and/or inclusion complex formulations (e.g., to treat a condition, such as cancer or systemic lupus erythematosus). These formulations also may provide improved pharmacokinetic properties as described herein (e.g., bioavailability, Cmax, Tmax, and time of onset) when compared to uncomplexed fulvestrant administered under the same conditions.
- In some embodiments, the formulation comprising fulvestrant and a cyclodextrin, a complex of fulvestrant with a cyclodextrin, or a mixture thereof, is a sterile formulation.
- Additives used with the inclusion complexes described herein (e.g., an inclusion complex of fulvestrant with a cyclodextrin) include, for example, one or more excipients (e.g., one or more excipients), antioxidants (e.g., one or more antioxidants), stabilizers (e.g., one or more stabilizers), preservatives (e.g., one or more preservatives, including antimicrobial preservatives), pH adjusting and buffering agents (e.g., one or more pH adjusting and/or buffering agents), tonicity adjusting agents (e.g., one or more tonicity adjusting agents), thickening agents (e.g., one or more thickening agents), suspending agents (e.g., one or more suspending agents), binding agents (e.g., one or more binding agents), viscosity enhancing agents (e.g., one or more viscosity enhancing agents), sweetening agent (e.g., one or more sweetening agent) and the like, either alone or together with one or more additional pharmaceutical agents, provided that the additional components are pharmaceutically acceptable. In some embodiments, the formulation may include combinations of two or more of the additional components as described herein (e.g., any of 2, 3, 4, 5, 6, 7, 8, or more additional components).
- In some embodiments, antioxidants include, but are not limited to, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, malic acid, propyl gallate, sodium bisulfite, sodium sulfite, sodium metabisulfite, potassium metabisulfite, potassium bisulfite, sodium thiosulfate, sodium formaldehyde sulfoxylate, L-ascorbic acid, D-ascorbic acid, acetylcysteine, cysteine, thioglycerol, thioglycoUic acid, thiolactic acid, thiourea, dithiothreitol, dithioerythreitol, glutathione, nordihydroguaiaretic acid, tocophcrol, sodium ascorbate, hypophophorous acid, and fumaric acid. In some embodiments, the antioxidant is selected from the group consisting of sodium bisulfite, sodium sulfite, sodium metabisulfite, potassium metabisulfite, potassium bisulfite, sodium thiosulfate, sodium formaldehyde sulfoxylate, L-ascorbic acid, D-ascorbic acid, acetylcysteine, thioglycerol, thioglycoUic acid, thiolactic acid, thiourea, dithiothreitol, dithiocrythreitol, glutathione, nordihydroguaiaretic acid, sodium ascorbate and hypophophorous acid.
- In some embodiments, the antioxidant is a dietary antioxidant, including, but not limited to, vitamin E, vitamin C, beta-carotene, and selenium.
- In some embodiments, the additives include processing agents and drug delivery modifiers and enhancers, such as, for example, calcium phosphate, magnesium stearate, talc, monosaccharides, disaccharides, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, dextrose, polyvinylpyrrolidinone, low melting waxes, ion exchange resins, and the like, as well as combinations of any two or more thereof. Other suitable pharmaceutically acceptable excipients are described in R
EMINGTON'S PHARMACEUTICAL SCIENCES , Mack Pub. Co.,New Jersey 18 edition (1996), HANDBOOK OF PHARMACEUTICAL EXCIPIENTS , Pharmaceutical Press and American Pharmacists Association, 5 edition (2006), and REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY , Lippincott Williams & Wilkins, Philadelphia, 20th edition (2003) and 21st edition (2005). - Formulations suitable for oral administration may comprise, for example, (a) liquid solutions, such as an effective amount of fulvestrant or cyclodextrin inclusion complex thereof dissolved in diluents, such as water, saline, er other ingestable liquid such as orange juice, (b) capsules, sachets or tablets, each containing a predetermined amount of fulvestrant or inclusion complex thereof, as solids or granules, (c) suspensions in an appropriate liquid, (d) suitable emulsions, and (e) powders. Tablet forms can include one or more of lactose, mannitol, corn starch, potato starch, microcrystalline cellulose, acacia, gelatin, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, stearic acid, and other excipients, colorants, diluents, buffering agents, moistening agents, preservatives, flavoring agents, and pharmacologically compatible excipients. Lozenge forms can comprise fulvestrant or an inclusion complex thereof in a flavor, usually sucrose and acacia or tragacanth, as well as pastilles comprising fulvestrant or an inclusion complex thereof in an inert base, such as gelatin and glycerin, or sucrose and acacia, emulsions, gels, and the like containing, in addition to the active ingredient, such excipients as are known in the art. Oral formulations may include any suitable dosage, including those described herein, such as any of about 0.1 mg, 1 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 250 mg, 275 mg, 300 mg, 350 mg, 400 mg, 450 mg, or 500 mg of fulvestrant per unit dose. As described below, the formulations may be used for the treatment of a condition (e.g., cancer or systemic lupus erythematosus). Solid dosage forms for oral administration may be particularly useful for the treatment of cancer.
- The inclusion complexes can be enclosed in a hard or soft capsule, can be compressed into tablets, or can be incorporated with beverages or food or otherwise incorporated into the diet. Capsules can be formulated by mixing the inclusion complex with an inert pharmaceutical diluent and inserting the mixture into a hard gelatin capsule of the appropriate size. If soft capsules are desired, a slurry, suspension or solution of the inclusion complex may be encapsulated by machine into a gelatin capsule.
- Liquid dosage forms for oral administration may include pharmaceutically acceptable solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water or buffers. Such formulations may also comprise adjuvants, such as wetting, emulsifying, suspending, antioxidants, preservatives (e.g., antimicrobial preservative), enhancing (e.g., viscosity-enhancing), sweetening, flavoring, and perfuming agents. Liquid dosage forms of the inclusion complexes for oral administration may be particularly useful for the treatment of cancer.
- It is understood that when a formulation comprising a fulvestrant cyclodextrin inclusion complex is employed, wherein the formulation further comprises an additional agent, which may be an additional pharmaceutical or other agent, that the additional agent may be employed in a manner that reduces the number or severity of adverse effects that the additional agent may have on the fulvestrant cyclodextrin inclusion complex. For example, although an additional agent may confer a benefit on a formulation comprising a fulvestrant cyclodextrin inclusion complex, such an agent may also have the potential to displace fulvestrant in the inclusion complex or otherwise prevent or reduce the quality of fulvestrant inclusion. Such agents may still confer a benefit but their adverse consequences may be reduced or avoided if used in reduced amounts. Alternatively, additional agents may be selected such that the additional agent or combination thereof is less likely to adversely affect the inclusion complex.
- Formulations suitable for parenteral administration include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain anti-oxidants, buffers, bacteriostats, and solutes that render the formulation compatible with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizing agents, and preservatives. The formulations can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid for reconstitution (e.g., water for injection), immediately prior to use. Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described.
- Injectable preparations (for example, sterile injectable aqueous or oleaginous suspensions) may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in propylene glycol. The sterile injectable preparation may also be a sterile powder to be reconstituted using acceptable vehicles prior to administration. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils may be employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid may be used in the preparation of injectables.
- Formulation of the inclusion complex in liquid form (for oral administration, parenteral administration, intranasal administration, or otherwise) may have a pH in the range of about 1.0 to about 10.0, including for example pH ranges of any of about 5.0 to about 8.0, about 5.0 to about 7.0, about 5.0 to about 6.0, about 6.5 to about 7.5, and about 6.5 to about 7.0. In some embodiments, the pH of the composition is formulated to no less than about 6, 5, or 4, including for example a pH of any of about 8, 7.5, 7, 6.5, 6, 5.5, 5, 4.5, or 4. The formulation can also be made to be isotonic with blood by the addition of a suitable tonicity modifier, such as glycerol.
- The inclusion complexes may also be formulated for administration by inhalation. Formulations suitable for aerosol administration which comprise the inclusion complex may include, for example, aqueous and non-aqueous, isotonic sterile solutions, which can contain anti-oxidants, buffers, bacteriostats, and solutes, as well as aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizing agents, and preservatives, alone or in combination with other suitable components, which can be made into aerosol formulations to be administered via inhalation. These aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like. They also can be formulated as pharmaceuticals for non-pressured preparations, such as in a nebulizer or an atomizer.
- The inclusion complexes may also be formulated in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.
- The inclusion complexes may also be formulated for topical administration, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.
- Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-applied transdermal patches may also be used.
- Also provided are unit dosage forms comprising the inclusion complexes and formulations described herein. These unit dosage forms can be stored in a suitable packaging in single or multiple unit dosages and may also be further sterilized and sealed. For example, the pharmaceutical formulation (e.g., a dosage or unit dosage form of a pharmaceutical formulation) may include (i) a mixture of fulvestrant with a cyclodextrin, and/or an inclusion complex thereof and (ii) a pharmaceutically acceptable carrier. In some variations, the amount of fulvestrant within the formulation is in any of the following ranges: about 0.1 to about 50 mg, about 1 to about 50 mg, about 5 to about 50 mg, about 20 to about 50 mg, about 50 to about 100 mg, about 100 to about 125 mg, about 125 to about 150 mg, about 150 to about 175 mg, about 175 to about 200 mg, about 200 to about 225 mg, about 225 to about 250 mg, about 250 to about 300 mg, about 300 to about 350 mg, about 350 to about 400 mg, about 400 to about 450 mg, about 450 to about 500 mg, about 500 mg to about 550 mg, about 550 mg to about 600 mg, about 600 mg to about 650 mg, about 650 mg to about 700 mg, about 700 mg to about 750 mg, about 750 mg to about 800 mg. In some embodiments, the amount of fulvestrant within the formulation (e.g., a dosage or unit dosage form) is in the range of about 1 mg to about 500 mg, such as any of about 5 mg to about 250 mg, about 20 mg to about 400 mg, or about 50 mg, 100 mg, 150 m, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, or 800 mg. In some of these embodiments, the formulation may comprise a molar ratio of a cyclodextrin to fulvestrant that is greater than, less than, or any of about 1:1, 2:1, 3:1, 4:1, 5:1, 7.5:1, 10:1, 15:1, 25:1, 50:1, 75:1, 100:1, 150:1 or 300:1. For example, in some embodiments wherein the amount of the amount of fulvestrant within the formulation is in the range of about 1 mg to about 800 mg, such as any of about 5 mg to about 700 mg, 20 mg to about 500 mg, or about 20 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, or 800 mg, the amount of a cyclodextrin in the formulation may be any of about 5 mg to about 2500 mg, such as any of about 15 mg to about 1500 mg, about 30 mg to about 750 mg, about 60 mg to about 300 mg, about 100 mg to about 200 mg, or about 60 mg, 75 mg, 100 mg, 125 mg, 150 mg, 200 mg, 225 mg, 250 mg, 275 mg or 300 mg. In some embodiments, the carrier is suitable for parental administration (e.g., intravenous administration). In some embodiments, the carrier is suitable for intramuscular administration. In some embodiments, the carrier is suitable for oral administration. In some embodiments, the carrier is suitable for intranasal administration. In some embodiments, the carrier is suitable for sublingual, rectal or vaginal administration. In some embodiments, fulvestrant of the inclusion complex is the only pharmaceutically active agent for the treatment of the condition (e.g., cancer or systemic lupus erythematosus) that is contained in the formulation.
- In some embodiments, are provided dosage forms (e.g., a unit dosage form) for the treatment of cancer or systemic lupus erythematosus, comprising (i) a mixture of a fulvestrant with a cyclodextrin, and/or an inclusion complex thereof wherein the amount of fulvestrant is in the range of about 0.1 mg to about 500 mg per unit dose, and (ii) a pharmaceutically acceptable carrier. In some embodiments, the amount of fulvestrant in the unit dosage form includes any of about 0.1 mg, 1 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 250 mg, 275 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, or 800 mg of fulvestrant.
- In some embodiments, are provided formulations of the inclusion complexes described herein comprising one or more of a complexing agent, a filler, a diluent, a granulating agent, a disintegrant, a lubricant, or a glidant. The complexing agent, filler, diluent, granulating agent, disintegrant, lubricant, or glidant may be chosen from among the ingredient listed in Table 1. In some embodiments, formulations may contain zero, one, or more than one ingredient from each use category in Table 1. Formulations may additionally contain other complexing agents, fillers, diluents, granulating agents, disintegrants, lubricants, or glidants not listed in Table 1. Formulations may also contain additional ingredients that are not complexing agents, fillers, diluents, granulating agents, disintegrants, lubricants, or glidants.
-
TABLE 1 Use Ingredients Complexing agent Sodium hydrogen carbonate; ethanol; methanol Filler/diluent Microcrystalline cellulose; calcium carbonate; glucose; calcium hydrogen phosphate; lactose; mannitol; sodium chloride; sucrose; dextrates; microfine cellulose; modified starch; sucrose-dextrin co-precipitate Granulating agent Acacia mucilage; glucose; gelatine; povidone (PVP); starch mucilage; sucrose; tragacanth mucilage Disintegrant Sodium hydroxymethylcellulose; alginic acid; sodium alginate; aluminium magnesium silicate; carbon dioxide; carmellose sodium; cationic exchange resins; croscarmellose sodium; microcrystalline cellulose; modified starch; sodium lauryl sulphate; sodium glycine carbonate; sodium starch glycollate; starch Lubricant Magnesium stearate; calcium stearate; stearic acid; fumaric acid; hydrogenated vegetable oil; liquid paraffin; magnesium lauryl sulphate; macrogol 4000 and 6000; sodium benzoate; sodium lauryl sulphate; sodium stearyl fumarate Glidant Colloidal silica; talc - Exemplary formulations are shown in Table 2.
-
TABLE 2 Formulation 1Formulation 2Formulation 3Formulation 4Formulation 5Complexing Sodium Ethanol None Methanol None agent hydrogen carbonate Filler/diluent Glucose Mannitol; Microcrystalline Sodium Glucose; sucrose modified starch cellulose; lactose chloride; dextrates Granulating None Acacia mucilage None Starch mucilage Tragacanth agent mucilage Disintegrant Alginic acid; Aluminum Crosscarmellose Microcrystalline Sodium lauryl carbon dioxide magnesium sodium cellulose sulphate silicate Lubricant Calcium stearate Fumaric acid Magnesium Liquid paraffin Sodium stearate benzoate Glidant Colloidal silica Talc Colloidal silica Talc Talc Other Dye Dye Dye; PVA-based PVA-based film None ingredients film coating coating - In some embodiments, the complexing agent, filler, diluent, granulating agent, disintegrant, lubricant, or glidant is present in the amount per tablet indicated in Table 3.
-
TABLE 3 Amount per Ingredient tablet Complexing agent 1-200 mg Filler/diluent 100-200 mg Granulating agent 1-50 mg Disintegrant 1-50 mg Lubricant 1-10 mg Glidant 5-30 mg - In some embodiments, the inclusion complex is formulated as a tablet comprising fulvestrant and a cyclodextrin in amounts per tablet as indicated in Table 4 and one or more additional ingredients listed in Table 4 in an amount per tablet as indicated in Table 4.
-
TABLE 4 Ingredient Amount Per Tablet fulvestrant 0.1 mg, 1 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 250 mg, 275 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, or 800 mg cyclodextrin 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 275, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, or 800 mg Microcrystalline cellulose, glucose, mannitol, 150, 160, 165, 170, 180, 185, 190, 195, or 200 mg or sucrose Aluminum magnesium silicate, carmellose 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, or 60 mg sodium, crosscarmellose, or modified starch Colloidal silica or talc 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 mg Dextrates, lactose, or sodium chloride 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, or 5.0 mg Dye 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, or 5.0 mg Polymer-based film coating 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 mg - In some embodiments, are provided formulations of the inclusion complexes described herein comprising one or more of a vehicle, a suspending agent, antimicrobial preservatives, antioxidants, viscosity enhancing agents, sweetening agents, flavoring agents or coloring agents. The vehicle, suspending agent, antimicrobial preservatives, antioxidants, viscosity enhancing agents, sweetening agents, flavoring agents or coloring agents may be chosen from among the ingredients listed in Table 5. In some embodiments, formulations may contain zero, one, or more than one ingredient from each use category in Table 5. Formulations may additionally contain another vehicle, a suspending agent, antimicrobial preservatives, antioxidants, viscosity enhancing agents, sweetening agents, flavoring agents or coloring agents not listed in Table 5. Formulations may also contain additional ingredients that are not vehicles, suspending agents, antimicrobial preservatives, antioxidants, viscosity enhancing agents, sweetening agents, flavoring agents, or coloring agents. In some embodiments, the formulations described herein are oral formulations.
-
TABLE 5 Use Ingredients Vehicle Water, distilled water, purified water, water for injection, aromatic water, juices, syrups, spirits Suspending agent Agar, alginic acid, bentonite, calcium stearate, carbomers, carboxymethylcellulose calcium, carboxymethylcellulose sodium, carrageenan, cellulose, ceratonia, colloidal silicon dioxide, dextrin, gelatin, guar gum, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose, hypromellose, kaolin, magnesium aluminum silicate, maltitol, medium-chain triglycerides, methylcellulose, microcrystalline cellulose, polycarbophil, polyethylene glycol, potassium alginate, povidone, propylene glycol alginate, sesame oil, sodium alginate, sodium starch glycolate, sorbitan esters, sucrose, tragacanth, xanthan gum. Antimicrobial Alcohol, benzalkonium chloride, benzethonium chloride, benzoic acid, preservative benzyl alcohol, boric acid, bronopol, butylated hydroxyanisole, butylparaben, cetrimide, cetylpyridinium chloride, chlorbutanol, chlorhexidine, chlorobutanol, chlorocresol, chloroform, chloroxylenol, cresol, dimethyl ether, ethylparaben, glycerin, hexetidine, imidurea, isopropyl alcohol, lactic acid, methylparaben, monothioglycerol, parabens, alkyl chain length, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric acetate, phenylmercuric borate, phenylmercuric nitrate, potassium benzoate, potassium metabisulfite, potassium sorbate, propionic acid, propyl gallate, propylene glycol, propylparaben, sodium acetate, sodium benzoate, sodium borate, sodium lactate, sodium metabisulfite, sodium propionate, sodium sulfite, sorbic acid, thimerosal, xylitol. Antioxidant Ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, malic acid, propyl gallate, sodium bisulfite, sodium sulfite, sodium metabisulfite, potassium metabisulfite, potassium bisulfite, sodium thiosulfate, sodium formaldehyde sulfoxylate, L-ascorbic acid, D-ascorbic acid, acetylcysteine, cysteine, thioglycerol, thioglycoUic acid, thiolactic acid, thiourea, dithiothreitol, dithioerythreitol, glutathione, nordihydroguaiaretic acid, tocopherol, sodium ascorbate, hypophophorous acid, fumaric acid. Viscosity Acacia, agar, alginic acid, bentonite, carbomers, carboxymethylcellulose enhancing agent calcium, carboxymethylcellulose sodium, carrageenan, ceratonia, cetostearyl alcohol, chitosan, colloidal silicon dioxide, cyclomethicone, ethylcellulose, gelatin, glycerin, glyceryl behenate, guar gum, hectorite, hydrogenated vegetable oil type I, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose, hydroxypropyl starch, hypromellose, magnesium aluminum silicate, maltodextrin, methylcellulose, polydextrose, polyethylene glycol, poly(methylyinyl ether/maleic anhydride), polyvinyl acetate phthalate, polyvinyl alcohol, potassium chloride, povidone, propylene glycol alginate, saponite, sodium alginate, sodium chloride, stearyl alcohol, sucrose, tragacanth, xanthan gum Sweetening agent Acesulfame potassium, alitame, aspartame, dextrose, erythritol, fructose, glycerin, inulin, isomalt, lactitol, glucose, maltitol, maltitol, maltose, mannitol, neohesperidin dihydrochalcone, polydextrose, saccharin, saccharin sodium, sodium cyclamate, sorbitol, sucralose, sucrose, syrups, honey, thaumatin, trehalose, xylitol. - Exemplary formulations (e.g., oral formulation) are shown in Table 6.
-
TABLE 6 Formulation 1Formulation 2Formulation 3Formulation 4Formulation 5Vehicle Water for Aromatic water Syrup Water for Water for injection injection injection Suspending None None None None Microcrystalline agent cellulose Antimicrobial None Benzoic acid Chloroform Benzoic acid Benzoic acid preservative Antioxidant None Thioglycerol Acetyl cysteine Thioglycerol Ascorbic acid Viscosity None None None None Carboxymethyl enhancing cellulose agent Sweetening Aspartame Acesulfame Fructose Saccharin Aspartame agent potassium Other Flavouring & Flavouring & Flavouring & Flavouring & Flavouring & ingredients coloring agent coloring agent coloring agent coloring agent coloring agent - In some embodiments, are provided formulations of the inclusion complexes described herein comprising one or more of a vehicle, suspending agents, antimicrobial preservatives, antioxidants, viscosity enhancing agents. The vehicle, suspending agents, antimicrobial preservatives, antioxidants, viscosity enhancing agents may be chosen from among the ingredients listed in Table 7. In some embodiments, formulations may contain zero, one, or more than one ingredient from each use category in Table 7. Formulations may additionally contain other vehicles, suspending agents, antimicrobial preservatives, antioxidants and viscosity enhancing agents not listed in Table 7. Formulations may also contain additional ingredients that are not vehicles, suspending agents, antimicrobial preservatives, antioxidants or viscosity enhancing agents. In some embodiments, the formulations described herein are intranasal formulations.
-
TABLE 7 Use Ingredients Vehicle Water, distilled water, purified water, water for injection, ethanol, buffers Suspending agent Alginic acid, bentonite, calcium stearate, carbomers, carboxymethylcellulose calcium, carboxymethylcellulose sodium, carrageenan, cellulose, ceratonia, colloidal silicon dioxide, dextrin, gelatin, guar gum, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose, hypromellose, kaolin, magnesium aluminum silicate, maltitol, medium-chain triglycerides, methylcellulose, microcrystalline cellulose, polycarbophil, polyethylene glycol, potassium alginate, povidone, propylene glycol alginate, sesame oil, sodium alginate, sodium starch glycolate, sorbitan esters, sucrose, tragacanth, xanthan gum Antimicrobial Alcohol, benzalkonium chloride, benzethonium chloride, benzoic acid, preservative benzyl alcohol, boric acid, bronopol, butylated hydroxyanisole, butylparaben, cetrimide, cetylpyridinium chloride, chlorbutanol, chlorhexidine, chlorobutanol, chlorocresol, chloroform, chloroxylenol, cresol, dimethyl ether, ethylparaben, glycerin, hexetidine, imidurea, isopropyl alcohol, lactic acid, methylparaben, monothioglycerol, parabens, alkyl chain length, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric acetate, phenylmercuric borate, phenylmercurie nitrate, potassium benzoate, potassium metabisulfite, potassium sorbate, propionic acid, propyl gallate, propylene glycol, propylparaben, sodium acetate, sodium benzoate, sodium borate, sodium lactate, sodium metabisulfite, sodium propionate, sodium sulfite, sorbic acid, thimerosal, xylitol Antioxidant Ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, malic acid, propyl gallate, sodium bisulfite, sodium sulfite, sodium metabisulfite, potassium metabisulfite, potassium bisulfite, sodium thiosulfate, sodium formaldehyde sulfoxylate, L-ascorbic acid, D-ascorbic acid, acetylcysteine, cysteine, thioglycerol, thioglycoUic acid, thiolactic acid, thiourea, dithiothreitol, dithioerythreitol, glutathione, nordihydroguaiaretic acid, tocopherol, sodium ascorbate, hypophophorous acid, fumaric acid Viscosity enhancing Acacia, agar, alginic acid, bentonite, carbomers, carboxymethylcellulose agent calcium, carboxymethylcellulose sodium, carrageenan, ceratonia, ectostearyl alcohol, chitosan, colloidal silicon dioxide, cyclomethicone, ethylcelluose, gelatin, glycerin, glyceryl behenate, guar gum, hectorite, hydrogenated vegetable oil type I, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose, hydroxypropyl starch, hypromellose, magnesium aluminum silicate, maltodextrin, methylcellulose, polydextrose, polyethylene glycol, poly(methylvinyl ether/maleic anhydride), polyvinyl acetate phthalate, polyvinyl alcohol, potassium chloride, povidone, propylene glycol alginate, saponite, sodium alginate, sodium chloride, stearyl alcohol, sucrose, tragacanth, xanthan gum - Exemplary formulations (e.g., intranasal formulation) are shown in Table 8.
-
TABLE 8 Formulation 1Formulation 2Formulation 3Formulation 4Formulation 5Vehicle Water for Water for Water for pH 6 BufferedWater for injection injection injection water for injection injection Suspending None None None None Microcrystalline agent cellulose Antimicrobial None Benzoic acid Benzalkonium Benzoic acid Benzoic acid preservative chloride Antioxidant None Thioglycerol Acetyl cysteine Thioglycerol Ascorbic acid Viscosity None None None None Carboxymethyl enhancing cellulose agent Other pH modifying pH modifying None pH modifying pH modifying ingredients agents agents agents agents - Also provided are kits containing materials useful for the treatment of a condition that is responsive to fulvestrant (e.g., cancer or systemic lupus erythematosus). The kits may contain an inclusion complex of fulvestrant and a cyclodextrin, and optionally contain instructions for use (e.g., instructions for preparation and/or administration of a formulation comprising the complex). Information detailing possible side effects of the formulation, and any other relevant information may also be enclosed. The instructions may be in any suitable format, including, but not limited to, printed matter, videotape, computer readable disk, optical disc or directions to internet-based instructions.
- In one aspect, is provided a kit for treating an individual who suffers from or is susceptible to one or more of the conditions described herein, comprising a first container comprising a dosage amount of a formulation containing an inclusion complex as disclosed herein, and instructions for use. The container may be any of those known in the art and appropriate for storage and delivery of intravenous, intranasal or oral formulations. In certain embodiments the kit further comprises a second container comprising a pharmaceutically acceptable carrier, diluent, adjuvant, etc. for preparation of the formulation to be administered to the individual.
- In some embodiments, the kits comprise a container with a label. Suitable containers include, for example, bottles, vials, and test tubes. The containers may be formed from a variety of materials such as glass or plastic. The containers may hold an inclusion complex comprising fulvestrant and a cyclodextrin. In some embodiments, the containers may further comprise one or more additional pharmaceutical agents (e.g., an anti-cancer agent). The label on the container may indicate that the inclusion complex or the formulation is used for treating or suppressing a condition that is responsive to fulvestrant (e.g., cancer or systemic lupus erythematosus), and may also indicate directions for in vivo use, such as those described herein.
- The kit may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for performing any methods described herein. In some embodiments, the kit comprises the container described above and a second container comprising a buffer.
- The kits may include additional pharmaceutical agents for use in conjunction with the formulation described herein. In one aspect, the additional pharmaceutical agent is fulvestrant in uncomplexed form, such as in the product FASLODEX® (AstraZeneca Pharmaceuticals LP). In some variations, the additional pharmaceutical agent(s) may be one or more drug(s) for the treatment of conditions responsive to fulvestrant (e.g., cancer or systemic lupus erythematosus). In some variations, the additional pharmaceutical agent(s) may be one or more drug(s) for the treatment of one or more side effects from the use of the inclusion complexes described herein. These agents may be provided in a separate form, or mixed with the complexes described herein, provided such mixing does not reduce the effectiveness of either the pharmaceutical agent or formulation described herein and is compatible with the route of administration. Similarly the kits may include additional agents for adjunctive therapy or other agents known to the skilled artisan as effective in the treatment or prevention of the conditions described herein.
- In some embodiments, the additional pharmaceutical agent is an anti-cancer agent. In some embodiments, the anti-cancer agent is an aromatase inhibitor (AI), including, but not limited to, anastrozole (e.g., ARIMIDEX®), letrozole (e.g., FEMARA®), exemestane (e.g., AROMASIN®), aminoglutethimide (Cytadren®), vorozole (e.g., RIVIZOR®), formestane (e.g., LENTARON®), fadrozole (e.g. AFEMA®), or testolactone (e.g., TESLAC®). In some embodiments, the anti-cancer agent is an epidermal growth factor receptor (EGFR) inhibitor, including, but not limited to, gefitinib (e.g., IRESSA®), trastuzumab (e.g., HERCEPTIN®), or erlotinib (e.g., TARCEVA®). In some embodiments, the anti-cancer agent is a farnesyl transferase inhibitor, including, but not limited to tipifarnib (e.g., ZARNESTRA®). In some embodiments, the anti-cancer agent is uncomplexed fulvestrant, such as uncomplexed fulvestrant administered as an intramuscular injection (e.g., FASLODEX®). In some embodiments, the anti-cancer agent is an antioxidant, including, but not limited to vitamin E, vitamin C, beta-carotene, and selenium.
- In some embodiments, the anti-cancer agent is selected from the group consisting of anastrozole (e.g., ARIMIDEX®), letrozole (e.g., FEMARA®), exemestane (e.g., AROMASIN®), aminoglutethimide (e.g., Cytadren®), vorozole (e.g., RIVIZOR®), formestane (e.g., LENTARON®), fadrozole (e.g., AFEMA®), testolactone (e.g., TESLAC®), gefitinib (e.g., IRESSA®), trastuzumab (e.g., HERCEPTIN®), erlotinib (e.g., TARCEVA®), tipifarnib (e.g., ZARNESTRA®), uncomplexed fulvestrant (e.g., FASLODEX®), and an antioxidant (e.g., vitamin E, vitamin C, beta-carotene, and selenium).
- Kits may also be provided that contain sufficient dosages of the compounds described herein (including formulations thereof) to provide effective treatment for an individual, such as a human in need of such treatment, for an extended period, such as any of 1-3 days, 1-5 days, a week, 2 weeks, 3, weeks, 4 weeks, 6 weeks, 8 weeks, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months or more.
- The kits may include the composition as described herein packaged in either a unit dosage form or in a multi-use form. The kits may also include multiple units of the unit dose form. The kits may be used for any of the methods described herein, including, for example, to treat an individual with a condition described herein, or to delay a condition described herein. In certain embodiments the kits may include a dosage amount of at least one formulation as disclosed herein. Kits may also comprise a means for the delivery of the formulation thereof, such as a syringe, inhaler, intranasal spray, patch or other such device.
- The inclusion complexes described herein comprising fulvestrant and a cyclodextrin, formulations thereof, and formulations comprising an uncomplexed fulvestrant and a cyclodextrin, or mixtures thereof, may be used for the treatment of indications that are believed to be or are responsive to fulvestrant therapy (e.g., cancer and systemic lupus erythematosus). In some embodiments, provided is a method of treating a cancer in an individual in need thereof, comprising administering to the individual an effective amount of an inclusion complex comprising fulvestrant and a cyclodextrin, or a formulation thereof.
- For purposes herein, beneficial or desired results in a treatment include, but are not limited to, one or more of the following: decreasing one or more symptoms resulting from the condition (e.g., cancer or systemic lupus erythematosus), diminishing the extent of the disease, stabilizing the condition, delaying or slowing the progression of the condition, reversing the progression or severity of the condition, ameliorating the condition, decreasing the dose of one or more other medications required to treat the condition, and/or increasing the quality of life of an individual who has been or is suspected of having the condition. The methods described herein contemplate any one or more of these aspects of treatment. In one aspect, a method of delaying the development of a condition is provided, wherein the method reduces the probability of developing the condition in a given time frame and/or reduces the extent of the condition in a given time-frame, when compared to not using the method. Such comparisons may be based on clinical studies, using a statistically significant number of subjects. In a particular aspect, a method of delaying the development of a condition is provided, wherein the method encompasses preventing a recurrence of the condition in a given time frame, such as 3 months, 6 months, 1 year, 2 years, 3 years, 5 years, 10 years or more.
- In some embodiments, the methods and/or inclusion complex formulations used herein reduce the severity of one or more symptoms associated with the condition (e.g., cancer or systemic lupus erythematosus) by at least any of about 10%, 20%, 30%, 400/%, 50%, 60%, 70%, 80%, 90%, 95%, or 100% compared to the corresponding symptom in the same individual prior to treatment or compared to the corresponding symptom in other individuals not receiving the methods and/or inclusion complex formulations.
- In some variations, the individual being treated for a condition described herein (e.g., cancer or systemic lupus erythematosus) has been identified as having one or more of the symptoms described herein. Identification of the conditions as described herein by a skilled physician is routine in the art such as routine physical exams or clinical detection.
- In some embodiments of a method directed to cancer, the cancer is early stage cancer, non-metastatic cancer, primary cancer, advanced cancer, locally advanced cancer, metastatic cancer, cancer in remission, recurrent cancer, cancer in an adjuvant setting, cancer in a neoadjuvant setting, or cancer substantially refractory to hormone therapy. In some embodiments, the cancer includes, but is not limited to, breast cancer, endometrial cancer, prostate cancer, and lung cancer.
- The methods detailed herein may be applicable to an individual in need thereof, which may be an individual who has been diagnosed with, previously treated for, and/or suspected of having the condition to be treated (e.g., cancer or systemic lupus erythematosus). With respect to prevention, the individual in need thereof may also be an individual who is at risk for a condition (e.g., age, a family or self history of the condition, life-style factors indicative of risk for the condition, etc.). In a particular variation, an individual is an individual who has previously had the condition and is at risk fir recurrence of the condition.
- In some embodiments, the individual is a mammal, including, but not limited to human, bovine, horse, feline, rabbit, canine, rodent, or primate. In some embodiments, the mammal is a primate. In some embodiments, the primate is a human. In some embodiments, the individual is human, including adults and children. The human may be of either sex and the methods may be applicable to either a man or a woman. In one aspect, the individual is a human who is believed to be or is in need of treatment. In some embodiments, the individual is a pre-menopausal, per-menopausal or post-menopausal woman. In some embodiments, the individual is a post-menopausal woman with disease (e.g., breast cancer) progression following hormone (e.g., antiestrogen) therapy. In some embodiments, the individual is a pre-menopausal woman with disease (e.g., breast cancer) progression following hormone (e.g., anti-estrogen) therapy. In some embodiments, the individual is a non-mammal. In some variations, the primate is a non-human primate such as chimpanzees and other apes and monkey species. In some embodiments, the mammal is a farm animal such as cattle, horses, sheep, goats, and swine; pets such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice, and guinea pigs; and the like. In some embodiments, the individual is a non-mammal, including, but not limited to, birds, and the like. The term “individual” does not denote a particular age or sex.
- In some embodiments, provided is a method of treating breast cancer in an individual in need thereof, comprising administering to the individual an effective amount of an inclusion complex comprising fulvestrant and a cyclodextrin (e.g., MBCD or HPBCD), or a formulation thereof. In some embodiments, the individual is a pre- or peri-menopausal individual with breast cancer progression following anti-estrogen therapy. In some embodiments, the individual is a post-menopausal individual with breast cancer progression following anti-estrogen therapy. In some embodiments, the breast cancer is early stage breast cancer, non-metastatic breast cancer, advanced breast cancer, stage IV breast cancer, locally advanced breast cancer, metastatic breast cancer, hormone receptor positive metastatic breast cancer, advanced breast cancer, breast cancer in remission, breast cancer in an adjuvant setting, ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC), or breast cancer in a neoadjuvant setting. In some specific embodiments, the breast cancer is hormone receptor positive metastatic breast cancer. In some embodiments, the breast cancer is advanced breast cancer. In some embodiments, the breast cancer is ductal carcinoma in situ. In some embodiments, there are provided methods of treating breast cancer (which may be HER2 positive or HER2 negative), including, for example, advanced breast cancer, stage IV breast cancer, locally advanced breast cancer, and metastatic breast cancer. In some embodiments, the individual may be a human who has a gene, geneticmutation, or polymorphism associated with breast cancer (e.g., BRCA1, BRCA2, ATM, CHEK2, RAD51, AR, DIRAS3, ERBB2, TP53, AKT, PTEN, and/or PI3K) or has one or more extra copies of a gene (e.g., one or more extra copies of the HER2 gene) associated with breast cancer. In some embodiments, the method further comprises identifying a cancer patient population (e.g., breast cancer population) based on a hormone receptor status of patients having tumor tissue not expressing both ER and PgR and administering to the patient population an effective amount of the inclusion complex comprising fulvestrant and a cyclodextrin.
- In some embodiments, provided is a method of treating endometrial cancer (or uterine cancer) in an individual in need thereof, comprising administering to the individual an effective amount of an inclusion complex comprising fulvestrant and a cyclodextrin (e.g., MBCD or HPBCD), or a formulation thereof. In some embodiments, the individual is a pre- or peri-menopausal woman. In some embodiments, the individual is a post-menopausal woman. In some embodiments, the endometrial cancer is endometrial stromal sarcoma, uterine carcinosarcoma, endometrial adenocarcinoma, Type I endometrial carcinoma, or Type II endometrial carcinoma. In some embodiments, the endometrial carcinoma is stage IA, stage IB, stage IC, stage IIA, stage IIB, stage IIIA, stage IIB, stage IIIC, stage IVA, or stage IVB endometrial carcinoma.
- In some embodiments, provided is a method of treating prostate cancer in an individual in need thereof, comprising administering to the individual an effective amount of an inclusion complex comprising fulvestrant and a cyclodextrin (e.g., MBCD or HPBCD), or a formulation thereof. In some embodiments, the prostate cancer is an adenocarcinoma. In some embodiments, the prostate cancer is a sarcoma, neuroendocrine tumor, small cell cancer, ductal cancer, or a lymphoma. There are provided methods of treating prostate cancer at any of the four stages, A, B, C, or D, according to the Jewett staging system. In some embodiments, the prostate cancer is stage A prostate cancer (the cancer cannot be felt during a rectal exam.). In some embodiments, the prostate cancer is stage B prostate cancer (the tumor involves more tissue within the prostate, it can be felt during a rectal exam, or it is found with a biopsy that is done because of a high PSA level.). In some embodiments, the prostate cancer is stage C prostate cancer (the cancer has spread outside the prostate to nearby tissues.). In some embodiments, the prostate cancer is stage D prostate cancer. In some embodiments, the prostate cancer may be androgen independent prostate cancer (AIPC). In some embodiments, the prostate cancer may be androgen dependent prostate cancer. In some embodiments, the prostate cancer may be refractory to hormone therapy. In some embodiments, the prostate cancer may be substantially refractory to hormone therapy. In some embodiments, the individual may be a human who has a gene, genetic mutation, or polymorphism associated with prostate cancer (e.g., RNASEL/HPC1, ELAC2/HPC2, SR-A/MSR1, CHEK2, BRCA2, PON1, OGG1, MIC-1, TLR4, and/or PTEN) or has one or more extra copies of a gene associated with prostate cancer.
- In some embodiments, provided is a method of treating lung cancer in an individual in need thereof, comprising administering to the individual an effective amount of an inclusion complex comprising fulvestrant and a cyclodextrin (e.g., MBCD or HPBCD), or a formulation thereof. In some embodiments, the hmg cancer is a non-small cell lung cancer (NSCLC). Examples of NSCLC include, but are not limited to, large-cell carcinoma (e.g., large-cell neuroendocrine carcinoma, combined large-cell neuroendocrine carcinoma, basaloid carcinoma, lymphoepithelioma-like carcinoma, clear cell carcinoma, and large-cell carcinoma with rhabdoid phenotype), adenocarcinoma (e.g., acinar, papillary (e.g., bronchioloalveolar carcinoma, nonmucinous, mucinous, mixed mucinous and nonmucinous and indeterminate cell type), solid adenocarcinoma with mucin, adenocarcinoma with mixed subtypes, well-differentiated fetal adenocarcinoma, mucinous (colloid) adenocarcinoma, mucinous cystadenocarcinoma, signet ring adenocarcinoma, and clear cell adenocarcinoma), neuroendocrine lung tumors, and squamous cell carcinoma (e.g., papillary, clear cell, small cell, and basaloid). In some embodiments, the NSCLC may be, according to TNM classifications, a stage T tumor (primary tumor), a stage N tumor (regional lymph nodes), or a stage M tumor (distant metastasis). In some embodiments, the lung cancer is a carcinoid (typical or atypical), adenosquamous carcinoma, cylindroma, or carcinoma of the salivary gland (e.g., adenoid cystic carcinoma or mucoepidermoid carcinoma). In some embodiments, the lung cancer is a carcinoma with pleomorphic, sarcomatoid, or sarcomatous elements (e.g., carcinomas with spindle and/or giant cells, spindle cell carcinoma, giant cell carcinoma, carcinosarcoma, or pulmonary blastoma). In some embodiments, the cancer is small cell lung cancer (SCLC; also called oat cell carcinoma). The small cell lung cancer may be limited-stage, extensive stage or recurrent small cell lung cancer. In some embodiments, the individual may be a human who has a gene, genetic mutation, or polymorphism suspected or shown to be associated with lung cancer (e.g., SASH1, LATS1, IGF2R, PARK2, KRAS, PTEN, Kras2, Krag, Pas1, ERCC1, XPD, IL8RA, EGFR, afAD, EPHX, MMP1, MMP2, MMP3, MMP12, IL1p\RAS, and/or AKT) or has one or more extra copies of a gene associated with lung cancer.
- In another aspect, the inclusion complexes described herein (e.g., an inclusion complex comprising fulvestrant and a cyclodextrin) may be used for the treatment of systemic lupus erythematosus. In some embodiments is provided a method of treating systemic lupus erythematosus in an individual, comprising administering to the individual an effective amount of an inclusion complex comprising fulvestrant and a cyclodextrin, or a formulation thereof.
- The method detailed herein may use any inclusion complex or composition detailed herein. As described below, the inclusion complex may be administered via any route (e.g., orally, intranasally, sublingually, parenterally, such as intravenously, rectally, intravaginally).
- In another aspect, provided is a method of treating a cancer in an individual in need thereof, comprising administering to the individual an effective amount of an inclusion complex comprising fulvestrant and a cyclodextrin, or a formulation thereof, and one other pharmaceutical agent.
- In another aspect, provided is a method of treating systemic lupus erythematosus in an individual in need thereof, comprising administering to the individual an effective amount of an inclusion complex comprising fulvestrant and a cyclodextrin, or a formulation thereof and one other pharmaceutical agent.
- In the context of an inclusion complex of fulvestrant, the additional pharmaceutical agent in one aspect refers to an active agent other than complexed fulvestrant, for example, an anti-cancer agent other than fulvestrant, which is administered to elicit a therapeutic effect or fulvestrant in an uncomplexed form. In one aspect, the additional pharmaceutical agent is an anti-cancer agent other than fulvestrant. More than one additional pharmaceutical agent may be employed. An additional pharmaceutical agent may be directed to a therapeutic effect related to one or more conditions that fulvestrant is intended to treat or prevent (e.g., cancer or systemic lupus erythematosus) or the pharmaceutical agent may be intended to treat or prevent a symptom of the underlying condition (e.g., pain, swelling, warmth and redness throughout the breast, Paget's disease of the breast, malar rash, fatigue, loss of appetite, inflammation (e.g., pericarditis, myocarditis, or endocarditis), bone or joint pain, arthritis, anemia and iron deficiency, pleuritis, pleural effusion, lupus pneumonitis, pulmonary hypertension, pulmonary emboli, pulmonary hemorrhage, chronic diffuse interstitial lung disease, hematuria, headache, or proteinuria, etc.) or to further reduce the appearance or severity of side effects of fulvestrant (e.g., asthenia, pain, headache, back pain, vasodilatation, nausea, vomiting, constipation, anemia, bone pain, arthritis, dizziness, insomnia, rash, or urinary tract infection).
- In some embodiments, the pharmaceutical agent is an anti-cancer agent. In some embodiments, the anti-cancer agent is an aromatase inhibitor (AI), including, but not limited to, anastrozole (e.g., ARIMIDEX®), letrozole (e.g., FEMARA®), exemestane (e.g., AROMASIN®), aminoglutethimide (Cytadren®), vorozole (e.g., RIVIZOR®), formestane (e.g., LENTARON®), fadrozole (e.g., AFEMA®), or testolactone (e.g., TESLAC®). In some embodiments, the anti-cancer agent is an epidermal growth factor receptor (EGFR) inhibitor, including, but not limited to, gefitinib (e.g., IRESSA®), trastuzumab (e.g., HERCEPTIN®), or erlotinib (e.g., TARCEVA®). In some embodiments, the anti-cancer agent is a farnesyl transferase inhibitor, including, but not limited to tipifamib (e.g., ZARNESTRA®). In some embodiments, the anti-cancer agent is fulvestrant in uncomplexed form (e.g., FASLODEX®). In some embodiments, the anti-cancer agent is an antioxidant, including, but not limited to vitamin E, vitamin C, beta-carotene, and selenium. In some embodiments, the formulation may include combinations of two or more of the anti-cancer agents as described herein (e.g., any of 2, 3, or more anti-cancer agents).
- In some embodiments, the antioxidant includes, but is not limited to, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, malic acid, propyl gallate, sodium bisulfite, sodium sulfite, sodium metabisulfite, potassium metabisulfite, potassium bisulfite, sodium thiosulfate, sodium formaldehyde sulfoxylate, L-ascorbic acid, D-ascorbic acid, acetylcysteine, cysteine, thioglycerol, thioglycoUic acid, thiolactic acid, thiourea, dithiothreitol, dithiocrythreitol, glutathione, nordihydroguaiaretic acid, tocopherol, sodium ascorbate, hypophophorous acid, and fumaric acid.
- In some embodiments, the anti-cancer agent is selected from the group consisting of anastrozole (e.g., ARIMIDEX®), letrozole (e.g., FEMARA®), exemestane (e.g., AROMASIN®), aminoglutethimide (Cytadren®), vorozole (e.g., RIVIZOR®), formestane (e.g., LENTARON®), fadrozole (e.g., AFEMA®), testolactone (e.g., TESLAC®), gefitinib (e.g., IRESSA®), trastuzumab (e.g., HERCEPTIN®), erlotinib (e.g., TARCEVA®), tipifarnib (e.g., ZARNESTRA®), fulvestrant in uncomplexed form (e.g., FASLODEX®), and an antioxidant (e.g., vitamin E, vitamin C, beta-carotene, and selenium).
- In some embodiments, provided is a method of treating a hormone receptor positive metatstatic breast cancer in an individual in need thereof, comprising administering to the individual an effective amount of an inclusion complex comprising fulvestrant and a cyclodextrin, or a formulation thereof, and anastrozole.
- In some embodiments, provided is a method of treating a hormone receptor positive metatstatic breast cancer in an individual in need thereof comprising administering to the individual an effective amount of an inclusion complex comprising fulvestrant and a cyclodextrin, or a formulation thereof, and exemestane.
- In some embodiments, provided is a method of treating a hormone receptor positive metatstatic breast cancer in an individual in need thereof, comprising administering to the individual an effective amount of an inclusion complex comprising fulvestrant and a cyclodextrin, or a formulation thereof, and uncomplexed fulvestrant (e.g., FASLODEX®).
- In some embodiments, provided is a method of treating a hormone receptor positive metatstatic breast cancer in an individual in need thereof comprising administering to the individual an effective amount of an inclusion complex comprising fulvestrant and a cyclodextrin, or a formulation thereof and gefitinib.
- In some embodiments, provided is a method of treating a hormone receptor positive metatstatic breast cancer in an individual in need thereof comprising administering to the individual an effective amount of an inclusion complex comprising fulvestrant and a cyclodextrin, or a formulation thereof and lapatinib.
- In some embodiments, provided is a method of treating a hormone receptor positive metatstatic breast cancer in an individual in need thereof, comprising administering to the individual an effective amount of an inclusion complex comprising fulvestrant and a cyclodextrin, or a formulation thereof and tipifarnib.
- In some embodiments, the inclusion complex comprising fulvestrant and a cyclodextrin, or a formulation thereof, and the other pharmaceutical agent are administered simultaneously. In some embodiments, the inclusion complex comprising fulvestrant and a cyclodextrin, or a formulation thereof, and the other pharmaceutical agent are administered sequentially. Either the inclusion complex or the other pharmaceutical agent may be administered first. The inclusion complex and the other pharmaceutical agent may be contained in the same or different packages or compositions.
- The amount of the inclusion complex administered to an individual (such as a human) and/or the amount administered in order to achieve an effective amount may vary based on a variety of factors, including, for example, the particular condition being treated, the frequency of administration, the particular formulation being administered, the severity of the condition being treated and the age, weight and general health of the individual, the adverse effects experienced by the individual being treated, etc. A pharmaceutical unit dosage chosen may be fabricated and administered to provide a defined final concentration of drug in the blood, tissues, organs, or other targeted region of the body. Determination of an effective amount for a given situation can be readily determined by routine experimentation (e.g., using in vivo animal models) and is within the skill and judgment of the ordinary clinician, particularly in view of the teachings provided herein.
- In various embodiments, an effective amount of the inclusion complex or therapy may do any one or more of the following: (i) reduce the number of cancer cells; (ii) reduce tumor size; (iii) inhibit, retard, slow to some extent, and preferably stop cancer cell infiltration into peripheral organs; (iv) inhibit (e.g., slow to some extent and preferably stop) tumor metastasis; (v) inhibit tumor growth; (vi) prevent or delay occurrence and/or recurrence of a tumor, and (vii) relieve to some extent one or more of the symptoms associated with the cancer. In various embodiments, the amount is sufficient to ameliorate, palliate, lessen, and/or delay one or more of symptoms of cancer. In various embodiments, an effective amount of the inclusion complex or therapy may inhibit, retard, slow to some extent, prevent, delay occurrence and/or recurrence of; or relieve to some extent one or more of the symptoms associated with systemic lupus erythematosus.
- The effective amount may vary depending on the composition being administered, the condition being treated/prevented, the severity of the condition being treated/prevented, the age, body size, weight, and relative health of the individual, the route and form of administration, the judgement of the attending medical or veterinary practitioner (if applicable), and other factors appreciated by the skilled artisan in view of the teaching provided herein. An effective amount may be assessed, for example, by using data from one or more clinical, physiological, biochemical, histological, electrophysiological, and/or behavioral evaluations.
- In some embodiments, the amount of the inclusion complex comprising fulvestrant and a cyclodextrin is effective to result in an objective response (such as a partial response or a complete response). In some embodiments, the amount of inclusion complex is sufficient to result in a complete response in the individual. In some embodiments, the amount of the inclusion complex is sufficient to result in a partial response in the individual. In some embodiments, the amount of the inclusion complex administered alone is sufficient to produce an overall response rate of more than about any of about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% among a population of individuals treated with the complex. Responses of an individual to treatment can be determined by the skilled artisan using, for example routine physical exams and/or clinical detection known in the art and/or described herein.
- In some embodiments, the amount of the inclusion complex is below the level that induces a toxicological effect (where the toxicological effect in one aspect is an effect above a clinically acceptable level of toxicity) or is at a level where a potential side effect can be controlled or tolerated when the complex is administered to the individual. In some embodiments, the amount of the inclusion complex is close to a maximum tolerated dose (MTD) of the complex following the same dosing regime. In some embodiments, the amount of the inclusion complex is more than any of about 80%, 90%, 95%, or 98% of the MTD.
- In some embodiments, the amount of fulvestrant from an inclusion complex comprising fulvestrant and a cyclodextrin is included in any of the following ranges: about 0.1 to about 5 mg, about 1 to about 10 mg, about 5 to about 10 mg, about 10 to about 15 mg, about 15 to about 20 mg, about 20 to about 25 mg, about 20 to about 50 mg, about 25 to about 50 mg, about 50 to about 75 mg, about 50 to about 100 mg, about 75 to about 100 mg, about 100 to about 125 mg, about 125 to about 150 mg, about 150 to about 175 mg, about 175 to about 200 mg, about 200 to about 225 mg, about 225 to about 250 mg, about 250 to about 300 mg, about 300 to about 350 mg, about 350 to about 400 mg, about 400 to about 450 mg, about 450 to about 500 mg, about 550 to about 600 mg, about 650 to about 700 mg, or about 750 to about 800 mg. In some embodiments, the amount of fulvestrant from an inclusion complex is in the range of about 1 mg to about 800 mg, such as about 5 mg to about 700 mg, 10 mg to about 500 mg, 20 mg to about 250 mg, or about 25 mg, 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 500 mg, 600 mg, 700 mg, or 800 mg. In some embodiments of the liquid formulations, the concentration of fulvestrant from an inclusion complex comprising fulvestrant and cyclodextrin as inclusion complex is dilute (about 0.1 mg/ml) or concentrated (about 200 mg/ml), including for example any of about 0.1 to about 200 mg/ml, about 0.1 to about 100 mg/ml, about 1 to about 50 mg/ml, about 2 mg/ml to about 25 mg/ml, about 4 to about 10 mg/ml, about 5 mg/ml. In some embodiments, the concentration of fulvestrant of the inclusion complex is at least about any of 0.5 mg/ml, 1.3 mg/ml, 1.5 mg/ml, 2 mg/ml, 3 mg/ml, 4 mg/ml, 5 mg/ml, 6 mg/ml, 7 mg/ml, 8 mg/ml, 9 mg/ml, 10 mg/ml, 15 mg/ml, 20 mg/ml, 25 mg/ml, 30 mg/ml, 40 mg/ml, 50 mg/ml, 60 mg/ml, 70 mg/ml, 80 mg/ml, 90 mg/ml, 100 mg/ml, 150 mg/ml, or 200 mg/ml.
- Exemplary effective amounts of fulvestrant from an inclusion complex comprising fulvestrant and a cyclodextrin include, but are not limited to, any of about 2.5 mg/m2, 5 mg/m2, 10 mg/m2, 15 mg/m2, 20 mg/m2, 25 mg/m2, 30 mg/m2, 50 mg/m2, 60 mg/m2, 75 mg/m2, 80 mg/m2, 90 mg/m2, 100 mg/m2, 120 mg/m2, 160 mg/m2, 175 mg/m2, 180 mg/m2, 200 mg/m2, 210 mg/m2, 220 mg/m2, 250 mg/m2, 260 mg/m2, 300 mg/m2, 350 mg/m2, 400 mg/m2, 500 mg/m2, 540 mg/m2, 750 mg/m2, 1000 mg/m2, or 1080 mg/m2. In various variations, a formulation includes less than about any of 350 mg/m2, 300 mg/m2, 250 mg/m2, 200 mg/m2, 150 mg/m2, 120 mg/m2, 100 mg/m2, 90 mg/m2, 50 mg/m2, or 30 mg/m2 of fulvestrant. In some embodiments, the amount of fulvestrant within the inclusion complex per administration is less than any of about 25 m/m, 22 m/m2, 20 mg/m2, 18 mg/m2, 15 mg/m2, 14 mg/m2, 13 mg/m2, 12 mg/m2, 11 mg/m2, 10 mg/m2, 9 mg/m2, 8 mg/m2, 7 mg/m2, 6 mg/m2, 5 mg/m2, 4 mg/m2, 3 mg/m2, 2 mg/m2, or 1 mg/m. In some embodiments, the effective amount of fulvestrant from the inclusion complex is included in any of the following ranges: about 1 to about 5 mg/m, about 5 to about 10 mg/m2, about 10 to about 25 mg/m2, about 25 to about 50 mg/m2, about 50 to about 75 mg/m2, about 75 to about 100 mg/m2, about 100 to about 125 mg/m2 about 125 to about 156 mg/m2, about 150 to about 175 mg/m2, about 175 to about 200 mg/m2, about 200 to about 225 mg/m2, about 225 to about 250 mg/m2, about 250 to about 300 mg/m2, about 300 to about 350 mg/m2, or about 350 to about 400 mg/m2.
- In some embodiments of any of the above aspects, the effective amount of fulvestrant from an inclusion complex comprising fulvestrant and a cyclodextrin includes at least any of about 0.01 mg/kg, 0.05 mg/kg, 0.1 mg/kg, 0.25 mg/kg, 0.5 mg/kg, 1 mg/kg, 1.5 mg/kg, 2 mg/kg, 2.5 mg/kg, 3.5 mg/kg, 5 mg/kg, 6.5 mg/kg, 7.5 mg/kg, 10 mg/kg, 15 mg/kg, or 20 mg/kg. In various variations, the effective amount of fulvestrant includes less than any of about 350 mg/kg, 300 mg/kg, 250 mg/kg, 200 mg/kg, 150 mg/kg, 100 mg/kg, 50 mg/kg, 25 mg/kg, 20 mg/kg, 10 mg/kg, 7.5 mg/kg, 6.5 mg/kg, 5 mg/kg, 3.5 mg/kg, 2.5 mg/kg, 2 mg/kg, 1.5 mg/kg, 1 mg/kg, 0.75 mg/kg, 0.5 mg/kg, 0.25 mg/kg, 0.1 mg/kg, 0.05 mg/kg.
- Exemplary dosing frequencies include, but are not limited to, weekly without break; weekly, three out of four weeks; once every three weeks; once every two weeks; weekly, two out of three weeks. In some embodiments, the inclusion complex is administered any of about once every 2 weeks, once every 3 weeks, once every 4 weeks, once every 6 weeks, or once every 8 weeks. In some embodiments, the composition is administered at least any of about 1×, 2×, 3×, 4×, 5×, 6×, or 7× (i.e., daily) a week. In some embodiments, the intervals between each administration are less than any of about 6 months, 3 months, 1 month, 20 days, 15, days, 12 days, 10 days, 9 days, 8 days, 7 days, 6 days, 5 days, 4 days, 3 days, 2 days, or 1 day. In some embodiments, the intervals between each administration are more than any of about 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 8 months, or 12 months. In some embodiments, there is no break in the dosing schedule. In some embodiments, the interval between each administration is no more than about a week. The administration of the inclusion complex can be extended over an extended period of time, such as from about a month up to about seven years. In some embodiments, the composition is administered over a period of at least any of about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 18, 24, 30, 36, 48, 60, 72, or 84 months. The dosing frequency of the inclusion complex may be adjusted over the course of the treatment based on the judgment of the administering physician. For example, a multiple daily dosage routine of the inclusion complex may be included.
- The inclusion complexes described herein allow, in some embodiments, infusion of the complex to an individual over an infusion time that is shorter than about 24 hours. For example, in some embodiments, the inclusion complex is administered over an infusion period of less than any of about 24 hours, 12 hours, 8 hours, 5 hours, 3 hours, 2 hours, 1 hour, 30 minutes, 20 minutes, or 10 minutes. In some embodiments, the inclusion complex is administered over an infusion period of about 30 minutes.
- Any of the inclusion complexes described herein (e.g., an inclusion complex comprising fulvestrant and a cyclodextrin) can be administered to an individual (such as human) via various routes, including, for example, intravenous, intra-arterial, intraperitoneal, intrapulmonary, oral, inhalation, intravesicular, intramuscular, intra-tracheal, subcutaneous, intraocular, intrathecal, transmucosal, intranasal, rectal, intravaginal and transdermal. In some embodiments, sustained continuous release formulation of the composition may be used. In one variation, inclusion complex is administered by any acceptable route including, but not limited to, orally, intramuscularly, transdermally, intravenously, intranasally, rectally, intravaginally through an inhaler or other air borne delivery systems and the like. Additional methods of administration are known in the art.
- In some embodiments, the inclusion complexes described herein (e.g., an inclusion complex comprising fulvestrant cyclodextrin) are administered parenterally (e.g., intravenously). For example, in some embodiments are provided methods of treating a cancer in an individual (e.g., an adult) comprising intranasally administering an inclusion complex comprising fulvestrant and a cyclodextrin.
- The physiochemical properties of the inclusion complexes described herein (e.g., an inclusion complex comprising fulvestrant and a cyclodextrin) may allow the complexes to be taken orally or sublingually. In some embodiments, the inclusion complexes or formulations comprising the complexes are suitable for oral or sublingual administration.
- As described herein, the inclusion complexes may be administered with an additional therapeutic agent and/or an additional treatment modality. The dosing frequency of the inclusion complex and the additional pharmaceutical agent may be adjusted over the course of the treatment based on the judgment of the administering physician. When administered separately, the inclusion complex and the additional therapeutic agent can be administered at different dosing frequency or intervals. For example, the inclusion complex can be administered weekly, while the additional therapeutic agent can be administered more or less frequently. In some embodiments, sustained continuous release formulation of the inclusion complex and/or the additional therapeutic agent may be used. Various formulations and devices for achieving sustained release are known in the art. A combination of the administration configurations described herein can be used.
- In some embodiments, the inclusion complex (e.g., the inclusion complex comprising fulvestrant and a cyclodextrin) can be administered daily and the additional therapeutic agent (e.g., FASLODEX®) can be administered monthly. In some embodiments, the inclusion complex (e.g., the inclusion complex comprising fulvestrant and a cyclodextrin) can be administered weekly and the additional therapeutic agent (e.g., FASLODEX®) can be administered monthly.
- In some embodiments of any of the aspects of the inventions provided herein, the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD). In some embodiments, the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD), wherein HPBCD or MBCD is used in a formulation for intravascular administration. In some embodiments, the cyclodextrin is hydroxypropyl beta-cyclodextrin (HPBCD) or methyl beta-cyclodextrin (MBCD), wherein HPBCD or MBCD is used in a formulation for slow intravascular administration.
- The commercial product (e.g., FASLODEX®) is to be stored under refrigerated conditions (2-8° C.), whilst the inventor has found that excellent stability at room temperature may be attained by the inclusion complex of the present invention: an inclusion complex of the invention has been found to be stable at temperatures of over 25° C. and at 40° C. for over 24 months.
- The present invention will be understood more readily by reference to the following examples, which are provided by way of illustration and are not intended to be limiting of the present invention.
- It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application.
- The fulvestrant used in the Examples was obtained from Hangzhou Hysen Pharma Co., Ltd., Hangzhou, China.
- A comprehensive selection of pharmaceutically acceptable cyclodextrins was selected for the solubility enhancement evaluation with fulvestrant. The most relevant characteristics of these cyclodextrins are presented in Table 9.
-
TABLE 9 Characteristics summary of cyclodextrins used in fulvestrant aqueous solubility evaluation. Water Number of Solubility Glucopyranose Molecular (25° C.) Cyclodextrin Type Trade Name Units Abbreviation Weight (mg/mL) Alpha- cyclodextrin CAVAMAX ® 6 ACD 973 145 W6 Pharma Beta-cyclodextrin CAVAMAX ® 7 BCD 1135 18.5 W7 Pharma Methyl beta- CAVASOL ® 7 MBCD 1310 >750 cyclodextrin W7 M Pharma Hydroxypropyl KLEPTOSE ® 7 HPBCD 1100 >750 beta-cyclodextrin HPB Pharma Sulfobutylether 7 SBEBCD 2163 >500 beta-cyclodextrin Gamma- CAVAMAX ® 8 GCD 1297 232 cyclodextrin W8 Pharma Hydroxypropyl CAVASOL ® 8 HPGCD 1574 >750 gamma-cyclodextrin W8 HP Pharma - The HPLC system used for the chromatographic determination of fulvestrant consisted of a Waters 600E quaternary gradient pump, a Waters 717plus WISP autosampler and a Waters 2487 Dual A, Absorbance detector. Separation was performed using a Phenomenex Luna C18 column (250×4.6 mm; 5 urn) (Phenomenex, Torrance, Calif.) (supplied by Separations, South Africa) and a mobile phase consisting of 50% MeCN:22.5% ddH20:27.5% MeOH. The mobile phase was degassed and filtered prior to use. An injection volume of 50 uL was selected, together with a flow rate of 1.2 mL/min, which resulted in fulvestrant peak retention times of approximately 11.2 minutes. Sample run times were 15 minutes. The UV detector wavelength was set to 280 nm.
- The fulvestrant used for preparation of standard solutions, was of pharmaceutical grade. The acetonitrile used as mobile phase was of HPLC grade (Merck Chemicals, South Africa). Double distilled water (ddH20) was used at all times during the assay.
- Stock fulvestrant solution was prepared according to the following steps: 1) 10 mg of fulvestrant powder was accurately weighed into a 10 mL volumetric flask; 2) the fulvestrant powder was dissolved and made to volume in mobile phase; 3) this solution was then vortexed for at least 20 seconds to ensure complete dissolution of the analyte. A concentration range of 10-500 μg/mL fulvestrant was prepared in the mobile phase. Calibration data generated during the fulvestrant aqueous solubility study for one of the fulvestrant calibration plots is presented in Table 10, with the graphical presentation of the data presented in
FIG. 1 . The method, which produced a linear plot, is suitable for the evaluation of fulvestrant. -
TABLE 10 Fulvestrant HPLC calibration data. Fulvestrant Concentration (μg/mL) Peak Area 10 6017.79 20 11356.84 50 29814.88 100 57946.34 200 114870.10 300 173177.22 400 229736.60 500 287091.62 - a. Alpha-Cyclodextrin (ACD)
- The aqueous solubility of fulvestrant was evaluated in the presence of increasing concentrations of ACD and the absence thereof.
- 1 mL of each of the following aqueous solutions was prepared containing 0; 25; 50; 75 and 100 mg/mL ACD in ddHiO. Excess fulvestrant was added to each of these solutions and the samples were shaken for 24 hours on an orbital shaker at 200 rpm and at 22° C. room temperature. Excess fulvestrant was present in all samples at all times. After 24-hours, the samples were filtered through 0.45 μm syringe tip filters, diluted according to requirements and assayed by HPLC. The fulvestrant aqueous solubility results are presented in Table 11 and
FIG. 2 . -
TABLE 11 Fulvestrant aqueous solubility data in the presence and absence of various concentrations of ACD. Quantity of Quantity of ACD Fulvestrant Fulvestrant Average True Fulvestrant Sample Concentration Diluted (μg/mL) Diluted (μg/mL) Concentration Concentration No. (mg/mL) Run 1Run 2 (μg/mL) (mg/mL) 1 0 <10.000 <10.010 <10.00 <0.010 2 25 33.620 32.970 33.30 0.033 3 50 110.600 110.880 110.74 0.111 4 75 310.460 310.170 310.32 0.310 5 100 162.660 173.850 168.26 1.683
b. Beta-Cyclodextrin (BCD) - The aqueous solubility of fulvestrant was evaluated in the presence of increasing concentrations of BCD and the absence thereof.
- 1 mL of each of the following aqueous solutions was prepared containing 0; 5; 7.5; 10 and 15 mg/mL BCD in ddH2O. Excess fulvestrant was added to each of these solutions and the samples were shaken for 24 hours on an orbital shaker at 200 rpm and at 22° C. room temperature. Excess fulvestrant was present in all samples at all times. After 24-hours, the samples were filtered through 0.45 μm syringe tip filters, diluted according to requirements and assayed by HPLC. The fulvestrant aqeuous solubility results are presented in Table 12 and
FIG. 3 . -
TABLE 12 Fulvestrant aqueous solubility data in the presence and absence of various concentrations of BCD. Quantity of Quantity of BCD Fulvestrant Fulvestrant Average True Fulvestrant Sample Concentration Diluted (μg/mL) Diluted (μg/mL) Concentration Concentration No. (mg/mL) Run 1Run 2 (μg/ml) (mg/mL) 1 0 <10.000 <10.000 <10.00 <0.010 2 5 <10.000 <10.000 <10.00 <0.010 3 7.5 <10.000 <10.000 <10.00 <0.010 4 10 <10.000 <10.000 <10.00 <0.010 5 15 13.060 12.940 13.00 0.013
c. Methyl Beta-Cyclodextrin (MBCD) - The aqueous solubility of fulvestrant was evaluated in the presence of increasing concentrations of MBCD and the absence thereof.
- 1 mL of each of the following aqueous solutions was prepared containing 0; 50; 100; 150; 200; 250; 300; 350 and 400 mg/mL MBCD in
ddH 20. Excess fulvestrant was added to each of these solutions and the samples were shaken for 24 hours on an orbital shaker at 200 rpm and at 22° C. room temperature. Excess fulvestrant was present in all samples at all times. After 24-hours, the samples were filtered through 0.45 μm syringe tip filters, diluted according to requirements and assayed by HPLC. The fulvestrant aqueous solubility results are presented in Table 13 andFIG. 4 . -
TABLE 13 Fulvestrant aqueous solubility data in the presence and absence of various concentrations of MBCD. Quantity of Quantity of MBCD Fulvestrant Fulvestrant Average True Fulvestrant Sample Concentration Diluted (μg/mL) Diluted (μg/mL) Concentration Concentration No. (mg/mL) Runl Run 2 (μg/mL) (mg/mL) 1 0 <10.00 <10.00 <10.00 <0.010 2 50 74.61 75.37 74.99 0.750 3 100 302.12 301.99 302.06 3.021 4 150 67.40 67.47 67.44 6.744 5 200 106.87 107.01 106.94 10.694 6 250 174.30 174.28 174.29 17.429 7 300 226.52 226.94 226.73 22.673 8 350 293.21 292.29 292.75 29.275 9 400 359.13 358.71 358.92 35.892
d. Hydroxypropyl Beta-Cyclodextrin (HPBCD) - The aqueous solubility of fulvestrant was evaluated in the presence of increasing concentrations of HPBCD and the absence thereof.
- 1 mL of each of the following aqueous solutions was prepared containing 0; 50; 100; 150; 200; 250; 300; 350 and 400 mg/mL HPBCD in
ddH 20. Excess fulvestrant was added to each of these solutions and the samples were shaken for 24 hours on an orbital shaker at 200 rpm and at 22° C. room temperature. Excess fulvestrant was present in all samples at all times. After 24-hours, the samples were filtered through 0.45 μm syringe tip filters, diluted according to requirements and assayed by HPLC. The fulvestrant aqueous solubility results are presented in Table 14 andFIG. 5 . -
TABLE 14 Fulvestrant aqueous solubility data in the presence and absence of various concentrations of HPBCD. Quantity of Quantity of HPBCD Fulvestrant Fulvestrant Average True Fulvestrant Sample Concentration Diluted (μg/mL) Diluted (μg/mL) Concentration Concentration No. (mg/mL) Runl Run 2 (μg/mL) (mg/mL) 1 0 <10.00 <10.00 <10.00 <0.010 2 50 21.09 20.81 20.95 0.210 3 100 48.32 48.27 48.30 0.483 4 150 93.82 93.50 93.66 0.937 5 200 156.30 42.30 99.30 1.563 6 250 118.71 118.97 118.84 2.377 7 300 164.70 166.54 165.62 3.312 8 350 215.41 215.10 215.26 4.305 9 400 275.20 272.14 273.67 5.473
e. Sulfobutylether Beta-Cyclodextrin (SBEBCD) - The aqueous solubility of fulvestrant was evaluated in the presence of increasing concentrations of SBEBCD and the absence thereof.
- 1 mL of each of the following aqueous solutions was prepared containing 0; 50; 100; 150; 200; 250; 300; 350 and 400 mg/mL SBEBCD in
ddH 20. Excess fulvestrant was added to each of these solutions and the samples were shaken for 24 hours on an orbital shaker at 200 rpm and at 22° C. room temperature. Excess fulvestrant was present in all samples at all times. After 24-hours, the samples were filtered through 0.45 μm syringe tip filters, diluted according to requirements and assayed by HPLC. The fulvestrant aqueous solubility results are presented in Table 15 andFIG. 6 . -
TABLE 15 Fulvestrant aqueous solubility data in the presence and absence of various concentrations of SBEBCD. Quantity of Quantity of SBEBCD Fulvestrant Fulvestrant Average True Fulvestrant Sample Concentration Diluted (μg/mL) Diluted (μg/mL) Concentration Concentration No. (mg/mL) Runl Run 2 (μg/mL) (mg/mL) 1 0 <10.00 <10.00 <10.00 <0.010 2 50 76.98 77.61 77.30 0.077 3 100 167.7 166.49 167.10 0.167 4 150 273.01 272.83 272.92 0.273 5 200 398.52 399.09 398.81 0.399 6 250 304.32 305.15 304.74 0.609 7 300 425.82 425.96 425.89 0.852 8 350 382.24 377.67 379.96 1.140 9 400 503.13 501.21 502.17 1.507
f. Gamma-Cyclodextrin (GCD) - The aqueous solubility of fulvestrant was evaluated in the presence of increasing concentrations of GCD and the absence thereof.
- 1 mL of each of the following aqueous solutions was prepared containing 0; 50; 100; 150; and 200 mg/mL GCD in
ddH 20. Excess fulvestrant was added to each of these solutions and the samples were shaken for 24 hours on an orbital shaker at 200 rpm and at 22° C. room temperature. Excess fulvestrant was present in all samples at all times. After 24-hours, the samples were filtered through 0.45 μm syringe tip filters, diluted according to requirements and assayed by HPLC. The fulvestrant aqueous solubility results are presented in Table 16 andFIG. 7 . -
TABLE 16 Fulvestrant aqueous solubility data in the presence and absence of various concentrations of GCD. Quantity of Quantity of GCD Fulvestrant Fulvestrant Average True Fulvestrant Sample Concentration Diluted (μg/mL) Diluted (μg/mL) Concentration Concentration No. (mg/mL) Runl Run 2 (μg/mL) (mg/mL) 1 0 <10.000 <10.000 <10.00 <0.010 2 50 10.700 10.530 10.62 0.011 3 100 <10.000 <10.000 <10.00 <0.010 4 150 <10.000 <10.000 <10.00 <0.010 5 200 <10.000 <10.000 <10.00 <0.010
g. Hydroxypropyl Gamma-Cyclodextrin (HPGCD) - The aqueous solubility of fulvestrant was evaluated in the presence of increasing concentrations of HPGCD and the absence thereof.
- 1 mL of each of the following aqueous solutions was prepared containing 0; 50; 100; 150; 200; 250; 300; 350 and 400 mg/mL HPGCD in
ddH 20. Excess fulvestrant was added to each of these solutions and the samples were shaken for 24 hours on an orbital shaker at 200 rpm and at 22° C. room temperature. Excess fulvestrant was present in all samples at all times. After 24-hours, the samples were filtered through 0.45 μm syringe tip filters, diluted according to requirements and assayed by HPLC. The fulvestrant aqueous solubility results are presented in Table 17 andFIG. 8 . -
TABLE 17 Fulvestrant aqueous solubility data in the presence and absence of various concentrations of HPGCD. Quantity of Quantity of IIPGCD Fulvestrant Fulvestrant Average True Fulvestrant Sample Concentration Diluted (μg/mL) Diluted (μg/mL) Concentration Concentration No. (mg/mL) Runl Run 2 (μg/mL) (mg/mL) 1 0 <10.00 <10.00 <10.00 <0.010 2 50 38.66 37.97 38.32 0.037 3 100 116.80 115.74 116.27 0.107 4 150 220.67 220.94 220.81 0.203 5 200 334.75 334.66 334.71 0.300 6 250 474.68 472.99 473.84 0.215 7 300 400.24 384.76 392.50 0.603 8 350 500.71 505.22 502.97 0.802 9 400 486.39 450.47 468.43 1.061 - From the results presented in Tables 11 to 17 and
FIGS. 2 to 8 , it is clear that fulvestrant forms inclusion complexes with cyclodextrins to greater and lesser extents, depending on the specific cyclodextrin. Fulvestrant aqueous solubility enhancements with ACD; SBEBCD and HPGCD yielded fulvestrant aqueous solubilities of between 1 to 2 mg/mL, which was a significant enhancement over the aqueous solubility of fulvestrant in the absence of these cyclodextrins. The aqueous solubility enhancements of fulvestrant with BCD and GCD were lower. The aqueous solubility of fulvestrant in the presence of HPBCD was enhanced from below 0.010 mg/mL to 5.5 mg/mL in 400 mg/mL HPBCD. The greatest aqueous solubility enhancement of fulvestrant was, however, achieved with MBCD, whereby the fulvestrant aqueous solubility was significantly enhanced from below 0.010 mg/mL to 35.9 mg/mL in 400 mg/mL MBCD. - The comparative oral absorption of two novel aqueous cyclodextrin based formulations of fulvestrant versus an uncomplexed fulvestrant aqueous suspension (without any cyclodextrins) following oral administrations of 10 mg/kg by gavage to adult male Whistar rats was assessed.
- The study was conducted using eighteen male adult Whistar rats. Each rat partook in a single experiment. Fulvestrant was administered at a dose of 10 mg/kg by oral gavage to each animal, with blood concentrations measured hourly over a 3-hour period.
- The test articles were considered to be >99% pure and contained 5 mg/mL of fulvestrant. The vehicles used to prepare the two novel batches comprised 400 mg/mL hydroxypropyl beta-cyclodextrin (HPBCD) (Batch 1) and 400 mg/mL methyl beta-cyclodextrin (MBCD) (Batch 2). The control fulvestrant formulation comprised of a 5 mg/mL fulvestrant suspension in ddH20 (Batch 3). All animals were fasted for approximately 24 hours prior to dose administration. Water was available ad libitum. Pre-dose, and 1 h and 2 h post dose blood sampling was conducted by means of the tail snip procedure, whereby 0.5 mL was collected at each sampling point. Five minutes prior to the final (3 h) blood sampling point, rats were anaesthetised with 0.5
ml 6% sodium pentobarbitone and 5 mL blood was collected. Prior to drug administration by means of gavage, each of the rats was anaesthetized with halothane gas, following which a gavage tube was inserted through the mouth and through which the various solutions were administered. 0.5 mL saline was administered through the gavage tubes immediately following drug administration. - The information for Experiments I to III are summarized in Tables 18 to 20 respectively.
-
TABLE 18 Experiment I Information. Formulation Rat No. Dose Dose volume Rat Mass Fulvestrant Batch 1 1 10 mg/kg 0.58 mL 0.290 kg Fulvestrant Batch 1 2 10 mg/kg 0.54 mL 0.270 kg Fulvestrant Batch 1 3 10 mg/kg 0.51 mL 0.254 kg Fulvestrant Batch 1 4 10 mg/kg 0.62 mL 0.309 kg Fulvestrant Batch 1 5 10 mg/kg 0.53 mL 0.264 kg Fulvestrant Batch 1 6 10 mg/kg 0.54 mL 0.270 kg -
TABLE 19 Experiment II Information Formulation Rat No. Dose Dose volume Rat Mass Fulvestrant Batch 2 1 10 mg/kg 0.52 mL 0.261 kg Fulvestrant Batch 2 2 10 mg/kg 0.54 mL 0.271 kg Fulvestrant Batch 2 3 10 mg/kg 0.61 mL 0.304 kg Fulvestrant Batch 2 4 10 mg/kg 0.57 mL 0.287 kg Fulvestrant Batch 2 5 10 mg/kg 0.60 mL 0.300 kg Fulvestrant Batch 2 6 10 mg/kg 0.57 mL 0.284 kg -
TABLE 20 Experiment III Information. Formulation Rat No. Dose Dose volume Rat Mass Fulvestrant Batch 3 1 10 mg/kg 0.56 mL 0.278 kg Fulvestrant Batch 3 2 10 mg/kg 0.51 mL 0.253 kg Fulvestrant Batch 3 3 10 mg/kg 0.54 mL 0.271 kg Fulvestrant Batch 3 4 10 mg/kg 0.53 mL 0.267 kg Fulvestrant Batch 3 5 10 mg/kg 0.53 mL 0.265 kg Fulvestrant Batch 3 6 10 mg/kg 0.57 mL 0.284 kg - All of the animals that were dosed by means of oral gavage were bled pre-dose, and at 1 hour (h) and 2 h post dose, with blood sampling having been conducted by means of the tail snip procedure, whereby 0.5 mL was collected at each sampling point. Five minutes prior to the terminal blood sampling point (3 h), rats were anaesthetised with 0.5
ml 6% sodium pentobarbitone and 5 mL blood was collected from each, after which the rats were sacrificed. - The tail snip blood was collected in 1 mL K3E (K3EDTA) MINICOLLECT® (Greiner Bio-one; Lot 090319; Exp. 2010-08) blood collection tubes, with the terminal samples having been collected in 9 mL K3E (K3EDTA) VACUETTE® (Greiner Bio-one; Lot A090602D; Exp. 2010-12) blood collection tubes. Following collection, the samples were placed on ice and then centrifuged at 4° C. for 15 minutes. 0.2 mL and 2 mL plasma aliquots were obtained from the tail snip and terminal sampling points respectively. These samples were frozen (−60° C. to −80° C.) prior to being shipped on dry ice to a facility for analysis of fulvestrant concentrations.
- The test article, fulvestrant, was measured in adult Whistar rat plasma via a liquid chromatography-mass spectroscopy (LC-MS) method, as described below.
- A sensitive and selective LC-MS/MS method was developed and used to determine fulvestrant in rat plasma. Prior to assay, rat plasma samples were thawed at room temperature, briefly vortexed, after which 100 uL plasma was pipetted into 1.5 ml Eppendorf® Safe-Lock® microcentrifuge tubes. Samples were then precipitated with methanol (200 uL) containing the internal standard, doxepin (245 ng/mL). These samples were vortexed for 30 seconds and centrifuged for 5 minutes at 15 000 rpm. The supernatant (200 uL) was transferred to 96 well plates and 5 uL was injected onto the HPLC column. Calibration standards were prepared in rat plasma (anticoagulant lithium heparinate), whereby a stock solutions of fulvestrant in methanol was used to spike a pool of blank rat plasma which was serially diluted with blank rat plasma to attain the desired concentrations, spanning a range of 4.5 ng/mL to 1149 ng/mL (STD 1-STD 9).
- Chromatography was performed on a Phenomenex, Luna Phenyl Hexyl, (150×2.1 mm, 5 um) analytical column. The mobile phase consisted of methanol and 5 mM ammonium formate (80:20 v/v) and was delivered at a constant flow rate of 0.3 mL/min for 7.5 minutes. An Agilent 1100 series autosampler injected 5 uL onto the HPLC column. The injection needle was rinsed with water:methanol (50:50) for 10 seconds using the flush port wash station. Samples were cooled to ˜5° C. while awaiting injection. Detection was performed on an API 4000 mass spectrometer (ESI in the positive ion mode, MRM) and the settings on the apparatus are summarized in tables below.
-
TABLE 21A ESI settings Curtain gas 30 Collision gas 7 Ionspray voltage (V) 5500 Source temperature (° C.) 450 Gas 1 (psi) 30 Gas 2 (psi) 40 -
TABLE 21B MS/MS settings Fulvestrant Internal standard Q1 mass [M + II]+ 607.3 279.9 Q3 mass 589.2 107.2 Dwell time (ms) 150 150 Declustering potential (V) 76 61 Entrance potential (V) 10 10 Collision energy (V) 23 31 Collision cell exit potential (V) 22 8 Scan type MRM MRM Polarity positive positive Pause time (ms) 5 5 - a. Plasma Concentration-Time Profiles for Orally Administered Fulvestrant
- Individual fulvestrant plasma concentrations for Experiments I, II, and III are presented in Tables 22 to 24. Individual and mean plasma fulvestrant concentration-time profiles following oral administration by gavage for Experiments I, II, and III are presented in
FIGS. 9 to 12 . -
TABLE 22 Fulvestrant plasma concentration data generated for Experiment I (HPBCD). Plasma concentration (ng/mL) 0 h 1 h 2 h 3 h Rat 1 0.00 30.90 20.10 11.20 Rat 20.00 23.80 11.60 9.63 Rat 3*0.00 608.00 239.00 45.70 Rat 40.00 76.70 30.30 21.80 Rat 50.00 237.00 103.00 26.40 Rat 60.00 62.00 135.00 20.50 *The data from rat 3 in Experiment I was regarded as being an outlier and as such, it was not included in the average data calculation. -
TABLE 23 Fulvestrant plasma concentration data generated for Experiment II (MBCD). Plasma concentration (ng/mL) 0 h 1 h 2 h 3 h Rat 1 0.00 45.40 58.20 15.50 Rat 20.00 72.10 98.90 21.30 Rat 30.00 121.00 71.60 14.00 Rat 40.00 177.00 102.00 10.60 Rat 50.00 191.00 83.00 36.40 Rat 60.00 68.90 61.60 18.80 Average 0.00 96.63 68.19 17.09 -
TABLE 24 Fulvestrant plasma concentration data generated for Experiment III (No CD). Plasma concentration (ng/ml) 0 h L h 2 h 3 h Rat 1 0.00 0.00 0.00 0.00 Rat 20.00 0.00 0.00 0.00 Rat 30.00 0.00 0.00 0.00 Rat 40.00 32.40 4.75 0.00 Rat 50.00 0.00 0.00 0.00 Rat 60.00 0.00 0.00 0.00 Average 0.00 5.40 0.79 0.00 - From the data generated during this study, it is clear that very little to no oral absorption was observed for the
control 5 mg/mL fulvestrant inddH 20 suspension, which is in agreement with published literature, indicating that oral administration of fulvestrant presents with very poor bioavailability, thus rendering the compound unsuitable for oral formulation. In contrast to the control fulvestrant suspension formulation, both of the cyclodextrin based fulvestrant formulations (HPBCD and MBCD) presented with oral absorption. The HPBCD and vMBCD based formulations presented with similar absorption plots, as can be seen inFIG. 12 , whereby the mean Cmax values for the HPBCD and MBCD were measured at 86.1 ng/mL and 96.6 ng/mL respectively and Tmax occurring for both formulations at the 1 hour sampling point. The data fromrat 3 in the HPBCD group was not included in the pooled data, as its Cmax of 608.0 ng/mL is regarded as being an outlier - Comparison of the data generated following the administration by oral gavage for the two novel cyclodextrin based fulvestrant formulations and the reference fulvestrant suspension formulation, revealed that very limited to no oral absorption was observed for the
control 5 mg/mL fulvestrant in WFI suspension, whereby low fulvestrant concentrations were observed in two samples ofrat 4 only. This observation is in agreement with published literature, indicating that oral administration of fulvestrant presents with very poor bioavailability, thus rendering the compound unsuitable for oral formulation. In contrast to the control fulvestrant suspension formulation, both of the cyclodextrin based fulvestrant formulations (HPBCD and MBCD) presented with fulvestrant being recovered from all post-dose samples collected from these two groups of animals, thus indicating that the two cyclodextrin based formulations do enhance oral bioavailability of fulvestrant significantly. - The HPBCD and MBCD based formulations presented with similar fulvestrant plasma concentrations over time, as may be evidenced by the data presented in
FIG. 12 , whereby the mean Cmax values for the HPBCD and MBCD formulations were measured at 86.1 ng/mL and 96.6 ng/mL respectively and Tmax occurring for both formulations at the 1 hour sampling point. - The data generated during the present study indicates that aqueous formulations of fulvestrant complexed with HPBCD or MBCD offer viable opportunities as oral formulations. Oral formulations present with distinct advantages over the currently marketed long acting IM fulvestrant formulations, which present with pain upon injection, owing to the 5 mL injection volume. In addition to the formulation related side effects, long acting IM fulvestrant (250 mg/5 mL), takes 3-6 months to achieve steady state. A viable oral formulation can achieve the desired plasma levels immediately, thus replacing the need for an IM formulation, or can be used together with the IM formulation as part of a loading-dose regimen.
- Fulvestrant was administered at a dose of 5 mg/kg by oral gavage to each animal, with blood concentrations measured hourly over a 4-hour period. The vehicle used to prepare the novel batch comprised 450 mg/mL hydroxypropyl beta-cyclodextrin (HPBCD) (Batch 7_4). All animals were fasted for approximately 24 hours prior to dose administration. Water was available ad libitum. Pre-dose, and 1, 2 and 3 hour post dose blood sampling for the oral gavage group was conducted by means of the tail snip procedure, whereby 0.5 mL was collected at each sampling point. Five minutes prior to the final (4-hour) blood sampling point, rats were anaesthetised with 0.5
ml 6% sodium pentobarbitone and 5 mL blood was collected. Prior to drug administration by means of gavage, each of the rats were anaesthetized with halothane gas, following which a gavage tube was inserted through the mouth and through which the various solutions were administered. 0.5 mL saline was administered through the gavage tubes immediately following drug administration. The information for this example is summarized in Table 25. -
TABLE 25 Experiment information (HPBCD Oral) Rat Formulation No. Sex Dose Dose volume Rat Mass Fulvestrant Batch7_4 1 Male 5 mg/kg 0.305 mL 0.305 kg Fulvestrant Batch7_4 2 Male 5 mg/kg 0.325 mL 0.325 kg Fulvestrant Batch7_4 3 Male 5 mg/kg 0.350 mL 0.350 kg Fulvestrant Batch7_4 4 Male 5 mg/kg 0.335 mL 0.335 kg Fulvestrant Batch7_4 5 Male 5 mg/kg 0.310 mL 0.310 kg Fulvestrant Batch7_4 6 Male 5 mg/kg 0.274 mL 0.274 kg - The tail snip blood was collected in 1 mL K3E (K3EDTA) MINICOLLECT® (Greiner Bio-one; Lot 090319; Exp. 2010-08) blood collection tubes, with the terminal samples having been collected in 4 mL K3E (K3EDTA) VACUETTE® (Greiner Bio-one; Lot L020902; Exp. 2010-08) blood collection tubes. Following collection, these samples were placed on ice and then centrifuged at 4° C. for 15 minutes. 0.2 mL and 2 mL plasma aliquots were obtained from the tail-snip and terminal sampling points respectively. These samples were frozen (−60° C. to −80° C.) prior to being shipped on dry ice to a facility for analysis of fulvestrant concentrations. The test article, fulvestrant, was measured in adult Whistar rat plasma by via an LC-MS method. Individual and mean plasma fulvestrant concentration-time profiles following oral administration by gavage in this example are presented in
FIG. 13 and Table 26. -
TABLE 26 Fulvestrant plasma concentration (ng/mL) data generated for oral fulvestrant-HPBCD (5 mg/kg) Time (h) 0 1 2 3 4 Rat 10.0 33.6 24.3 25.6 15.4 Rat 20.0 87.5 65.0 37.0 9.2 Rat 30.0 22.1 14.3 22.0 16.1 Rat 40.0 10.9 9.4 11.1 15.7 Rat 50.0 62.4 36.7 19.7 5.6 Rat 60.0 31.3 28.2 22.9 12.2 Average 0.0 41.3 29.7 23.1 12.4 - The purpose of the study was to investigate the pharmacokinetics of a novel fulvestrant-hydroxypropyl-beta-cyclodextrin (fulvestrant-HPBCD) solution following oral administration at various dose levels, to that of a short acting (SA) fulvestrant intramuscular formulation in fasted male and female beagle dogs (n=6).
- The study was conducted using three male and three female adult beagle dogs for a total sample size of n=6. Each dog participated in each of the five experiments. Experiments began with the lowest oral dose and progressed to the highest oral dose, with the study concluding with the Short Acting (SA) IM formulation. Animals were fasted for 12 hours prior to each study with access to ad libitum water. A minimum washout-period of 48-hours was allowed between experiments. Oral drug administration comprised the use of oro-gastric tubes for the administration of the fulvestrant-HPBCD solution (5 mg/mL fulvestrant), with the IM administration into the buttock. The following dosages of fulvestrant were administered for the various experiments:
-
- 1. Experiment 1: 2.5 mg/kg fulvestrant (5 mg/mL fulvestrant; 450 mg/mL HPBCD)
- 2. Experiment 2: 5 mg/kg fulvestrant (5 mg/mL fulvestrant; 450 mg/mL HPBCD)
- 3. Experiment 3: 10 mg/kg fulvestrant (5 mg/mL fulvestrant; 450 mg/mL HPBCD)
- 4. Experiment 4: 15 mg/kg fulvestrant (5 mg/mL fulvestrant; 450 mg/mL HPBCD)
- 5. Experiment 5: 2.5 mg/kg fulvestrant (Short Acting (SA) IM fulvestrant injection)
- The oral fulvestrant solutions contained 5 mg/mL of fulvestrant in 450 mg/mL HPBCD. The fulvestrant SA IM control fulvestrant formulation was a short acting formulation, developed, described and used by AstraZeneca (20 mg/mL fulvestrant).
- Venous blood samples (1 ml) were obtained from each animal at pr-dose and the following times post-dose (in minutes): 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 210, 240, 300, 360, 480, 720, 1080 and 1440. Samples were collected via implanted vascular ports in the jugular veins of the dogs and into tubes containing K2EDTA anticoagulant. Following collection, the blood samples were placed on ice and then centrifuged for 15 minutes. The plasma was harvested and approximately 0.5 mL aliquots were stored frozen (−18° C.) prior to being shipped on dry ice to a contract laboratory for the determination of fulvestrant in the plasma samples. The same liquid chromatography-mass spectroscopy (LC-MS) analytical method was employed as that described in Example 3.
- Results generated during this study demonstrated that absorption, following oral ingestion, was rapid and followed a first order process, with fulvestrant present in all of the first post-dose blood samples (T=15 min). A plot of the mean fulvestrant plasma concentrations over time is presented in
FIG. 14 (Exp 1=2.5 mg/kg oral; Exp 2-5 mg/kg oral;Exp 3=10 mg/kg oral;Exp 4=15 mg/kg oral andExp 5=2.5 mg/kg IM). - The consistency of the pharmacokinetic parameters, following oral administration, over a six-fold dose range, suggests that the pharmacokinetics of fulvestrant-HPBCD is linear. These parameters include Tmax; absorption and elimination halftimes; clearance and mean residence times. As the pharmacokinetics derived from oral administration did not differ statistically between the various doses, a more accurate estimation of the pharmacokinetics of the new fulvestrant formulation administered orally to dogs can be obtained by averaging and comparing the pharmacokinetic parameters of each individual subject. Mean values for these parameters are: Absorption halftime—19 min; Estimated bioavailability—6.5% (relative to and assuming 100% bioavailability for the LA IM fulvestrant formulation); Tmax≦74 min; MRT—258 min; elimination halftime—55 min.
- Absorption from the gastro-intestinal tract occurs more rapidly than from the site of IM injection, as evidenced by the prolonged mean absorption halftime of the latter (77 min) and longer Tmax (223 min). Mean elimination halftimes calculated from IM dosing were considerably longer (467 min), as was the mean MRT (801 min), than those obtained following oral administration. Bioavailability for the IM administration was assumed to be complete. The Cmax attained following the IM administration at a dose of 2.5 mg/kg, was as great as those values that were achieved by the 10 mg/kg and 15 mg/kg oral doses. IM administration resulted in a mean AUC0-t that was significantly greater those values that resulted from all oral doses.
- Whilst the oral administration of fulvestrant-HPBCD presented with low oral bioavailability (approximately 6.5%), clinically effective concentrations of fulvestrant are systemically absorbed, due to the absorption halftime (20 min) being significantly shorter than the elimination halftime (55 minutes). During the study, systemic fulvestrant concentrations in excess of purported therapeutic levels (approximately 23 ng/mL) were achieved using the lowest administered oral dose of 2.5 mg/kg. Simulations suggest that eight-hour dosing to dogs (5 mg/kg) would achieve average concentrations (26 ng/mL) that are in excess of the proposed therapeutic levels.
FIG. 15 illustrates a simulation of oral dosing to an “average” beagle dog, employing a regimen of 5 mg/kg every eight hours for 24 hours. It is postulated that similar rapid absorption may be achieved in humans. - In total, six stability batches of fulvestrant in the presence of cyclodextrins were produced to evaluate different fulvestrant concentrations with different cyclodextrins exposed to 2° C.; 25° C.; 40° C. over 24-months.
- The batch details are summarized in Table 27 below:
-
TABLE 27 Fulvestrant-HPBCD stability study batch summaries. Fulvestrant Batch Complexation Storage Vials per Batch Conc. CD size Complexation temperature volume storage Storage No. (mg/mL) CD Type Conc. (mL) Time (h) (° C.) (mL) condition Temperatures 1_1 5.0 HPBCD 400 40 24 RT 0.8 25 25° C.; 40° C. 1_2 2.5 HPBCD 350 40 24 RT 0.8 25 25° C.; 40° C. 1_3 5.0 HPBCD 400 60 24 RT 1.0 30 2° C. 1_4 2.5 HPBCD 350 60 24 RT 1.0 30 2° C. 2_1 10 RAMEB 350 70 1.5 60° C. 1.0 23 2° C.; 25° C.; 40° C. 2_2 25 RAMEB 350 70 1.5 60° C. 1.0 23 2° C.; 25° C.; 40° C. RT = Room temperature ~25° C. - Each of the batches were produced, whereby the pre-weighed cyclodextrin quantity was dissolved in ˜80% final volume double distilled water at ambient temperature (˜25° C.). Pre-weighed fulvestrant API was then added to the cyclodextrin solution with vigorous stirring. The stirring was conducted for 24-hours for batches 1_1; 1_2; 13 and 1_4 under ambient conditions. Complexation was optimize for batches 2_1 and 2_2, whereby complexation duration was reduced to 1.5 hours with heating to 60° C. Following complexation, all batches were made to volume with double distilled water and filtered through 0.45 μm syringe filters, prior to being filled into storage vials. Samples were assayed via HPLC for fulvestrant content following manufacture and at each evaluation point (3; 6; 9; 12; 18 and 24-months post manufacture). The HPLC method used was also specific to the detection of the presence of the principle fulvestrant degradation product, fulvestrant sulphone. The HPLC method employed is the same as that described in Example 1. At each sampling point, three vials were selected for fulvestrant quantification; evaluation for the presence of fulvestrant sulphone and pH determination.
- Summary plots for the average recoveries of the various batches and storage conditions are presented in
FIGS. 16-21 . - HPLC analysis of all stability samples of all batches indicated that all evaluated samples are stable, with none falling outside the 90-110% fulvestrant recovery range during the 18-24-month evaluation period at 2° C.; 25° C. and 40° C. There was no visible precipitation present, nor any increase in the presence of the principle fulvestrant degradation product, fulvestrant sulphone.
- The disclosures of all publications, patents, patent applications and other references referred to herein are hereby incorporated herein by reference in their entireties.
Claims (18)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/615,295 US10758547B2 (en) | 2010-09-16 | 2017-06-06 | Fulvestrant compositions and method of use |
US16/932,382 US11452729B2 (en) | 2010-09-16 | 2020-07-17 | Fulvestrant compositions and method of use |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38366010P | 2010-09-16 | 2010-09-16 | |
PCT/IB2011/054058 WO2012035516A1 (en) | 2010-09-16 | 2011-09-16 | Fulvestrant compositions and methods of use |
US201313823078A | 2013-06-07 | 2013-06-07 | |
US15/615,295 US10758547B2 (en) | 2010-09-16 | 2017-06-06 | Fulvestrant compositions and method of use |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2011/054058 Division WO2012035516A1 (en) | 2010-09-16 | 2011-09-16 | Fulvestrant compositions and methods of use |
US13/823,078 Division US9724355B2 (en) | 2010-09-16 | 2011-09-16 | Fulvestrant compositions and methods of use |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/932,382 Continuation US11452729B2 (en) | 2010-09-16 | 2020-07-17 | Fulvestrant compositions and method of use |
Publications (3)
Publication Number | Publication Date |
---|---|
US20170266203A1 US20170266203A1 (en) | 2017-09-21 |
US20180071309A9 true US20180071309A9 (en) | 2018-03-15 |
US10758547B2 US10758547B2 (en) | 2020-09-01 |
Family
ID=45831075
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/823,078 Active 2032-06-17 US9724355B2 (en) | 2010-09-16 | 2011-09-16 | Fulvestrant compositions and methods of use |
US15/615,295 Active 2032-10-20 US10758547B2 (en) | 2010-09-16 | 2017-06-06 | Fulvestrant compositions and method of use |
US16/932,382 Active 2031-12-09 US11452729B2 (en) | 2010-09-16 | 2020-07-17 | Fulvestrant compositions and method of use |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/823,078 Active 2032-06-17 US9724355B2 (en) | 2010-09-16 | 2011-09-16 | Fulvestrant compositions and methods of use |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/932,382 Active 2031-12-09 US11452729B2 (en) | 2010-09-16 | 2020-07-17 | Fulvestrant compositions and method of use |
Country Status (15)
Country | Link |
---|---|
US (3) | US9724355B2 (en) |
EP (1) | EP2616078B1 (en) |
JP (1) | JP2013537219A (en) |
CN (1) | CN103221052A (en) |
AU (1) | AU2011303475B2 (en) |
BR (1) | BR112013006331B1 (en) |
CA (1) | CA2811258C (en) |
CL (1) | CL2013000718A1 (en) |
EA (1) | EA201300341A1 (en) |
ES (1) | ES2784497T3 (en) |
IL (1) | IL225227B (en) |
NZ (1) | NZ609420A (en) |
PT (1) | PT2616078T (en) |
SG (1) | SG188990A1 (en) |
WO (1) | WO2012035516A1 (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9950850B2 (en) * | 2011-02-14 | 2018-04-24 | Juliet Agatha Boghossian | Therapeutic rinse |
WO2015033302A2 (en) * | 2013-09-06 | 2015-03-12 | Salah Uddin Ahmed | Fulvestrant compositions |
HUP1300646A2 (en) | 2013-11-12 | 2015-05-28 | Druggability Technologies Ip Holdco Jersey Ltd | Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
WO2015179239A1 (en) * | 2014-05-17 | 2015-11-26 | University Of Rochester | Compositions and methods to inhibit estrogen receptor beta for the treatment of renal cell carcinoma |
US9421793B2 (en) * | 2014-06-26 | 2016-08-23 | Cellresin Technologies, Llc | Electrostatic printing of cyclodextrin compositions |
JP2017523231A (en) * | 2014-08-15 | 2017-08-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Afatinib drug kit for cancer treatment |
CN106146599A (en) * | 2015-04-07 | 2016-11-23 | 江苏希迪制药有限公司 | A kind of recovery is because of the method for sulfoxide configuration ratio underproof fulvestrant or derivatives thereof |
CN105412005A (en) * | 2015-12-04 | 2016-03-23 | 昆明积大制药股份有限公司 | Reduced glutathione injection and preparation method thereof |
US11590077B2 (en) | 2016-05-06 | 2023-02-28 | Eagle Pharmaceuticals, Inc. | Fulvestrant formulations and methods of their use |
CA3022834A1 (en) * | 2016-05-06 | 2017-11-09 | Eagle Pharmaceuticals, Inc. | Fulvestrant formulations and methods of their use |
IT201600075246A1 (en) * | 2016-07-19 | 2018-01-19 | Jointherapeutics S R L | Compositions comprising a polysaccharide matrix for the controlled release of active principles. |
EP3706719A1 (en) * | 2017-11-08 | 2020-09-16 | Eagle Pharmaceuticals, Inc. | Fulvestrant formulations and methods of their use |
WO2019113361A1 (en) * | 2017-12-07 | 2019-06-13 | Nevakar Inc. | Concentrated fulvestrant compositions |
IT201800004082A1 (en) * | 2018-03-29 | 2019-09-29 | Berlin Chemie Ag | ANTI-CANCER PHARMACEUTICAL COMPOSITIONS FOR COMBINED THERAPY |
CN111035613A (en) * | 2018-10-12 | 2020-04-21 | 江苏恒瑞医药股份有限公司 | Injectable pharmaceutical composition containing fulvestrant and preparation method thereof |
CN113260353A (en) * | 2019-12-11 | 2021-08-13 | 上海博志研新药物技术有限公司 | Fulvestrant pharmaceutical composition, preparation method and application thereof |
CN114099518A (en) * | 2020-05-25 | 2022-03-01 | 江苏先声药业有限公司 | Oral fulvestrant pharmaceutical composition and preparation method thereof |
WO2022155507A1 (en) * | 2021-01-15 | 2022-07-21 | Jubilant Pharma Holdings Inc. | Transmucosal dosage forms of brexanolone |
HUP2100456A1 (en) * | 2021-12-28 | 2023-08-28 | Semmelweis Egyetem | Eye drop formulation |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4383992A (en) * | 1982-02-08 | 1983-05-17 | Lipari John M | Water-soluble steroid compounds |
US4596795A (en) * | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
GB9126209D0 (en) | 1991-12-10 | 1992-02-12 | Orion Yhtymae Oy | Drug formulations for parenteral use |
DE4426709A1 (en) * | 1994-07-20 | 1996-01-25 | Schering Ag | Solid dosage forms containing steroidal sex hormones |
US6632447B1 (en) | 1998-05-07 | 2003-10-14 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
US6413533B1 (en) | 1998-05-07 | 2002-07-02 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
WO2002020020A1 (en) * | 2000-09-08 | 2002-03-14 | Pharmacia Italia S.P.A. | Exemestane as chemopreventing agent |
WO2004035089A1 (en) | 2002-10-09 | 2004-04-29 | Kyowa Hakko Kogyo Co., Ltd. | Remedy for hormone-dependent cancer |
ATE342722T1 (en) | 2003-05-07 | 2006-11-15 | Osteologix As | TREATMENT OF CARTILAGE/BONE DISEASES WITH WATER SOLUBLE STRONTIUM SALTS |
WO2005123130A2 (en) | 2004-06-17 | 2005-12-29 | Osteologix A/S | Improved treatments of rheumatic and arthritic diseases comprising combinations of a 5-lipoxygenase inhibitor |
ATE482966T1 (en) * | 2004-07-27 | 2010-10-15 | Sicor Inc | METHOD FOR PRODUCING 7-ALPHA-ALKYLATED 19-NORSTEROIDS |
US20060270641A1 (en) | 2005-05-31 | 2006-11-30 | Steiner Mitchell S | Method for chemoprevention of prostate cancer |
US20070044662A1 (en) | 2005-08-25 | 2007-03-01 | The University Of Chicago | Method for fabricating dense thin film cermet hydrogen separation membrane |
TW200804408A (en) * | 2005-10-05 | 2008-01-16 | Sicor Inc | Separation of fulvestrant isomers |
ES2718912T3 (en) * | 2007-10-16 | 2019-07-05 | Repros Therapeutics Inc | Trans-clomiphene for the treatment of diabetes in hypogonadal men |
-
2011
- 2011-09-16 NZ NZ609420A patent/NZ609420A/en unknown
- 2011-09-16 JP JP2013528818A patent/JP2013537219A/en not_active Withdrawn
- 2011-09-16 CN CN201180051993XA patent/CN103221052A/en active Pending
- 2011-09-16 ES ES11824680T patent/ES2784497T3/en active Active
- 2011-09-16 PT PT118246800T patent/PT2616078T/en unknown
- 2011-09-16 AU AU2011303475A patent/AU2011303475B2/en active Active
- 2011-09-16 US US13/823,078 patent/US9724355B2/en active Active
- 2011-09-16 BR BR112013006331-9A patent/BR112013006331B1/en active IP Right Grant
- 2011-09-16 EP EP11824680.0A patent/EP2616078B1/en active Active
- 2011-09-16 CA CA2811258A patent/CA2811258C/en active Active
- 2011-09-16 EA EA201300341A patent/EA201300341A1/en unknown
- 2011-09-16 SG SG2013018684A patent/SG188990A1/en unknown
- 2011-09-16 WO PCT/IB2011/054058 patent/WO2012035516A1/en active Application Filing
-
2013
- 2013-03-14 IL IL225227A patent/IL225227B/en active IP Right Grant
- 2013-03-15 CL CL2013000718A patent/CL2013000718A1/en unknown
-
2017
- 2017-06-06 US US15/615,295 patent/US10758547B2/en active Active
-
2020
- 2020-07-17 US US16/932,382 patent/US11452729B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
PT2616078T (en) | 2020-03-31 |
US20130274236A1 (en) | 2013-10-17 |
US20200345751A1 (en) | 2020-11-05 |
SG188990A1 (en) | 2013-05-31 |
NZ609420A (en) | 2015-06-26 |
IL225227B (en) | 2019-01-31 |
US9724355B2 (en) | 2017-08-08 |
US11452729B2 (en) | 2022-09-27 |
JP2013537219A (en) | 2013-09-30 |
EP2616078A1 (en) | 2013-07-24 |
IL225227A0 (en) | 2013-06-27 |
ES2784497T3 (en) | 2020-09-28 |
EP2616078A4 (en) | 2016-05-18 |
EP2616078B1 (en) | 2019-12-25 |
BR112013006331B1 (en) | 2021-09-21 |
AU2011303475B2 (en) | 2016-07-14 |
US20170266203A1 (en) | 2017-09-21 |
CN103221052A (en) | 2013-07-24 |
CL2013000718A1 (en) | 2013-08-30 |
US10758547B2 (en) | 2020-09-01 |
AU2011303475A1 (en) | 2013-05-02 |
CA2811258A1 (en) | 2012-03-22 |
EA201300341A1 (en) | 2013-09-30 |
CA2811258C (en) | 2019-10-15 |
US20210315905A9 (en) | 2021-10-14 |
WO2012035516A1 (en) | 2012-03-22 |
BR112013006331A2 (en) | 2017-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11452729B2 (en) | Fulvestrant compositions and method of use | |
US10639305B2 (en) | Liquid preparation comprising pimobendan | |
US11572334B2 (en) | Methods for making and using endoxifen | |
US20210046071A1 (en) | Tetracyclic compounds and their salts, compositions, and methods for their use | |
US20220395498A1 (en) | Targeted therapeutics | |
US20100184722A1 (en) | Inclusion complexes of alpha-cyclodextrin and sildenafil salt | |
AU2018404329B2 (en) | Antitumor agent for biliary tract cancer and method for treating biliary tract cancer | |
WO2017107894A1 (en) | Drug inclusion compound, preparation thereof, and preparation method therefor | |
WO2017107895A1 (en) | Oral preparation and preparation method therefor | |
JP2010502691A (en) | Aqueous preparation containing antitumor agent | |
CN118215503A (en) | Conjugate pharmaceutical formulation, process for its preparation and use | |
JPH10265495A (en) | Fluoroprogesterone derivative clathrate compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SHIMODA BIOTECH (PTY) LTD, SOUTH AFRICA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SWART, HENK;REEL/FRAME:042730/0316 Effective date: 20130416 |
|
FEPP | Fee payment procedure |
Free format text: PETITION RELATED TO MAINTENANCE FEES GRANTED (ORIGINAL EVENT CODE: PTGR); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT RECEIVED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 4 |